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Abstract 
Staphylococcus aureus (including methicillin-resistant S. aureus - MRSA) remains a leading 
cause of both nosocomial and community acquired infections globally and despite 
constant improvement efforts to patient safety within healthcare, it still remains 
associated with considerable rates of morbidity and mortality. S. aureus is a common 
cause of biofilm-associated infections observed in chronic wounds, exhibiting a reduced 
susceptibility to the action of conventional antimicrobial agents and are often difficult to 
eradicate. The acquisition of resistance to almost any antibiotic with reference to MRSA 
has greatly reduced the number of alternative antimicrobial agents effective in the 
treatment of infections. Current development pipeline for new classes of antibiotics are 
greatly limited, requiring new, alternative approaches for therapeutic and prophylactic 
intervention in attempt to effectively control and overcome this current global health 
threat. Bacteriophage therapy exploits the natural killing ability of lytic bacteriophage 
(phage) as a means of controlling multidrug-resistant pathogenic bacteria. The utility of 
phage and their derivatives has been shown to effectively reduced the biofilms of major 
MRSA clones in vitro and in vivo. Global MRSA infections are caused by highly-successful 
isolates from a small number of epidemic lineages (clones). ST22 and ST36 are two of the 
most prevalent clones with global impact and largely responsible for the national epidemic 
of MRSA infections within UK healthcare system throughout the mid-1990s up until the 
mid-2000s. Understanding the phenotypic and genotypic characteristics of these clones in 
relation to the ability of bacteriophage to infect and disrupt established biofilms has yet 
to be explored. 
 
 In this study, a total of 46 novel obligately lytic phage were isolated from wastewater 
samples by utilising a modified Staphylococcus carnosus TM300 isolate with expressed S. 
aureus wall teichoic acids to aid in phage adsorption. The addition of 32 more phage from 
IV 
 
our current laboratory stocks helped to establish a collection of 78 phage that were 
screened against a panel of 185 genetically diverse S. aureus, consisting of major clonal 
groups with high prevalence within the UK and United States, including 43 ST22 and 24 
ST36 strains. The majority of the members displayed a wide host range against our panel. 
Based on this, the four most effective (wide host-range) phage were assessed for their 
anti-biofilm properties in polystyrene plates biofilm assays produced using four ST22 and 
four ST36 isolates. Treatment of mature biofilms was shown to significantly reduce biofilm 
biomass and viable cell counts. However these assays selected for the emergence of phage 
resistant mutants.  
 
Whole genome sequencing was performed on 22 phage isolates and these were found to 
share a high degree of similarity to genomes of 38 previously classified Twortvirinae 
phages represented in GenBank.  Comparisons of these 60 phage genomes found a 
surprisingly high level of genetic diversity. Pairwise distances resolved groups of phage in 
distinct clusters representing individual genera within the Twortvirinae subfamily. Pan-
genome analysis identified no single gene present amongst all phage genomes, however 
phage displayed a core genome amongst other members of the cluster. The structural 
homology tool HHpred was used to predict the protein structure of genes encoding for 
lytic enzymes among our phage genomes. We found that all phage encode a protein that 
shares high structural similarity to the same CHAP domain protein, a catalytic domain of 
endolysins employed by phage to degrade the bacterial host cell wall in order thus, 
mediate cell lysis. Suggesting that the all phage most likely share the same catalytic N-
terminal endopeptidase domain of endolysins which have a modular domain structure. 
Interestingly, endolysins have been proposed as possible candidates for the control of 
antibiotic resistant S. aureus infections. 
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 Current situation 
The development and introduction of antibiotics to treat bacterial infections was 
one of the key medical advances of the 20th century. Society relies heavily upon 
safe and effective antibiotics to treat an array of infections, but unregulated use, 
overuse and misuse within human healthcare, veterinary medicine and in food 
production has led to the evolution and spread of antibiotic resistance within all 
human pathogenic bacterial species [1]. Resistance to first choice, frontline 
antibiotics leads to delays in effective treatment and alternative drugs, if available 
may be more toxic, less effective and costlier and result in increased morbidity, 
mortality and increased hospital stays. Based on data acquired in 2015, researchers 
estimate that more than 33,000 deaths per year in Europe are attributable to 
healthcare-associated multidrug-resistant (MDR) infections due to pathogens that 
were once curable but are becoming increasingly difficult to treat [2]. Using current 
rising rates, the number of deaths attributed to drug-resistant pathogens is 
predicted to balloon to 10 million deaths per year presenting a major, growing 
public health challenge requiring a global response (Figure 1.1) [3]. 
 
There are over 15 classes of antibiotics that target different bacterial physiological 
and metabolic processes resulting in cell death or cessation of growth. Resistance 
mechanisms have evolved and spread to all these drug classes, with recent reports 
of strains even exhibiting resistance to ‘last resort’ antibiotics such as vancomycin, 
carbapenems and polymyxins [3].  
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Many pathogens are resistant to more than one antibiotic class and alternative 
agents may be prohibitively expensive especially in developing countries. These 
alternative antibiotics may be more toxic, more poorly absorbed and less effective 
than frontline therapies [4].   
 
 
The current problems caused by the evolution and spread of AMR pathogens has 
dramatically increased the need for safe and effective alternatives adjuncts to 
conventional antimicrobial chemotherapies [5]. Several alternatives to antibiotics 
do exist but are not yet widely available, these include bacteriophage therapy, 
immunotherapy and antimicrobial peptides. Research and development efforts in 
Figure 1.1: Predicted number of deaths worldwide attributable to antimicrobial-resistant pathogens each year by 
2050. Figure adapted from [384]. 
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these areas offers the possibility of regaining control over AMR infections and 
prolonging the utility of antibiotics [4].   
 
  Staphylococcus aureus 
Staphylococcus aureus remains as one of the primary causes of both hospital and 
community-acquired infections globally, an extremely versatile pathogen, it is 
responsible for causing a broad spectrum of diseases ranging in severity from 
minor skin and soft-tissue infections such as boils, furuncles and impetigo to more 
life-threatening invasive infections including pneumonia, osteomyelitis, 
endocarditis, meningitis and septicaemia [6]. It’s versatility has enabled the 
pathogen to quickly develop and acquire resistance to all antibiotic classes, whilst 
demonstrating an array of virulence factors that facilitates host colonisation and 
immune evasion such as cytolytic exotoxins, adhesins and biofilms production [7]. 
 
S. aureus is a frequent coloniser of the skin and mucous membranes of mammals 
with the anterior nares being its primary niche in humans. The epidemiology of S. 
aureus infections is multifactorial with both bacterial virulence factors and host 
factors thought to play a significant role. Around 30 % of the population are 
estimated to be asymptomatically colonised with this pathogen which may persist 
for long periods of time [8,9], with a further 60 – 80 % being intermittently 
colonised [10]. Despite being a normal component of the host microflora, it is 
considered an opportunistic pathogen as once it contaminates a breach in the skin 
or mucous membranes of the host, it can take advantage of the impaired host 
immune response and deploy a repertoire of host pathogenic molecules such as 
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hyaluronidase and exotoxins to break down host tissues, enabling the pathogen to 
invade deeper tissues [11]. Hospitalised patients are particularly prone to S. aureus 
infections due to the presence of compromised immune systems, surgical site 
infections caused by the implantation of indwelling medical devices such as 
protheses, stents and venous catheters [12]. Often leading to extended 
hospitalisation periods with increased risk for subsequent disease development, 
whilst causing significant financial burden to healthcare services [13]. 
 
 Pathogenicity 
The success of S. aureus as a major human pathogen is largely due to its extensive 
array of virulence determinants present among strains that are used to thwart host 
immune responses. The majority of which are encoded on mobile genetic elements 
(MGEs) such as pathogenicity islands (PIs), plasmids, bacteriophages and 
transposons that are an important means for transfer of genetic information within 
and between species [14]. MGEs play a significant role in the genome plasticity not 
only contributing to diversity among individual strains, but also allows the bacteria 
to adapt to constant changes in environment and its human host [15]. Horizontal 
gene transfer of virulence factors encoded within MGEs between strains has 
resulted in multiple combinations of virulence factors, that associate with 
particular host genetic backgrounds and clinically significant clones [16]. These 
virulence factors can be classed into three functional groups [17]: 
 
- Surface proteins that mediate adhesion of bacteria to cells or tissues. 
- Extracellular enzymes which promote tissue damage and spread. 
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- Toxins to help protect the bacteria from the host immune system. 
 
S. aureus possess the ability to produce a comprehensive repertoire of proteins 
that are collectively known as microbial surface components recognizing adhesive 
matrix molecules (MSCRAMMS) [18]. These surface proteins aid and promote the 
adherence and attachment to the surface of cells, tissues and prosthetic devices. 
MSCRAMMS are secreted primarily during exponential growth contributing to the 
pathogenesis of S. aureus and helping to establish infection [11,19]. Another 
protein known to mediate immune evasion is the surface associated protein A 
(spA), an immunoglobulin G (IgG)-binding protein present on the cell wall, which 
binds to the Fc regions of IgG subsequently preventing opsonophagocytosis 
(phagocytosis of bacteria or foreign cell initiated by an antibody) [20]. Other 
examples of MSCRAMMs include the extracellular adherence protein (EAP) which 
have been shown to promote invasion of eukaryotic cells and also bind to and 
interact with numerous plasma proteins including fibrinogen and fibronectin [21].  
Two closely related fibronectin-binding proteins (FnBPs) FnBPA and FnBPB are 
associated with inflammation and sepsis as well as facilitate the internalisation of  
S. aureus to host cells and attachment of the bacterial cell to fibronectin, elastin 
and fibrinogen [19,22]. 
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 Toxins 
Most S. aureus isolates are capable of producing an array of extracellular enzymes 
such as coagulase, proteases, haemolysins, hyaluronidase and collagenases [7]. 
These enzymes contribute to the spread and pathogenesis of bacteria against host 
cells. Additionally, S. aureus produce and secrete several cytotoxins in post-
exponential and early stationary phase. These are involved in tissue penetration 
and induce pro-inflammatory responses that facilitates the spread and 
dissemination of infection specifically targeting human cells and are grouped 
according to their mode of action as depicted in Figure 1.2 [23]. 
 
Hemolysins (α, β,γ and δ) are porin-like toxins that lyse various host cells including 
erythrocytes, platelets and monocytes. There are four types of hemolysins which 
are responsible for diseases such as food poisoning, toxic shock syndrome and 
exfoliative shock syndrome toxin-1 (TSST-1). Probably the best characterised and 
Figure 1.2: The virulence factors produced by Staphylococcus aureus, figure adapted from [385]  
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studied cytotoxin produced by S. aureus is α-toxin, which is capable of binding to 
target cell membranes and forming pores in the lipid bilayer subsequently resulting 
in cell lysis [7,24].  
 
Leukotoxins target white blood cells, forming pores in the polymorphonuclear cell 
membranes of neutrophils and macrophages [25]. Panton-Valentine leukocidin 
(PVL) is probably the most clinically significant toxin produced by S. aureus 
responsible for causing necrotising pneumonia, leukopenia and cutaneous 
infections [26–28]. The PVL toxin is encoded by a prophage incorporated into the 
S. aureus chromosome (see section 1.2.5.2),  PVL positive isolates originate from 
genetically diverse backgrounds and are associated with outbreaks of community-
associated MRSA infections [29,30]. 
 
Exfoliative toxins (ETs), also referred to as epidermolytic toxins are serine 
proteases that hydrolyse desmosome proteins present only in the superficial layers 
of the skin and are primarily responsible for staphylococcal scalded skin syndrome 
(SSSS). A generalised exfoliative disease affecting infants and children, SSSS 
manifests with fever and malaise, leading to blistering and severe exfoliation of 
skin surface [31].  
 
Staphylococcal superantigens (SAgs) are a family of exotoxins that induce T-cell 
proliferation resulting in uncontrolled release of cytokines that can lead to severe 
tissue inflammation,  hypovolemic shock, multiple organ failure and death [32]. 
These toxins include the notable toxic-shock syndrome toxin-1 (TSST-1) and 
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staphylococcal enterotoxin C (SEC) that play a critical role in the aetiology of S. 
aureus infective endocarditis [33]. Genes encoding for these superantigens are 
usually found within S. aureus pathogenicity islands (SaPI) as detailed in section 
1.2.5.1. 
 
 Biofilms  
Bacteria seldom exist in isolation and are more commonly found inhabiting various 
environments as mixed microbial communities consisting of more than one 
bacterial species termed as polymicrobial [34,35]. Biofilms are commonly defined 
as an assemblage of sessile microorganisms enclosed within a complex 
exopolysaccharide substance (EPS) or glycocalyx layer that accounts for up to 90 % 
of the biofilm biomass and acts as a cell survival mechanism [36]. The production 
of biofilms is an effective survival strategy employed by almost all bacterial species 
and has been extensively studied as these cells are often difficult to treat, largely 
owing to the protective nature of the glycocalyx layer that antibacterial agents 
have trouble penetrating and reaching its target [37]. Cells embedded deep within 
the biofilms layers tend to demonstrate a different physiology and biochemistry in 
comparison to their planktonic counterparts [38]. Such changes can be observed 
with the presence of metabolically inactive persister cells that exhibit reduced 
growth rates. This greatly reduces the uptake of antimicrobials that are designed 
to target fast growing and metabolically active bacteria, thus further contributes 
to their survival [39,40]. Biofilms cells are substantially more difficult to treat with 
conventional antibiotics and sanitising agents, often withstanding concentrations 
up to 1,000 times greater than those tolerated by planktonic cells [41]. The 
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formation of biofilms is classically described as a multistage process consisting of 
four key phases: adherence, accumulation, maturation and dispersal (Figure 1.3). 
There are a number of variables that mediate the initial attachment of bacteria to 
a surface and is a critical step in establishing an infection. 
 
 
 
  Adhesion 
Adherence between S. aureus and abiotic surfaces such as indwelling medical 
devices is mediated by non-specific interactions such as hydrophobic, Van der 
Waals and electrostatic forces [42]. Whereas, adhesion with human tissue is 
generally achieved by utilising one of the many adhesins encoded by S. aureus [43]. 
Adhesion and initial biofilm formation is achieved using a number of the proteins 
covalently anchored to the cell surface such as the MSCRAMMs, non-covalently 
associated proteins such as autolysins and non-proteinaceous surface-associated 
Figure 1.3: The multiple stages of biofilm formation and development, figure adapted from [386].  
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proteins that include wall teichoic acids (WTA) and polysaccharide intercellular 
adhesion (PIA) to recognise and interact with the host extracellular matrix 
components [18,43]. The surface is rapidly coated in host matrix proteins such 
fibrinogen, fibronectin and collagen which further encourages cell adhesion and 
colonisation [44]. Once attached a change in gene expression is observed allowing 
S. aureus cells to initiate irreversible attachment mechanisms [45]. 
 
  Accumulation 
Following initial attachment, cells start to multiply and accumulate together in to 
small multilayered aggregates called microcolonies. As cells begin to proliferate, 
they are linked together by adhesive biofilm molecules known as polysaccharide 
intercellular adhesin (PIA), also termed as poly-N-acetyl-glucosamine (PNAG) and 
are thought to play a crucial role in maintaining the stability of the immature 
biofilms [46]. In the absence of EPS, newly formed microcolonies are vulnerable to 
detachment particularly in the presence of shear forces such as flowing fluid [47]. 
PIA is partially de-acetylated resulting in a net positive charge, thus attracting the 
negatively charged bacterial cell surface partly provided by the WTA and 
subsequently adhering cells together through electrostatic interaction [48].  Cells 
begin to produce biofilm extracellular components forming a three-dimensional 
complex encasing the microcolony [45].  
 
  Maturation  
Biofilms develop as the cells continue to replicate, the agglomeration of 
microcolonies form in to large multi-layered biofilm structures increasing in density 
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and complexity. The glycocalyx layer of the biofilm begins to develop from the 
production of extracellular components by the adhered cells interacting with the 
organic and inorganic molecules within the immediate environment [49]. Bacteria 
use quorum sensing to regulate expression of genes that are actively involved and 
required during biofilm development. Quorum sensing is a cell-cell signaling 
mechanism that regulates gene expression in a cell-density dependent manner. It 
is mediated by hormone-like diffusible molecules called autoinducing peptides 
(AIP), whereby upon accumulation are recognized by cell surface receptors. The 
structured organization of cells allows the formation of interstitial voids and 
distinct water channels devoid of bacterial cells within the complex EPS structure 
separates microcolonies, these channels are necessary to allow the supply of 
nutrients, gas diffusion, signaling molecules to reach cells in the deeper layers of 
the biofilm as well as the removal of waste products [49,50]. However a number 
of factors including nutrient availability, internal pH and oxygen perfusion continue 
to limit the growth potential of the biofilm [49]. Once fully developed, the biofilm 
exopolysaccharide matrix is composed primarily of teichoic acids, polysaccharide 
intercellular antigen (PIA), extracellular DNA (eDNA) and staphylococcal/host 
proteins [47].  
 
  Dispersal  
The detachment and dispersal of mature, fully developed biofilms have been found 
to be an important step in the dissemination of infection in attempt to establish 
secondary biofilm infections elsewhere within the host or possibly non-biofilm 
associated systemic infections such as septicemia and infective endocarditis [51]. 
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Dispersal of biofilm cells has been found to be mediated by the accessory gene 
regulator (agr) locus of the quorum sensing system which controls virulence within 
S. aureus [52]. Activation of the agr system triggers a regulatory cascade 
suppressing the development of biofilms by downregulating the expression of 
surface adhesion proteins and by upregulating the expression of extracellular 
degrative enzymes such as proteases which facilitate detachment of biofilms, 
reverting cells back to a planktonic state thus encouraging the dispersal [48,52]. 
 
 S. aureus biofilms 
S. aureus is one of the most common causes of biofilm-associated and device-
related infections within healthcare, the bacterium presents a burden for 
healthcare systems and patient safety as it commonly colonises chronic wounds 
and the surfaces of indwelling medical devices such as intravenous catheters, 
cardiac pacemakers and joint prostheses [53,54], leading to biofilm-related 
diseases such as osteomyelitis, periodontitis and endocarditis [43]. Such infections 
are often difficult to treat using conventional antibiotics, with medical devices 
having to be replaced much more frequently compared to those infected by other 
staphylococcal species [55]. A notable characteristic of S. aureus biofilms is their 
ability to produce vast amounts of EPS, composed of teichoic acids, polysaccharide 
intercellular antigens (PIA), DNA and staphylococcal / host protein components 
[29]. Their success in biofilm production can be linked to their ability to produce 
an array of proteins known as MSCRAMMs that can help manipulate the human 
host defence, aid in adherence and attachment to the surface of cells, tissues and 
14 
 
prosthetic devices [18]. Their decreased susceptibility to antimicrobial agents 
contributes to their persistence in infections. 
 
S. aureus biofilms can be a major foci of infection with detachment and dispersal 
of aggregates through the vascular system leading to the colonisation of new 
niches. This can result in progression of disease from, for example, wound infection 
to disseminated / systemic disease including endocarditis, necrotising pneumonia, 
meningitis and septicaemia [56].  S. aureus is endemic in hospital environments, 
and is also a major cause of community-associated infections, these are typically 
skin and soft tissue MSSA infections but in some locales and population groups 
community-associated MRSA infections (CA-MRSA) are common in the absence of 
the risk factors associated with healthcare-associated infections [57]. 
 
 Evolution and genetic diversity  
The genomes of S. aureus are circular chromosomes that are on average around 
2.8 Mbp in length, however the length can vary depending on the size of additional 
extrachromosomal plasmids. Comparisons among S. aureus genomes typically 
reveals a core genome of roughly 78 % shared among isolates. The core genome 
refers to genes that are present across all strains, these orthologous genes are 
generally highly conserved and are essential for cellular metabolism, replication, 
surface-expressed proteins and genes encoding housekeeping functions [58]. 
Additionally, core-variable genes, a group of relatively stable genes that are 
variably shared between isolates and likely transferred vertically make up 
approximately 10 – 12 % of any S. aureus genome [58]. These core-variable genes 
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are mainly putative virulence or resistance genes carried on mobile genetic 
elements (MGEs), several unique combinations of such genes were found 
overrepresented in a number of specific clonal lineages inhabiting different 
ecological niches. Suggesting evolutionary and functional adaptation correlating 
with their pathogenicity and prevalence [59–61].  
 
The accessory components of the genome account for approximately 25 % of the 
total genome and is where the majority of genetic variation within a bacterial 
species is observed. Primarily consisting of MGEs including bacteriophage, 
staphylococcal pathogenicity islands (SaPIs), plasmids, transposons and 
staphylococcal cassette chromosomes (SCC), these components are frequently 
exchanged through horizontal gene transfer (HGT) despite the highly clonal 
population of S. aureus. The gain and loss of MGEs facilitates the rapid adaptation 
of bacteria to an ecological niche and are an important source of plasticity and 
diversity of the genome by driving bacterial evolution. Selective pressures from the 
environment drives the enrichment and need for specialised genes that promote 
fitness including virulence determinants or aid in the survival of the bacteria, such 
as acquiring genes that confer resistance to antimicrobial drugs [62]. 
 
  S. aureus pathogenicity islands (SaPIs) 
The majority of S. aureus pathogenicity islands (SaPIs) encode for one or more 
staphylococcal superantigens (SAgs) and are primarily responsible for causing SAg-
induced diseases such as TSST-1. These chromosomal elements range from 14 – 
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17 kilobase pairs in size and reside at one of six specific att sites on the 
chromosome [63,64]. SaPIs can be mobilised and disseminated amongst 
populations by the use of certain helper phage or induction by prophage and are 
an effecting method for genetic variation and transfer playing a significant role in 
the pathogenesis and virulence between strains [15]. 
 
  Bacteriophage 
Bacteriophage integrated within the bacterial chromosome (prophage) are 
widespread within S. aureus genomes, with almost all strains carrying at least one 
phage, with some possessing up to four in some cases. The prevalence and 
distribution of prophage has been linked to dominant S. aureus clonal complexes 
[65]. Phage encode a large portion of the virulence factors possessed by S. aureus 
strains such as PVL (encoded by the PV-luk operon), staphylokinase (sak) and 
enterotoxin A (sea) [66]. Phage are the primary vehicles for lateral transfer of genes 
among strains following activation and mediation between hosts, spreading 
chromosome-encoded virulence factors through generalised or specialised 
transduction. They play a significant impact on staphylococcal diversity and are 
tightly linked to host evolution and emergence of new pathogenic clones such as 
the community-associated MRSA strains.   
 
  Staphylococcal cassette chromosomes (SCC) 
Staphylococcal cassette chromosomes (SCC), such as SCCmec are a defining 
feature of methicillin-resistant S. aureus (MRSA) and not found present within 
methicillin-susceptible S. aureus (MSSA) isolates. These mobile genetic elements 
17 
 
vary in size from 21 – 67 kb, and there are currently 11 (I – XI) different SCCmec 
variants that have been described by the International Working Group on the 
staphylococcal Cassette Chromosome elements (IWG-SCC; 
http://www.sccmec.org/index.php/sccmec-uptodate - accessed 12-05-2019). 
Each of which grant various phenotypic characteristics such as antimicrobial 
resistance and are distinguished by the cassette chromosome recombinase (ccrA, 
ccrB and ccrC) gene complexes. There are eight various types of ccr gene 
complexes within staphylococci (1 - 8) and are responsible for the horizontal 
transfer and dissemination of the elements within the chromosome locus, 
contributing to the evolution of the SCCmec types and regulatory background 
mecA architecture.  There are currently six types of mecA gene complexes (class A, 
B, C1, C2, D and E) with each gene composed of mecA and its regulatory genes 
mecR1 and mecI.  
 
 Antibiotic Resistance  
Resistance to methicillin is mediated by the penicillin binding protein (PBP2A), this 
protein confers a lower affinity to all β-lactam antibiotics and as a result, 
preventing the disruption of the peptidoglycan layer and synthesis, thus allowing 
the bacteria to continue growing when in the presence of the antibiotic. PBP2A is 
encoded by the mecA gene which resides on the SSCmec element, following the 
acquisition of an SSCmec element, MRSA undergoes several mutational events 
allowing the bacteria to become one of the most difficult to treat pathogens with 
conventional antibiotics. 
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  Hospital-acquired methicillin-resistant S. aureus (HA-MRSA) 
The versatility of S. aureus has enabled it to withstand and adapt to the selective 
pressures of antimicrobial drug classes, by the start of the 1960s, roughly 80 % of 
S. aureus isolates exhibited resistance to penicillin. Resistance caused by the 
acquisition of a plasmid-encoding penicillinase led to the development of a semi-
synthetic β-lactam antibiotic known as methicillin (or meticillin). Introduced in to 
clinical practice in 1959 to treat infections caused by penicillin-resistant S. aureus, 
however by 1961, the first reports of nosocomial methicillin-resistant S. aureus 
(MRSA) isolates were already starting to be described [67]. Since then MRSA clones 
have subsequently emerged and disseminated worldwide becoming a global 
concern and still remains accountable for considerable rates of nosocomial 
infections [68]. 
 
SCCmec elements I - III are usually found within hospital-acquired MRSA (HA-
MRSA) isolates, possessing multiple combinations of ccr and mecA gene complexes 
that mediate antibiotic resistance [69]. Although predominantly restricted to 
healthcare, other successful MRSA clones possessing variants of SCCmec began to 
arise throughout the community in the late 1990s.  
 
 Community-associated MRSA 
S. aureus is also a major cause of community-associated infections,  such infections 
typically include minor skin and soft tissue diseases up to more severe and life-
threatening conditions such as, septicaemia, necrotising pneumonia [70,71]. The 
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prominence of MRSA lineages not related to HA-MRSA are appearing within the 
community at an increasing rate, and are frequently transmitted among individuals 
with no predisposing conditions or previous contact within a healthcare setting, 
often making it difficult in establishing the origin of the MRSA isolate. By contrast, 
CA-MRSA isolates can be distinguished from their nosocomial counterparts as they 
often carry smaller SCC variants such as SCCmec type IV and V, the smaller 
elements are more mobile and may be advantageous when transferring between 
other bacteria. Unlike HA-MRSA, CA-MRSA isolates tend to be more susceptible to 
non- β-lactam drug classes and are more likely to carry extra virulence 
determinants such as Panton-Valentine Leukocidin (PVL) encoding genes [72]. CA-
MRSA is becoming increasingly widespread across many countries around the 
world including the UK and USA, most notably the dominant epidemic clones USA 
300 (ST8-IV) and European CA-MRSA (ST80-IV) [73]. Furthermore, CA-MRSA has 
been spreading in epidemic proportions in recent years, leading to an increase in 
CA-MRSA incidences within hospitals being reported [68]. Not only does this 
further complicate the procedures in place for infection control within public 
health, but also suggests evidence of clonal spread and crossover between HA-
MRSA and CA-MRSA strains [74,75]  
 
  Global distribution of MRSA populations 
 Characterisation of MRSA 
Molecular typing plays an essential role in understanding the evolutionary and 
genetic relatedness of S. aureus populations. For MRSA it is an invaluable tool for 
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epidemiology studies allowing transmission cases to be traced and outbreaks 
related to specific clones to allow for preventative measures to be implemented. 
 
Multi-locus sequence typing (MLST) is one of the most widely used typing 
techniques employed to study the evolutionary history of S. aureus and MRSA 
isolates and their variation over time. MLST is a highly discriminatory and reliable 
approach used to characterise S. aureus isolates based on the internal fragments 
of seven housekeeping loci (arcC, aroE, glpF,gmk, pta, tpi and ygi) ranging from 
450 – 500 base pairs (bp) [76]. This sequence based approach analyses 
polymorphic variation of each gene fragment and assigns it to an allele number. 
The combination of these numbers for each housekeeping gene generates a 
numerical allelic profile (Table 1.1), which can then be used to determine its 
sequence type (ST) [76]. When two isolates are found to share identical sequences 
for these seven housekeeping genes and assigned in to the same ST, they are 
considered a clone.  
 
However, if closely related isolates that share the same allelic profile for five or six 
of the seven housekeeping loci, these are classified as members of the same clonal 
complex (CC) [77]. To date, the MLST database houses roughly 3110 unique S. 
aureus sequence types (http://saureus.beta.mlst.net/, accessed on 27th May 
2019).  
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SCCmec typing technique is used to detect regions of the SCCmec variant specific 
for that MRSA isolate, this approach identifies the unique combination of ccr and 
mec gene complexes used to classify the  11 SCCmec variants [78]. SCCmec typing 
has been employed in concert with MLST and has become an important tool used 
to discriminate between closely related MRSA and MSSA clones, including between 
HA-MRSA and CA-MRSA. Comparisons between the genomes of MRSA isolates 
from various geographical locations reveal a stable component present in all clones 
derived from a small and genetically distinct group [77–79]. The nomenclatural 
system currently employed for MRSA is based on MLST profiling in conjunction 
with SCCmec type; for example the EMRSA-16 clone MRSA252 is (ST36-II) [80]. 
 
 Global distribution of MRSA populations 
Molecular typing techniques have revealed that the population structure of S. 
aureus is highly clonal, with a relatively stable core genome, diversity is mainly due 
arcC arcC glpF gmk pta tpi  ygi 
Sequence 
Type (ST) 
Clonal Complex 
(CC) 
1 4 11 4 12 1 10 ST5 CC5 
3 3 1 1 4 4 3 ST8 CC8 
7 6 1 5 8 8 6 ST22 CC22 
2 2 2 2 3 3 2 ST36 CC30 
10 14 8 6 10 3 2 ST45 CC45 
 
Table 1.1: Allelic profile of seven housekeeping loci used to determine the sequence type (ST) of S. aureus 
isolates employed by multi-locus sequence typing (MLST). 
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to the accumulation of single nucleotide polymorphisms [77]. The rapid emergence 
of S. aureus infections and MRSA incidences in many parts of the world has partly 
been due to the dissemination of global clones. In fact, the majority of dominant 
isolates responsible for epidemic outbreaks of HA-MRSA (EMRSA) were associated 
with five distantly related but successful clonal complexes (CCs) CC5, CC8, CC22, 
CC30, and CC45 [81,82]. Which can also be described by their founder sequence 
type (ST) and descendants of pre-existing clones, or originating from epidemic 
MSSA lineages which had acquired the SCCmec element (Table 1.1) [80]. These 
clonal complexes can emerge when prevalence rates of independently evolving 
lineages rise within the population, which in turn diversifies through relative 
contributions of random genetic drift and recombination generating closely 
related variants that when combined form a clonal complex [77].  
 
The distribution of major clones varies geographically and their dominance shifts 
over time, eventually replaced by another clonal group through epidemic waves 
that correspond to evolutionary changes in the SCCmec within a clonal complex, 
which further supports the theory that horizontal transfer plays a key role in the 
dissemination of methicillin resistance [80,83]. The proportion of nosocomial HA-
MRSA incidences can vary considerably in each country, with low prevalence rates 
across northern European countries ranging from less than 1 % in Sweden, up to 
53 % in Romania and Portugal [84,85]. Further afield, in countries where 
preventative control measures are much lower can see higher prevalence of 
infection rates of more than 70 % in Asian countries such as Vietnam, Korea and 
China, even up to 87 % such as in Sri Lanka in some cases [75].  
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 Methicillin-resistant Staphylococcus aureus (MRSA) in the United Kingdom 
In the UK, while a number of notable MRSA clones have circulated, the MRSA 
epidemic dominating within hospitals and the community during the mid-1990s up 
until the mid-2000s can be largely associated with two waves of epidemic clones, 
UK EMRSA-15 (ST22-IV/CC22) and UK EMRSA-16 (ST36-II/CC30), both of which are 
collectively accountable for roughly 95 % of invasive hospital- and community- 
acquired MRSA bacteraemia reports throughout that time [80,86]. Their success at 
surviving and spreading throughout the UK can be largely due to the distinctive 
core genome and possession of unique accessory genes that contain several 
staphylococcal enterotoxin genes including seg and sei [87]. 
 
 Sequence Type 36 (EMRSA-16)  
Members of the ST36 (CC30) lineage include the pandemic clone EMRSA-16, which 
is responsible for many major outbreaks circulating around hospitals within the UK 
[88]. The first observations of EMRSA-16 in 1992 were reported within three 
hospitals in the town of Kettering in Northamptonshire [89], however it has been 
estimated that the most recent common ancestor to EMRSA-16 may have 
emerged roughly 22 years earlier around 1975 [90]. The rapid dissemination of 
EMRSA-16 around the UK was observed during a survey in 1995 (Figure 1.4), 
revealing 443 outbreaks of infection within hospitals caused by the clone occurred 
over 18 months, with surgical, medical and elderly-care wards accounting for 42 % 
(14 % each) of those reports. In the same study, patients colonised or infected with 
EMRSA-16 were found among 20 % of 150 nursing homes within the community. 
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Over the following 3 years, EMRSA-16 became widespread in most regions of the 
UK accounting for 25 - 30 % of all MRSA isolates across the south of England, 23 % 
in the Midlands and 12 % in the north, as well as 25 % and 30 % in Scotland and 
Wales, respectively [89]. Bayesian phylogenetic reconstruction using a number of 
UK CC30 isolates resolved them into three clades representing pandemic clones 
southwest pacific (SWP), phage type 80/81 and EMRSA-16 originating 
independently instead of sequentially [90]. Revealing several subclades of EMRSA-
16 (ST36) isolates unique to regions of the UK, correlating with the existence of  
Figure 1.4: The initial reported route and rapid dissemination of EMRSA-16 colonisation by 24 of 136 hospitals 
from 1992 – 1994 following its emergence in Kettering, Northamptonshire. Figure adapted from [89]. 
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EMRSA-16 isolates endemic to a particular hospital or region [90]. EMRSA-16 was 
commonly isolated in the UK, throughout the 1990s, however its prevalence within 
the UK rapidly declined from 21 % to 9 % between 2001 and 2007 and is not 
perceived as successful as the contending ST22 clones within the UK. Reports 
suggest that changes to infection control measures and antibiotic prescribing were 
possible factors for the decline of EMRSA-16 [91]. A shift in clonal structure of 
MRSA population across the UK was observed after 2003 as the dominant ST22 
clone subsequently took over ST36 [92].  
 
 Sequence Type 22 (EMRSA-15) 
ST22-IV-MRSA also known as the epidemic MRSA 15 (EMRSA-15) clone became the 
most successful and dominant MRSA clone associated with invasive disease in 
healthcare within the UK. Following the first reports in the early 1990s [93], 
EMRSA-15 outbreaks were reported across several European countries including 
Germany, Portugal and Czech Republic [94–96]. It has since then disseminated 
across to Australia, the Middle- and Far- East [91], where it has been found to 
replace previously dominant HA-MRSA lineages including CC5 and ST239 [97–101]. 
The reason for EMRSA-15 (ST22) and its dominance is not entirely understood, 
however it has been speculated that the smaller more mobile SCCmecIV element 
carried by the clone compared to the larger, more burdensome SCCmecII element 
in ST36 is thought to play a key role behind the success of EMRSA-15 [92]. This 
flexibility may allow the rapid adaptation to the selective pressures of multiply 
antibiotics and their various targets increasing its ability to acquire an array of new 
resistances such as ciprofloxacin (fluoroquinolone), which was introduced in to 
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clinical medicine within the UK in 1987 [92], clinal studies of the antibiotic were 
performed in the midlands prior to licensing. It might be argued that the EMRSA-
15 isolates are generally biologically fitter due to the smaller MGE without carrying 
large resistance genes that often come at a cost to fitness and growth rate. 
 
 
Through phylogeographic modelling, evidence suggests that the emergence of 
ciprofloxacin resistance among an EMRSA-15 subclone (ST22-A2) within the UK 
during the 1980s, originated in the West Midlands [102]. Ciprofloxacin resistance 
was acquired with mutations in genes encoding topoisomerase IV (gyrA) and DNA 
Figure 1.5: Predicted dissemination of ST22-A2 clone within the UK using Bayesian reconstruction reported 
from [105]. 
27 
 
gyrase (grlA) which are the primary targets of fluoroquinolones [103]. This 
acquisition closely resides to the introduction date and is thought to have 
significantly facilitated the rapid expansion and dominance of EMRSA-15 within 
those regions and across the UK (Figure 1.5). Throughout this period the 
proportion of S. aureus bacteraemia rates caused by MRSA increased from  < 2 % 
to ~ 37 %, of which EMRSA-15 accounted for more than 60 % of those incidences 
[104].  
 
Furthermore, phylogenetic reconstruction of 1013 MRSA genome sequences 
collected from the BSAC Bacteraemia Resistance Surveillance Programme between 
2001 and 2010 across the UK and Ireland, discovered that 783 (77 %) isolates were 
members of clonal complex 22 (ST22). Over the following decades, ST22 clones 
have continued to demonstrate resistance to an extended range of antibiotics of 
various classes including tetracyclines, oxazolidinones, aminoglycosides and 
mupirocin on numerous occasions [102]. 
 
  Bacteriophage 
Bacteriophage (phage) are obligate parasites that specifically infect bacterial cells 
are the most abundant living entity in the biosphere outnumbering their bacterial 
cells ten-fold with an estimated 1031 viral particles present on earth [105].  
Ubiquitous throughout all environments, their abundance and distribution is tied 
to the presence of their bacterial hosts, where they play a substantial role in 
regulating microbial balance and driving genetic diversity amongst bacteria.  
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 Phage structure and taxonomy 
Phage classification is governed by the International Committee for Taxonomy of 
Viruses (ICTV) based on key factors including phage morphology, nucleic acid 
constitution and the physiochemical properties of the virion [106]. The order 
Caudovirales (tailed phages) accounts of the majority (96 %) of bacteriophage 
described in the literature surpassing any other virus taxon [107], with members 
of this order currently characterised into three phylogenetically related families 
based on the morphology and function of the tail:- contractile (Myoviridae), long 
noncontractile (Siphoviridae) and short tailed (Podoviridae) [108]. These all have 
double stranded DNA genomes that are enclosed within a polyhedral capsid 
(head), a tail that acts as a passageway for the genomic material to enter the host 
during infection and tail fibers, that mediates the binding to the receptors on the 
surface of the host cell as depicted in Figure 1.6.  
 
The ICTV classification (https://talk.ictvonline.org/) has undergone some intense 
scrutiny over the last two decades [109–111], the level of diversity of bacterial 
viruses within the order of Caudovirales surpasses any other organisms especially 
at the nucleotide level yet bacterial viruses are currently assigned in to a hierarchy 
of taxonomic ranks consisting of three families. With the exponential increase in 
prokaryotic virus genome sequences deposited on to public databases and the 
large majority of those currently deposited yet to be officially classified by the ITCV, 
this approach is no longer deemed sufficient for correctly classifying viruses as 
similar phage morphology does not imply genetic similarity. In 2019, the re-
evaluation of current taxonomic assignment shifting towards a more genome-
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based classification approach that reflects the genetic relationship of these viruses 
at a higher taxonomic rank was explored. The ICTV subcommittee studied the 
diversity of the Spounavirinae genus, a large group of Myoviridae containing 
notable phage members including staphylococcal phage K, G1 and Twort, as well 
as Bacillus SPO1, Listeria phage P100 and A511 [112]. By disconnecting the 
classification of Caudovirales based on morphotypes and family, this approach 
retains the virus morphotype assignment, but allows taxonomically related clades 
to be grouped across morphotypes. The introduction of additional ranks in to the 
current virus taxonomy was proposed and subsequently approved by members of 
the ICTV (consisting of executive committee, life members, ICTV subcommittee 
members (including the study group chairs) and ICTV national representatives) by 
an absolute majority [113]. As a result, significant changes in the ICTV Code 
including the addition of seven new virus families were considered. The 
establishment of two new family ranks, Ackermannviridae and Herelleviridae 
within the order of Caudovirales, the latter now holds the previous members of 
the subfamily Spounavirinae, which has since been removed from the family 
Myoviridae [113–115].  
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  Phage life cycles 
Phage can be differentiated depending on the life cycles that they exhibit - lytic or 
lysogenic, although some phage may also have pseudolysogenic component in 
their life cycle (Figure 1.7), which describes a phage-host relationship that neither 
establishes a lytic nor lysogenic response, whereby a continuous secretion of 
Figure 1.6: Graphical representation of a typical Myoviridae phage.  
The icosahedral head that contains the double stranded DNA, tail fibers attached to the baseplate and the 
contracted tail can be identified, figure adapted from [387]. 
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phage occurs during a chronic infection that reduces the host cell growth rate 
[116]. Obligately lytic bacteriophage, adsorb to the bacterial membrane and 
introduce their genomic material into the host cytoplasm shutting down the 
bacterial hosts metabolic machinery before subverting it to resource the 
replication of phages own genome. This leads to the reproduction of multiple 
phage progeny before causing cell lysis through the use of lytic enzymes, these 
enzymes form holes in the bacterial cell wall, causing the cell to lyse due to the 
internal turgor, subsequently releasing mature virions that can go on to infect 
other host cells.  
 
Temperate bacteriophage that exhibit a lysogenic lifestyle incorporate their DNA 
into the bacterial host chromosome to form a prophage that is duplicated and 
vertically transmitted to progeny cells [117]. Following integration into the host 
genome, prophage DNA enters a latent state (temperate) whereby expression is 
controlled by a repressor gene system [118,119]. The prophage switches to a lytic 
life cycle in response to environmental stresses that downregulates the actions of 
prophage repressors leading to transcription of phage genes in the first stage of 
the lytic pathway. The induction of prophage can be spontaneous, or induced by 
environmental responses caused by UV, antibiotics or stress.  
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  Phage and HGT  
The lytic ‘switch’ can sometimes lead to improper incision of the prophage and 
neighbouring bacterial genes may also be packaged in virions. This acquisition of 
neighbouring bacterial genes known as transduction can result in the phage 
serving as carriers for pathogenicity islands and genes that encode for bacterial 
toxins and other virulence determinants [27,120]. Whilst can potentially increase 
the virulence of the recipient due to expression of virulence gene products during 
lysogeny, playing a significant role in influencing the evolution and emergence of 
new virulent bacteria strains [121,122]. This has been observed by the prevalence 
Figure 1.7: The replication stages of Lytic (A), Lysogenic (B) and Pseudolysogenic (C) phage life 
cycles, figure adapted from [123]. 
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of prophage carriage among S. aureus genomes. The success of notable CA-MRSA 
clones including ST8, ST30, ST59 and ST80 can be attributed to the multiple phage-
encoded virulence factors including PVL and Enterotoxin A [123,124]. 
 
  Phage evolution 
Recent advances in sequencing technology in the last decade has seen an 
exponential increase in bacteriophage genomes published on to online databases, 
such as the NCBI and the European Nucleotide Archive (ENA). Other than the rare 
jumbo phage that harbours a significantly larger genome, the majority of phage 
carry comparatively smaller genomes than their bacterial hosts [125]. Despite their 
size and considerable abundance, phage genomes sequencing continues to lag 
behind bacterial genome sequencing [126]. Phage genomes display extensive 
mosaicism revealing genes organised into functional modules that are frequently 
exchanged within a population and has been described among phage belonging to 
Myoviridae and Siphoviridae [127]. The size of these modules and their exchange 
rate are highly variable [128], homologous recombination has been found to play 
a central role in the re-assortment of phage genomes, with both point mutations 
and insertion/deletion also contributing to their diversity [129,130]. Comparative 
genomic studies have contributed immensely to developing a greater 
understanding of phage diversity, their genomic architecture and evolution 
[127,128,131]. However, the incredibly mosaic nature of phage genomes makes 
detailed comparisons extremely challenging [132]. Phage mosaicism can be 
assessed through nucleotide sequence comparisons or at the protein level by 
comparing gene products, the latter approach can be applied when some phage 
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groups share no nucleotide similarity, and protein sequence data can reveal genes 
that share older ancestry [133]. They also reveal regions that are commonly 
conserved and those which are more variable or unique to specific phage. 
Importantly, despite the high levels of observed mosaicism, the analyses also 
identify distinct genome lineages among phage of a specific host species [131]. 
 
  Phage lytic proteins 
Phage encode for a number of lytic proteins that are used to mediate cell lysis and 
release viral progeny from cells. In dsDNA phage, lysis is the result of 
permeabilization and disruption of the bacterial cell wall achieved through the 
holin and endolysin system. Both holins and endolysins are produced towards the 
late phase of phage gene expression, during virion assembly, endolysins 
accumulate in the cytosol whereas holins will accumulate in the membrane [134]. 
Phage-encoded endolysins are multi-domain peptidoglycan hydrolases that act by 
digesting the peptidoglycan of the bacterial cell wall and are classed based on the 
catalytic specificity, such as the target substrate in bacterial cell walls [135]. These 
evolutionary advanced hydrolases are highly efficient enzymes that target one of 
the four bonds of the peptidoglycan, this activity is achieved through cleavage of 
the glycosidic linkages, amide or peptide cross-bridges of the peptidoglycan [136]. 
The folded endolysin molecules typically harbours at least two functional domains, 
a catalytic N-terminal domain (EAD), containing either endopeptidase, amidase, 
glucosaminidase, muramidase or trasnglycosylase activity. They also possess a C-
terminal cell wall binding domain (CBD) which confers specificity for certain cell 
wall types playing a significant role in the activity range of the enzyme [137]. 
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Endolysins do not have signal sequences therefore accumulate in the cytosol and 
are translocated with the help of holins in a timely controlled fashion and at a 
genetically specified time, the holins form lesions in the cell membrane leading to 
its permeablisation allowing access for the endolysins [138,139]. Cleavage of the 
peptidoglycan will cause the cell to lose its structural integrity leading to 
unsustainable osmotic pressure, ultimately bursting the bacterial cell and releasing 
phage progeny.  
 
Endolysins require holins to essentially gain access to the cell wall and reach the 
peptidoglycan thus facilitating cell lysis terminating the infective cycle, therefore 
the holin is the direct determinant for the length of the phage infective cycle and 
effectively the burst size. The longer the latent period within a single cell, the more 
progeny are expected to be produced [139,140]. Endolysins are capable of causing 
rapid bacterial cell lysis when applied extracellularly against antibiotic-sensitive 
and antibiotic-resistant strains and have so far failed to instigate any form of 
bacterial resistance [141]. Several studies have demonstrated the antimicrobial 
efficacy of phage-derived lytic enzymes, including endolysins and their potential 
for controlling multiple Gram-positive and Gram-negative bacterial species over 
the past decade [142–146]. The ability to target and degrade several polymeric 
components of biofilm simultaneously further supports the potential of endolysins 
to combat biofilms. One of the most notable and well-studied endolysins is the 
staphylococcal phage lysin, LysK.  Which has demonstrated a high lytic ability 
against all tested staphylococcal strains including MRSA isolates within static 
biofilm and animal infection models [146–148]. 
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Virion-associated peptidoglycan hydrolases (VAPGH) are phage-encoded lytic 
enzymes that are involved in the initial stage of phage infection. Phage utilise 
VAPGHs to cleave the peptidoglycan polymers of the bacterial cell wall, facilitating 
the access of the phage tail tube to penetrate the bacterial cell wall, thus enabling 
the transfer of phage genetic material in to the host cytoplasm. Often located 
beneath the baseplate and locally degrade the peptidoglycan during infection 
[149,150], these structural components are not essential for phage replication. 
However their presence facilitates infection in less optimal conditions and may be 
used by phage to gain a selective advantage. Although VAPGHs biological 
characterisations are limited, comparisons of VAPGH from phages infecting S. 
aureus revealed that they share a high degree of similarity to endolysins at the 
amino acid level [151]. VAPGH have a modular structure, consisting of one or two 
enzymatically active domains (EADs), these catalytic domains are responsible for 
the cleavage of specific bonds within the peptidoglycan. Unlike endolysins, all 
VAPGHs described to date do not possess an identifiable cell-wall binding domain, 
this is likely due to that fact that VAPGHs are often delivered to the peptidoglycan 
by the phage particle structure [152]. This modular organisation enables the 
possibility of engineered domain swapping and deletion, subsequently enabling 
the ability to improve the lytic activity whilst also reducing the likelihood of 
resistance developing [151,153]. 
 
Bacteria display an array of polysaccharides on the surface of the cell such as 
capsular polysaccharides (CPS), exopolysaccharides (EPS) present in bacterial 
biofilms [154,155]. These often play a significant role in the pathogenesis of 
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bacteria by surrounding the cell and protecting it from desiccation, host immune 
responses, phagocytosis, antibiotics and phage [156]. This protective layer 
represents the first physical barrier phage encounter in the infection process by 
blocking the primary receptors phage bind to, subsequently inhibiting adsorption.  
 
To counter this, phage encode for polysaccharide degrading enzyme known as 
depolymerases that recognises and enzymatically degrades the polymeric 
components of the EPS and capsule enabling them to reach the bacterial host 
[150]. Whilst playing a key role in the liberation and release of phage that are 
trapped within the complex structures of the biofilm EPS. The bacteriostatic 
activity of depolymerases produced by capsule targeting phages can be observed 
using soft agar overlays by the presence of a turbid zone known as a halo 
surrounding the phage plaque. The formation of the halo is achieved by the 
diffusion of soluble depolymerases through the agar and stripping away the 
protective capsule layer of the bacterial host. Although not necessarily killing the 
cell, it essentially disarms the bacteria, making it vulnerable to phage infection as 
well as other antimicrobials [156,157]. 
 
  Phage therapy 
Phage therapy exploits the natural killing ability of lytic bacteriophage and their 
derivatives and has been explored as a means of controlling bacterial infection. 
Obligately lytic phage are regarded as the most appropriate candidates in human 
health as they are capable of rapidly killing the target host, greatly reducing the 
chances of bacteria developing phage resistance [158,159]. They also lack the 
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required genetic factors for genome incorporation associated with temperate 
phage, therefore reducing the possibility of integrating their genome into the host 
chromosome or mobilising bacterial DNA that could potentially carry genes 
encoding for antibiotic resistance and virulence determinants [160,161]. 
 
Despite widespread use in the 1930’s, the use of phage therapeutics were largely 
eclipsed by the discovery and clinical development of broad-spectrum antibiotics 
in Western countries. However, phage therapy has continued to be used 
throughout the Soviet Union with both the Eliava Institute of Bacteriophage, 
Microbiology and Virology in Tbilisi, Georgia and the Institute of Immunology and 
Experimental Therapy in Wroclaw, Poland becoming major centres for the 
development and application of phage therapeutics taking considerable strides in 
phage related research [162,163]. Which has since been integrated within their 
health care systems for use in the treatment of chronic and recurrent infections in 
patients, such as staphylococcal skin and soft-tissue infections in diabetic patients 
where lytic phage are matched to cultured wound organism apparently with 
success [164]. The efficacy of phage therapy has already demonstrated its potential 
when administered to patients exhibiting bacterial infections that are 
unresponsive to conventional antibiotics, resulting in an average success rate of 
around 85 % [165].  
 
  Advantages and limitations of phage therapy 
Phage exhibit a number of advantages for therapeutic application, the mechanisms 
involved in phage infection are distinct from those causing antibiotic resistance 
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therefore antibiotic susceptible- and multiply AMR bacteria are equally as likely to 
be susceptible to phage killing [166,167]. Phage can encode for auxiliary enzymatic 
activities such as cell wall (Gram positive bacteria) and capsular polysaccharide 
(Gram negative bacteria) degrading properties that can disrupt the extracellular 
polymeric substance (EPS) matrix of biofilms, facilitating phage penetration and 
subsequent multiplication deep within biofilm matrices [168]. Unlike antibiotics, 
that are synthetic or semi-synthetic in their production, bacteriophage are 
naturally occurring and their ability to proliferate at the site of infection means that 
only small doses of phage are required. Suitable lytic phage infecting most species 
of pathogenic bacteria are readily isolated from environments where their hosts 
are plentiful such as hospital effluents, sewage or watercourses. Lytic phage vary 
widely in their host specificity. Examples exist of phage that are specific for 
receptors carried by only a small proportion of a bacterial species, however, broad-
host range (polyvalent) phage are readily isolated that can infect a large number 
of strains within a species with some infecting strains of multiple species [169]. 
 
Despite their apparent advantages there remain several barriers to the widespread 
clinical use of phage in human therapy. Safety concerns exist regarding possible 
phage interactions with patient tissues and host microflora including potential 
immune responses that may limit their medium-long term efficacy [170]. Because 
phage generally exhibit a higher specificity for their host than antibiotics, 
identification of the infection-causing organism may be required to guide therapy 
whereas broad-spectrum antibiotics can be used empirically, in advance of 
knowledge of the etiology of the infection. The evolution of phage resistance in 
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bacteria occurs less frequently than for some antibiotics, however this can be 
addressed through the combined use of different phage targeting the same 
bacterial strain that require a number of independent mutations to confer 
resistance – analogous to the use of antibiotic combination [163]. The 
development of phage resistance and the limited host range of individual phage 
can be ameliorated by the rational formulation of combinations of multiple 
polyvalent phage. These ‘cocktails’ can enable the targeting of multiple strains and 
even species while greatly reducing the probability of bacteria developing phage 
resistance [159,171]. In order to satisfy regulatory requirements in human 
medicine it is essential to generate high purity phage lysates that satisfy existing 
regulations with regards to contaminants that may act as adventitious agents and 
pro-inflammatory molecules such as exotoxins [172,173]. Complete DNA 
sequencing of phage components is desirable in candidate therapeutics to ensure 
they do not contain lysogenic sequences such as integrase genes, or host DNA such 
as bacterial virulence genes [27]. 
 
 Bacteriophage resistance 
Bacteria have developed a number of anti-phage mechanisms as a response to 
defend and prevent the constant threat of phage infection (Figure 1.8). Despite 
this however, phage also have a number of adaptive strategies that allows them to 
circumvent this issue, and it is this evolutionary arms race between hosts and 
phages, that is one of the greatest drivers in genetic variation and diversity.  
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 Restriction Modification  
A major mechanism of resistance to bacteriophage infection are bacterial 
restriction-modification (R-M) systems. Characteristically, these consist of a 
number of enzymes including restriction endonucleases (REase) and DNA 
methyltransferases (MTase) that rapidly cleave and methylate foreign DNA at 
specific sites upon entry to the cell, deactivating it prior to phage DNA transcription 
[174]. R-M systems are typically classified in to four major types (I – IV) that are 
based on their subunit composition and number, enzymatic mechanism, cleavage 
position, sequence recognition and substrate specificity [175]. R-M systems are an 
extremely diverse group of enzymes and are widespread throughout prokaryotes, 
the variation and prevalence of this system indicates the success and importance 
as a defensive mechanism within the bacterial world. Due to this diversity, phage 
have evolved a number of anti-restriction strategies to counter and evade R-M 
systems. Such mechanisms include the incorporation of modified bases, altering 
the restriction site and reduction of endonuclease recognition sites through the 
accumulation of point mutations within their genomes [174]. 
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 CRISPR-Cas system 
Clustered regularly interspaced short palindromic repeats (CRISPR) as well as 
CRISPR-associated (Cas) proteins form part of the adaptive and heritable immune 
system within prokaryotes against mobile genetic elements such as phages and 
plasmids [176]. The system consists of several short palindromic repeats that are 
identical in length and sequence, these conserved repeats are interspaced by 
variable DNA segments called spacers derived from previous exposure to phage 
and other MGEs. The sequence of each spacer is 100 % identical to the spacer 
sequence found in the genome of the infecting phage known as the protospacer 
and enables the host to recognise and destroy specific phages acting as a 
resistance mechanism against foreign genetic elements [177]. Spacers are also 
flanked by a varying number of cas genes, that when transcribed, form an array of 
complex cas proteins with functional domains and are characteristic of nucleases, 
Figure 1.8: The various bacteriophage resistance mechanisms employed by bacteria to target different stages of 
the phages lytic life cycle. Figure adapted from [182]. 
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helicases, integrases and polymerases [178]. The CRISPR arrays (including the 
foreign DNA spacers) are then transcribed in to small non-coding interfering 
CRISPR RNAs (crRNA), which direct the Cas proteins to specifically target and cleave 
the foreign genetic material [174,178].  
 
The CRISPR-Cas system is widespread among bacteria and archaea, with most 
possessing only one CRISPR locus. However there are several bacterial species that 
contain multiple CRISPR loci [179]. To overcome this, phage resistance to the 
CRISPR-Cas system can be acquired through the presence of anti-CRISPR (acr) 
proteins that inhibit a range of Cas9 proteins. However, even a simple point 
mutation or deletion in the protospacer, or the protospacer adjacent motif (PAM). 
The PAM is a short (2 – 7 bp), conserved sequence of DNA located adjacent to the 
protospacer within the infecting phage genome, that is targeted by the Cas9 
nuclease can be enough to grant immunity and evade this defensive strategy [180]. 
 
 Adsorption blocking 
Bacteria present an array of host-specific components on the cell surface that play 
a significant role in bacterial metabolism but also the virulence and pathogenicity 
of the host. However these also serve as the key receptors that phage target and 
irreversibly bind to during the initial stage of infection in order to inject the 
genomic DNA through the host membrane [181]. Adaption to the structure of the 
surface components, production of extracellular matrix such as capsule or 
glycocalyx layer, or by competitive inhibitors that bind to phage receptors are some 
innate defensive strategies bacteria employ to inhibit phage infection [174,182]. 
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Receptor availability can be greatly decreased through phase variation, this 
heritable, but reversible process regulates gene expression enabling population 
heterogeneity in attempt to survive phage attack. Alternatively, such receptors can 
be physically masked by the production of exopolysaccharides to surround the 
bacterial cell in a slime or capsule preventing phages attachment [183]. To counter 
this, some phage encode a number of polysaccharide-degrading enzymes that are 
capable of breaking down the exopolysaccharide layer thus revealing the host-
specific receptors to initiate phage infection. These enzymes are covered in section 
1.4.5. 
 
 Abortive infection 
The abortive infection (Abi) system is an altruistic action that promotes the death 
of the phage-infected bacterial cell as a way of sacrificing itself, in attempt to 
protect the surrounding bacterial population from subsequent infection. This 
system can act at any stage of phage development by targeting the essential 
cellular processes within the host such as replication, transcription and translation 
in attempt to reduce or eliminate the production of phage progeny [183].  It has 
been found that Abi systems are often encoded on MGEs, and can be mediated 
through toxin-antitoxin systems, that are widespread within prokaryotes [184]. In 
order to circumvent this, some phage are capable of encoding for their own 
antitoxin molecules that are used to suppress the bacterial toxins required for Abi 
to occur [183]. 
 
45 
 
 Bacteriophage assembly interference 
Gram positive bacteria possess phage-inducible chromosomal islands (PICIs) that 
parasitise and interfere with the reproduction of infecting phage. One of the most 
well studied PICI is the Staphylococcus aureus pathogenicity islands (SaPIs) that 
encode for a number of virulence factors and contribute substantially to host 
adaptation and pathogenicity as described in section 1.2.5.1. 
 
Normally, SaPIs resides stably within the bacterial chromosome but can be 
mobilised by the presence of ‘helper’ phage through infection or lysogeny 
induction, subsequently leading to the excision, replication and packing of the SaPI. 
All known SaPIs described so far target essential phage functions and interfere with 
helper phage particle assembly and DNA packaging using several strategies [182]. 
They can remodel the capsid proteins of the infecting helper phage so that its 
smaller and more tailored to fit the SaPI genome. SaPIs also encode for phage 
packaging interference (Ppi) proteins that diverts phage packaging towards the 
SaPI by blocking the terminase small subunit of the helper phage, but not the 
corresponding SaPIs terminase small subunit [185]. A third mechanism involves 
interfering with late phage gene transcription, which is essential for phage 
packaging and cell lysis, however must be modulated precisely so that it does not 
also interfere with SaPI particle formation [186]. 
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  Phage effects on biofilms 
The therapeutic potential of bacteriophage is becoming increasingly explored over 
recent years, several studies have claimed promising success in the effective 
disruption and dispersal of biofilms produced by clinically relevant pathogens 
[187–191]. The extracellular matrix not only provides structural integrity but also 
acts as a protective barrier around the bacteria that increases their tolerance to 
antimicrobial agents and innate host defence mechanisms [192,193]. In a clinical 
scenario, biofilms present a major obstacle in the treatment of bacterial infections 
using conventional chemotherapeutic methods, requiring alternative strategies for 
eradicating or reducing complex microbial communities [194].  
 
Within the anoxic conditions of a natural biofilm environment, the high local 
concentration of cells are exposed to a myriad of threats such as depleted nutrients 
and antibiotics produced from competitors. This results in the programmed 
formation of persister cells that are metabolically dormant [195]. Due to this state 
of dormancy, persisters display a higher tolerance to antimicrobials that are mainly 
effective against actively growing cells by targeting metabolic pathways and are 
difficult to eliminate, resulting in waves of biofilm regrowth following disinfection 
procedures [39,196]. The down regulated metabolic machinery of persister cells 
required by phage for intracellular replication inhibits the completion of the phage 
infection cycle. However It has been previously reported that phage are still 
capable of adsorption to these persister cells, although no replication will occur, 
they too will enter a quiescent state within the cell until the host becomes 
metabolically active allowing the phage infection cycle to begin [197].  
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Phage are equipped with a number of other properties that make biofilms 
susceptible to their action [135,190,198]. Although larger than chemical 
antibiotics, phage are much smaller than their bacterial hosts and have the ability 
to penetrate deep within the protective layers of biofilms [168,194]. Water-filled 
channels run through the structure of mature biofilms in which nutrients can 
circulate, such channels are large enough for phage to pass through and invade the 
interior and basal layers of the biofilm [169]. Their ability to self-replicate within a 
host resulting in localised amplification of phage progeny that can go on to infect 
many more hosts, allowing them to reach bacterial cells that were once protected 
and out of reach (Figure 1.9). To circumvent such hurdles, phage-derived enzymes 
with antibacterial properties could be introduced as antimicrobials. Several studies 
have examined their ability to disrupt biofilms by targeting the key components of 
the glycocalyx that makes up the majority of the biofilm structure causing large 
Figure 1.9: Lytic phage infection within biofilms. Figure adapted from [64]. 
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masses to slough off, resulting in near complete dispersal of the entire biofilm 
[199]. 
 
  Staphylococcal phage  
Staphylococcal phage are widespread and have been extensively studied for many 
decades. Phage typing is one approach that utilises the high specificity of phages 
to successfully subtype S. aureus isolates, as a way of characterising the 
epidemiology of clones, especially those responsible for causing outbreaks of 
infectious disease [200]. Another approach is to utilise the lytic ability of phage as 
a means of treating multiply antibiotic resistant bacterial infections for over almost 
a century [172]. Staphylococcal phage in therapeutic use e.g. Eliava institute in 
Tbilisi, Georgia, are obligately lytic, polyvalent phage capable of infecting multiple 
strains of a S. aureus including MRSA and coagulase-negative S. aureus – CONS 
[201]. The most effective tend to be Twort-like phage myoviruses and lytic 
podoviruses that exhibit short eclipse times and high burst sizes [187,202–205]. To 
aid in the attachment, phage utilise a number of adhesins that recognise cell 
surface receptor proteins of the host cell. The specificity of these adhesins defines 
the host range of the phage. The adsorption of phage particle to the host cell is 
deemed to be the most important determinant for successful infection. Phage can 
infect host bacteria with great specificity, where they are capable of infecting 
bacteria from a single species, and in some cases a single strain. However, some 
phage do exhibit a wide host-range (polyvalent) with the ability to infect the 
majority of strains of a single species and in some cases even multiple species 
[206]. Host recognition is achieved through binding to molecules presented on the 
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host cell wall through the use of phage receptor binding proteins [207]. Such 
molecules include wall teichoic acid (WTA) polymer, which is abundantly found on 
the surfaces of S. aureus and are major constituents of their cell envelope [208]. 
The composition of these glycopolymers of backbone of WTA varies and can be 
lineage-specific, however the majority of S. aureus strains harbour a polyribitol 
phosphate (Rbo-P)-type WTA. Several studies have indicated that the N-
Acetylglucosamine (GlcNAc) residue of WTA is a key target for phage infecting S. 
aureus playing a pivitol role in host recognition and defining the host range of the 
phage [209,210]. 
 
The renewed interest in phage therapy has led to an increase in a variation of novel 
S. aureus phage isolated, with several recent studies describing the lytic activity of 
staphylococcal phage in the treatment of S. aureus and S. epidermis using 
experimental biofilm models [158,187,188,190,211]. The ability to prevent the 
formation and disperse pre-formed staphylococcal biofilms using phage cocktails 
has also been successfully demonstrated, whilst greatly reducing the rate of phage 
resistance [187,189,212]. The combinational use of phage could facilitate the 
adsorption and infection of polymicrobial biofilms, the disruptive ability of one 
phage against the glycocalyx structure of the biofilm through the use of lytic 
enzymes and depolymerases, can allow other phage within the cocktail to reach its 
bacterial host [213]. 
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  Phage antibiotic synergy 
Studies investigating the combined use of phage and their derivatives with 
antibiotics and their activity on biofilms are still in their infancy, however previous 
studies have already identified possibly synergies resulting in enhanced biofilm 
disruption in vitro when administered in combination, or sequentially [214–217]. 
A limited number of studies have approached the phage-antibiotic synergy (PAS), 
whereby sub-lethal concentrations of antibiotics may also stimulate the host 
production of virulent phages. Authors suggest that pre-treatment of S. aureus 
biofilms with phage yielded the greatest results, by disrupting the bacterial biofilm 
structures that were once protecting cells, it allows for deeper penetration of 
antibiotics leading to significant reductions in bacterial viability (Figure 
1.10)[218,219].  
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Figure 1.10: Sequential treatment of mature biofilms.  
Pre-treatment of biofilm with phage preparations in attempt to disrupt and disperse the extracellular 
polymeric substance of biofilms, thus allowing sub-inhibitory concentrations of antibiotics to activate phage 
mediated lysis of previously dormant cells. Figure adapted from [218] 
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 Staphylococcal phage classification 
Until late 2018, Myoviridae infecting S. aureus were classified in to the 
Spounavirinae subfamily which consists of six genera including Kayvirus, P100virus, 
Silviavirus, Spo1virus, Tsarbombavirus and Twortvirus and three unassigned 
species (Enterococcus virus phiEC24C, Lactobacillus virus Lb338-1 and 
Lactobacillus virus LP65) [112,220]. The Spounavirinae subfamily, initially proposed 
in 2009 are a group of phage that are related to the Bacillus phage SPO1 including 
notable phage such as staphylococcal phage Twort, staphylococcal phage K, 
staphylococcal phage G1, Listeria phage P100, and Listeria phage A511 [112]. The 
characteristics of these members exhibit a strictly virulent lifestyle, myovirion 
morphology, possessing terminally redundant, non-permuted dsDNA genomes 
that are typically organised in to functional modules. The phage share considerable 
amino acid homology, representing a distinct cluster within the dsDNA viruses with 
largely overlapping sets of genes [131,220]. The reorganisation of the current ICTV 
classification system led to the recent establishment of a two new families named  
Ackermannviridae and Herelleviridae [115,131]. As a result, Herelleviridae now 
contains the four new subfamilies within it including the previous Spounavirinae 
and the new Bastillevirinae, Brockvirinae, Jasinkavirinae and Twortvirinae 
subfamilies (Figure 1.11). Further to this, the genera (Kayvirus, Sepunavirus, 
Silviavirus, Twortvirus and unclassified Twortvirinae) containing staphylococcal 
phage now reside in the subfamily Twortvirinae [131]. As of June 2019, there are 
currently 55 staphylococcal phage genomes currently available on the NCBI 
database as seen in the taxonomy browser.  
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Figure 1.11: BLAST-based clustering of the newly established Herelleviridae subfamily.  
Clusters are based on original names of each genera representation by colour heatmap generated with 
Gegenees. Phylogeny adapted from [131]. 
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 Aims and objectives 
The main aim of this study was to develop a greater understanding of lytic 
bacteriophage effective against S. aureus and their potential to control biofilms 
produced by two dominant MRSA clones within the UK, ST22 and ST36. This study 
is divided in to three main objectives that are: 
 
- To establish a collection of lytic staphylococcal phage isolated from 
environmental samples and the determination of their host range against 
a diverse collection of clinical S. aureus (including MRSA) isolates.  
 
- To evaluate the disruptive anti-biofilm properties of candidate phage 
against a number of S. aureus biofilms produced by ST22 and ST36 isolates. 
 
- To examine the associations between the genomes of the phage collection 
and other lytic phage infecting S. aureus using comparative genomics. 
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Materials and methods 
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 Bacterial strains  
A total of 185 genetically diverse (based on multilocus sequence typing - MLST) 
Staphylococcus aureus isolates were used in this study (Appendix A). The isolates, 
from human carriage and disease, include some from the major methicillin-
resistant S. aureus (MRSA) clones, including 43 multilocus sequence type (ST)22 
and 27 ST36 from the UK and USA [77,80,102]. Additionally, a S. carnosus strain 
TM300 kindly provided by Dr. Guoqing Xia (University of Manchester, UK) was used 
for phage isolation and propagation. S. carnosus is a non-virulent staphylococcal 
species used in meat production and as such was considered a benign propagating 
host for phage production. This modified TM300 contains a plasmid encoding the 
minimum number of genes required for biosynthesis of S. aureus polyribitol-
phosphate (RboP) wall teichoic acid using antibiotic-resistance gene markers.  The 
use of an antibiotic-resistance gene marker requires chloramphenicol 
supplemented media at a concentration of 10 µg/mL. and is necessary for 
expressing the polyribitol-phosphate (RboP) repeating units of the wall teichoic 
acid, thus aiding phage adsorption and should increase the chances of isolating 
novel phage [210].  
 
 Maintenance and standardisation of bacterial cultures 
All strains were sourced from freezer stocks maintained in 25 % (v/v) glycerol in 
TSB at -80 ˚C. S. aureus isolates were plated on Tryptone Soy Agar (TSA) and 
incubated overnight at 37 ˚C in air. For liquid cultures individual colonies were 
picked and inoculated into 20 mL Tryptone soy broth (TSB) and incubated 
overnight 37 ˚C with shaking at 150 rpm. TSB-soft agar containing 0.6% Agar 
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Bacteriological (Agar No. 1) was used for bacteriophage propagation and plaque 
assays. Molten soft agar was stored in a water bath at 50 ˚C before use.  
 
 Normalisation of cells  
Bacterial cultures were standardised to the same concentration at the required 
optical density (nm). For this, liquid cultures were harvested by centrifugation for 
20 minutes at 4200 rpm, spent medium was decanted and bacterial pellet was 
resuspended in PBS using the pipette to break up the pellet. Cells were centrifuged 
again and washing of cells was further repeated once more, cells were this time 
resuspended in 5 mL of TSB to create a cell concentrate. Cells were diluted 
accordingly to normalise all cells to required optical density. Once the desired 
concentration of bacterial cultures was obtained, 10-fold serial dilutions were 
performed (102 - 109) in PBS and 100 µL was spread onto TSA plates in triplicate 
and incubated overnight at 37 °C. The plate dilution displaying 30 – 300 individual 
colonies were used to calculate the CFU/mL at each absorbance using the following 
equation: 
 
CFU ∕ 𝑚𝑙 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑦 𝑓𝑜𝑟𝑚𝑖𝑛𝑔 𝑢𝑛𝑖𝑡𝑠
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 𝑉𝑜𝑙𝑢𝑚𝑒
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 Sample collection  
 Collection of environmental samples 
Animal faecal samples were collected from various locations of fields holding 
grazing livestock, in addition to several animal pens at Chelford cattle market. 
Holding pens were immediately cleaned once livestock were relocated, especially 
cattle pens which were essentially large open rooms almost continuously sprayed 
down turning samples in to a mixed slurry. Solid animal faecal samples of similar 
size were collected in sterile falcon tubes. 
 
 Collection of Wastewater samples  
Wastewater treatment samples were initially collected from three different stages 
of the treatment process - inlet, primary sedimentation and aerated sludge process 
tanks. Using a PTFE dipper with a 500 mL beaker, wastewater samples were 
collected from the surface, the dipstick was also submerged 30 cm. Around 500 
mL were collected and poured into sterile sealable tubs, individually sealed again 
in food bags and then immediately transported to be processed. 
 
 Enrichment of animal samples for phage isolation 
Solid animal faecal samples were homogenised using 15 mL of PBS, with aggressive 
agitation using a vortex mixer every 10 minutes for one hour. About 20 mL of slurry 
was also collected from slurry drainage channels and combined with PBS so all 
animal samples were roughly the same viscosity. The homogenate was centrifuged 
at 4200 rpm for 30 minutes and the supernatant was filter sterilised using a 0.22 
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m Acrodisc syringe filter (Pall Corp., Mississauga, Ontario, Canada), to give a crude 
viral lysate. These lysates, from environmental and sewage samples, were enriched 
with staphylococcal liquid cultures to amplify phage numbers. Roughly, 5 mL of 
filtered sample was enriched with 20 mL of TSB and a mixed culture consisting of 
single or mixed cultures of actively growing bacterial cells. Enrichments were 
incubated overnight at 37 °C whilst shaking at 150 rpm, these were then 
centrifuged at 4200 rpm for 30 min to remove bacteria. The supernatant was 
passed through a 0.22 μm filter syringe to create an enriched phage lysate. 
 
 Enrichment of wastewater samples 
Sewage effluent samples were collected from various process tanks at Davyhulme 
and Eccles wastewater treatment works, England. Organic matter was removed 
from samples by centrifugation (4,200 rpm, 30 mins). 10 mL aliquots of 
supernatant were filtered  (0.22 µm), before being combined with 10 mL double-
strength TSB and 100 µL of exponentially growing S. aureus cultures, followed by 
incubation at 37 °C, shaking at 150 rpm for 24 h. Bacterial debris were removed by 
centrifugation (4200 rpm, 30 min) filter sterilised (0.22 µm) to give an enriched 
phage lysate. 
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 Phage methods  
 Soft agar overlay plaque assay 
Plaque assays are performed in order to identify the presence of phage and 
determine their titre using the soft agar overlay method [187]. This is fundamental 
to a number of methods that involve phage isolation and propagation. Soft agar 
overlays create a confluent lawn allowing to locate areas where phage a present 
based on zones of lysis known as plaques [221]. 100 μl of overnight liquid bacterial 
cultures were aliquoted out in to 4 mL single use sterile culture tubes, 100 μl of 
phage lysate was added to each tube and allowed to sit at room temperature for 
5 min. Working with one tube at a time, 3 mL of molten soft agar was added to the 
tube and immediately poured on to the surface of a TSA plate (Figure 2.1). Plates 
were left at room temperature for 15 min to allow the agar overlays to solidify 
before inverting and incubating overnight at 37 ˚C. S. carnosus strain TM300 was 
used for phage propagation whenever possible however for some phage S. aureus 
isolates D329 and H402 were used.  
 
 Single plaque purification  
Single isolated plaques were picked by touching a sterile toothpick or pipette tip 
into the plaque surface and this was then agitated in 1 mL of SM buffer. Harvested 
phage were vortexed for 30 seconds and serially diluted before being examined for 
purity using the soft agar method. Single isolated phage plaques and three rounds 
of plaque purification were used for each phage isolate to ensure purity of lysates.  
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 Phage propagation 
Concentrated phage stock lysates were created using a ‘flood plate’ method from 
purified phage lysates (above). To do this dilutions of the phage suspension were 
plated out using the soft agar overlay method to determine the ideal dilution that 
produced near confluent lysis of the bacterial lawn (Figure 2.2).  
 
The plate typically had a ‘spiderweb’ effect with very little delineation between 
each plaque. This near confluent has been found to be ideal for producing reliably 
high phage titers [222]. Ten plate replicates of each phage using the required 
dilution were created, and 5 mL of SM buffer was added to the surface of each 
plate before incubation at 4 °C overnight. Liquid was removed from the plate with 
a Pasteur pipette and transferred to a 50 mL falcon tube. These were centrifuged 
and the supernatant sterilised by filtration (0.22 μm pore size) to create high titre 
phage lysates, one or two drops of chloroform was added to each lysate and were 
then stored at 4 °C for short-term use. 
100μl 
Phage 
100μl 
Host 
3mL 
Soft agar 
Figure 2.1: Schematic representation of soft agar overlay. 
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Figure 2.2: Confluent lysis of S. aureus D329 lawn. Phage dilution causing near confluent 
lysis were used to produce high titre phage lysates. 
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 Phage quantification 
The titre for each phage lysate was determined by the soft agar overlay. Using SM 
buffer as diluent, 10-fold serial dilutions of lysates (104 - 109) were prepared, 100 
μl of each dilution was added to 100 μl of actively growing host strain and the soft 
agar overlay assay was performed, this process is performed in triplicate to obtain 
an average. The plates were examined for plaque presence following overnight 
incubation at 37 °C. if too high of a dilution is plated, confluent lysis is achieved on 
each plate and counting plaques is not possible. For each phage lysate, the number 
of plaque forming units per millilitre (PFU/mL-1) were calculated the plate dilution 
displaying 30 – 300 plaques whilst taking into account the dilution. The PFU/mL-1 
is used for determining the titre based on the following equation: 
 
PFU ∕ 𝑚𝑙 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑙𝑎𝑞𝑢𝑒𝑠
𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑥 𝑉𝑜𝑙𝑢𝑚𝑒
 
 
 Phage host range 
Prior to starting, 4 x 4 grids were drawn on the reverse side of each TSA plate to 
help with interpreting results and act as a guide when performing the spot assay 
(Figure 2.3). Overnight cultures of 185 genetically diverse (based on MLST) S. 
aureus strains (including MRSA) were prepared in 10 mL TSB  (Appendix A). Soft 
agar overlays containing 100 μl of S. aureus and 3 mL of molten soft agar were 
mixed in sterile culture tubes and immediately poured onto the surface of TSA 
plates. These were allowed to set by leaving for 15 min at room temperature. 10 
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μl of each phage lysate, normalised to a titre of 106 PFU/ml, were spotted onto the 
surface of each plate, and allowed to dry before overnight incubation at 37 °C. 
Three plates were used for each phage lysates to give three replicates. 
 
 
The lytic ability of the phage was assessed by analysing the clearing of bacterial 
lawns following the spot test method. Sensitivities are also assigned a colour to 
simplify the analysis of the recorded results:  
 (Name of bacterial strain) 
Figure 2.3: Representative plate layout used for host range assay. 
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- Sensitive (green) – completely clear spot with 100 % lysis.  
- Intermediate (yellow) – varies from clearing throughout with 
resistant mutants   (1), clearing throughout but hazy background 
(2), substantial turbidity where phage was spotted (3), individual 
plaques (4).  
- Resistant (red) - no clearing or disruption to bacterial lawn.  
 
       Sensitive                         Intermediate (A) 
 
 
 
 
 
 Intermediate (B)                         Resistant  
Figure 2.4: Schematic example of the degree of clearing of bacterial lawns following phage spot 
assay used to determine phage lytic ability against S. aureus isolates. 
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 In vitro growth experiments 
 Growth kinetics of bacterial hosts 
The growth rate of each bacterial isolate in liquid culture was studied in 96-well 
flat-bottomed microtitre plates, bacterial growth over time was assessed by 
measuring the turbidity of each well by absorbance (OD600). Initially, overnight 
cultures of actively growing cells were normalised to an optical density (OD600) of 
0.3 which corresponds to roughly 1-5 x106 CFU/mL, similarly to as mentioned in 
section 2.1.2. In a 96-well microtitre plate, 200 μl of sterile PBS was placed in each 
of the surrounding wells at the edge of the plate to help reduce sample 
evaporation. A 1:100 dilution of an overnight bacterial culture was performed by 
adding 2 μl of normalised bacterial suspension to 198 μl of fresh pre-warmed TSB, 
200 μl of TSB was added to a set of wells as a negative control. All wells were 
replicated in triplicate. Prior to incubation, the underside of each microplate lid 
was sprayed with 3 % (v/v) Triton X-100 in absolute ethanol to reduce 
condensation on the lid that could affect measurements. Bacterial growth was 
measured by absorbance (600 nm) over 19 hours at 37 ˚ C using a microplate reader 
(FLUOstar Omega, BMG LABTECH). The plate reader provided absorbance data 
points every 180 seconds following a 10 second agitation at 200 rpm. Average 
absorbance readings were standardised against blank controls, to allow 
determination of standard deviation / standard error for graphing purposes. Data 
points after every 30 minutes were used.  
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 Killing assays 
Time-kill assays were performed in order to determine the sensitivity of planktonic 
bacterial cells to phage infection and also to investigate the frequency of phage 
resistant bacterial mutants. Exponentially growing bacterial cultures were 
normalised and diluted using fresh pre-warmed TSB to an optical density of 0.300 
at 600 nm. Assays were performed in a 96-well flat-bottomed polystyrene 
microtitre plate and these were replicated in four wells. 200 μl of sterile PBS was 
placed in each of the surrounding wells at the edge of the plate and 150 L of 
normalised bacterial culture was added in to each test well. Lysates of selected 
phage were normalised to the same titre in TSB media, 50 μl was subsequently 
added to each well to achieve a multiplicity of infection (MOI) of 0.1 for each 
bacterial host. Two hundred microlitres of TSB was added to four wells as a blank 
control, 50 μl of sterile TSB was added to 150 μl of bacterial culture as a negative 
control. Microtitre plates were incubated at 37 ˚C in a plate reader and optical 
density was measured at 600 nm every 180s for 19 hours, experiments were 
performed on three separate occasions. 
 
 Formation of mature biofilms  
The method used for studying biofilm formation on cell-culture 96-well flat-
bottomed microtitre plates was based on the above method with some 
modifications [187]. 10 mL overnight liquid cultures were centrifuged at 4200 RPM 
for 10 mins and the pellet resuspended in 10 mL of sterile PBS. This was centrifuged 
as before and the final pellet was resuspended in 5 mL TSB. Bacterial cultures were 
normalised in TSB to an optical density of 0.6 nm, making a staring inoculum of 4-
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5 x106 CFU/mL. A 1:100 dilution was performed by adding 2 μl aliquots of 
normalised cells to 198 μl of TSB supplemented with 1 % D-(+)-glucose (TSBg) in 
each of the corresponding wells of a microtitre plate, TSBg was used as this has 
been found to promote the formation of S. aureus biofilms [223,224]. Two hundred 
microlitres of TSBg was added to a set of wells as blank controls. Microtitre plates 
with lids were sealed with Parafilm and carefully wrapped in moistened paper 
towel roll, then placed in a Tupperware box to further prevent moisture loss and 
contaminants over the incubation time. Plates were incubated at 37 ˚C for 48 h 
without agitation to allow biofilm formation. These plates were removed after 24 
h incubation time, 50 μl of spent media was carefully withdrawn from all test and 
control wells and replaced with 50 μl of fresh TSBg. Plates were then incubated for 
a further 24 h at 37 ˚C. 
 
 Optimisation of biofilm growth conditions 
To determine the optimal growth conditions to promote biofilm formation, a 
number of approaches were considered and investigated based on previous 
studies [223,225–227]. Biofilms were formed using the method previously 
described above, using two preparations of media - TSB and TSBg at concentrations 
of 100 %, 75 %, 50 % and 25 %. Additionally biofilm formation was assessed using 
standard microtitre plates and tissue culture microtitre plates (Thermo Scientific 
Nunc™ Microwell™).   
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 Staining of biofilms  
The level of biofilm produced by study isolates was estimated using crystal violet 
staining and measured by absorbance. Liquid media from biofilm experiment 
plates was gently removed by inversion onto tissue. Biofilms were washed (twice) 
by the addition and gentle removal of 200 μl of sterile PBS and then left to air-dry 
for several hours. Wells were then filled with 200 μl of 0.1 % (w/v) crystal violet 
(CV) and allowed to sit for 10 minutes at room temperature. Once stained, the CV 
was poured off and wells were twice rinsed with water to remove residual and 
unbound CV. The stained biofilms, now visible, were left to air-dry for several hours 
at room temperature. Stained biofilms were solubilised using 200 μl of 30 % (v/v) 
glacial acetic acid solution in water deionised water and left for 20 minutes. The 
contents of each well was resuspended by repeated pipetting to ensure the biofilm 
was completely solubilised before transfer to a new 96-well microtitre plate. 
Biofilm mass was estimated spectrophotometrically using a FLUOstar plate reader 
at absorbance = OD590.  
 
 Enumeration of biofilm cells  
Colony forming units (CFU) of S. aureus cells recovered from established biofilms 
were enumerated following 48 h incubation (see section 2.6.3). Media was 
removed from the wells where biofilms were grown and then washed twice with 
200 μl of sterile PBS to remove any non-adherent bacteria and residual media. Two 
hundred microlitres (200 μl) of sterile PBS was added to the selected wells for cell 
counts and the biofilms were scraped away from the walls and the bottom of the 
wells using a sterile toothpick. The biofilm suspension was pipetted up and down 
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five times to homogenise the content within each well.  An aliquot of 100 μl of 
disrupted biofilm suspension was used to make ten-fold serial dilutions in PBS for 
counting on TSA plates to determine the CFU for each sample. The number of 
viable cells within each well was calculated using the formula described in section 
2.1.2. 
 
 Phage lysate preparations  
When assessing the effect of phage on biofilms, the number of viable cell 
recovered from 48 h biofilms were initially obtained in section 2.6.6, phage lysates 
of a known titre were diluted accordingly in sterile growth media to obtain the 
desired MOI of 1, a 1/10 dilution was further performed to achieve an MOI 0.1.  
 
 Biofilm diminution using phage 
The formation of S. aureus biofilms was carried out as above (see section 2.6.3), 
after 48 h the media was poured off and washed twice with 200 μl PBS to remove 
any non-adhered cells. Biofilms were treated with 200 μl of diluted phage lysate at 
two different MOIs :- 1 and 0.1 which were added to each corresponding set of 
wells according to the layout below (Figure 2.5). Two hundred microlitres (200 μl) 
of TSBg/PBS was used as a negative control and the blank controls were 
replenished with 200 μl TSBg. Experiments were performed on three separate 
occasions. Quantification of the remaining biofilm biomass and viable cells 
following exposure to study phage for 6 and 24 h was performed as described in 
section 2.6.5 and 2.6.6.  
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 Biofilm visualisation 
Biofilms regularly formed on the walls and the bases of the microtitre plate wells. 
However the small well size made it difficult to visualise the biofilms using 
microscopy and therefore the base of the wells had to be cut away from the rest 
of the plate structure. The contents of each well were removed and biofilms were 
subsequently washed as mentioned in section 2.6.6. Within a fume cupboard, a 
sterile burning hot scalpel blade held under a Bunsen burner until glowing was 
used to obtain a clean cut through the polystyrene well, at roughly 0.5 cm up from 
the base as demonstrated in Figure 2.6. This was attached to the inside of a sterile 
petri dish using Vaseline. 
 
 
Isolate 1 
MOI 1
Isolate 1 
MOI 0.1
Isolate 2 
MOI 1
Isolate 2 
MOI 0.1
Isolate 3 
MOI 1
Isolate 3 
MOI 0.1
Isolate 4 
MOI 1
Isolate 4 
MOI 0.1
1 2 3 4 5 6 7 8 9 10 11 12
A PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS
B PBS PBS
C PBS <---
D PBS <---
E PBS <---
F PBS <---
G PBS PBS
H PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS
Biofilm sampling 
for CFU counts
For staining
Figure 2.5: Plate layout used for assessing the anti-biofilm properties of phage against mature S. aureus 
biofilms.  
Two MOIs were applied to four different bacterial hosts. Four wells were inoculated allowing one 
well for viable cell counts.  
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 Confocal laser scanning microscopy 
The level of biofilm disruption by phage infection and cell viability was assessed by 
confocal microscopy. Once placed inside a sterile petri dish, the base of the wells 
were treated with LIVE/DEAD stain (Live/Dead® BacLight™ Bacterial Viability Kit, 
Invitrogen Ltd) following the manufacturer’s instructions, carefully wrapped in foil 
and incubated for 15 minutes in the dark at room temperature. The well bases 
were rinsed several times with PBS to remove any residual stain and 20 mL of water 
was added in to the petri dish to submerge the well base. Biofilms were observed 
using a under a confocal scanning laser microscope (Leica TCS SPE 1000 CLSM) 
equipped with a x40 water dipping lens and examination carried out on Leica 
Application Suite X (LasX) software package. The LIVE/DEAD was used to stain 
biofilms following treatment of phage. The staining kit consists of a mixture of SYTO 
9 green fluorescent and propidium iodide red fluorescent stains. This allows the 
Figure 2.6: Schematic diagram demonstrating the removal of the microtitre plate base containing 
biofilm 
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discrimination of live cells (with intact membranes) that stain green and dead cells 
(compromised membranes) that stain red under CFLM. 
 
 Statistical analysis 
Experiments were performed with a minimum of three replicates and these values 
were used to plot mean ± standard deviation. Statistical analysis was performed 
using GraphPad Prism Version 7.0 software package, data was analysed as an 
ordinary one way ANOVA (Analysis of Variance) and Sidak’s multiple comparison 
test to determine significance of results. Results were taken as significantly 
different by a p value of 0.05 unless otherwise stated.  
 
 Phage genome sequencing 
 Isolation of phage genomic DNA 
Fresh phage lysates (107 - 109 pfu/mL) were prepared on their respective host using 
the flood plate method (see section 2.3.3). Phage genomic DNA was obtained by a 
phenol:chloroform isoamyl alcohol (25:24:1 [v/v]) extraction method [228]. For 
each phage, 1.5 mL of phage lysate was centrifuged at 13,000 rpm for 10 minutes 
at 4 °C, 1 mL of phage supernatant was transferred into a fresh microfuge tube and 
treated with DNase I (10 μl of 1 mg/ml DNase I) and RNase A (4 μl of 12.5 mg/ml 
RNase A) to remove host bacterial DNA and RNA respectively. An equal volume of 
phenol (pH 10) was added to each tube, vortexed for 30 s and centrifuged at 
13,000 rpm for 10 min at 4 °C. Depending on the quality of the phage lysate, two 
visible layers separated by a white protein interphase should be present within the 
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tube (Figure 2.7). The aqueous layer on top containing DNA was carefully extracted 
with a pipette leaving a small volume left over to prevent taking up the lower 
organic phase or protein interphase. The contents of the pipette was transferred 
to a fresh microfuge tube and an equal volume of phenol:chloroform (1:1) was 
added, vortexed for 30 s and centrifuged at 13,000 rpm for a further 10 min at 4 
°C. Again, the aqueous layer was collected and transferred to a fresh microfuge 
tube, an equal volume of phenol:chloroform:isoamylalcohol (25:24:1) was 
introduced to each tube, vortexed for 30 s and centrifuged at 13,000 rpm for 20 
min at 4 °C.  
 
 Precipitation of phage DNA 
The aqueous layer was transferred to a fresh microfuge tube and mixed with two 
volumes of ice-cold absolute ethanol and 1/10 volume freshly prepared 7.5M 
ammonium acetate, then allowed to precipitate at -20 °C overnight. The addition 
Figure 2.7: Extraction of phage DNA using phenol:chloroform.  
The aqueous phase (top) contains most of the DNA, a white layer of denatured proteins partitions the lower 
organic phase of mostly RNA and lipids in phenol. 
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of ammonium acetate was used to remove DNA associated proteins and reduce 
carryover of polyphenolics, if present, they may affect downstream enzymatic 
reactions during library preparation and sequencing issues. The following day, 
precipitated DNA (visible as white cotton strands) was centrifuged at 13,000 rpm 
for 20 min at 4 °C before absolute ethanol was pipetted off. The DNA pellet was 
washed twice with 1 mL 70 % ethanol (v/v), centrifuged at 13,000 rpm for 20 min 
at 4 °C, ethanol was pipetted off and the pellet was left to air dry to allow residual 
ethanol to evaporate. The pellet was eluted in 100 μl nuclease-free water and 
incubated at 37 °C to help dissolve DNA.  
   
 Quantification of DNA 
The purity of each DNA sample was assessed using a Nanodrop One 
spectrophotometer (Thermo Scientific). The absorbance ratio at 260 nm and 280 
nm is generally used as a measure of purity for both DNA and RNA sample 
extractions. For DNA the ratio considered as pure is ~1.8, values lower than this 
indicates contamination from possible residual chemicals used during extraction 
including phenol, guanidine or carbohydrate carryover. Yields were quantified 
using the fluorescent dye SYBR Green assay, SYBR Green I master mix was prepared 
using 1 x TE (pH 8), a 1:50 dilution for each purified phage DNA sample was 
performed in TE. 2-fold dilutions of Lambda DNA (10 ng/μl) were used to plot a 
standard curve. DNA samples were quantified by fluorescence on a FLUOstar plate 
reader at an excitation of 485 nM and emission of 535 nM. All DNA was diluted and 
normalised in 100 μl nuclease-free water to roughly 5 ng/μl using a Qubit 3.0 
Fluorometer (dsDNA High Sensitivity (HS) assay, Life Technologies), before further 
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diluting to 0.2 ng/μl required for sequencing. Measurements were determined 
using 2 μl of sample and measured in triplicate to obtain an average value.  
 
 Whole-genome sequencing 
The NextSeq 500 was Illumina’s first benchtop sequencing platform that provides 
middle and high throughput options in combination with highly complementary 
microarray scanning, allowing to successfully sequence exomes, transcriptomes 
and whole genomes. The NextSeq 500 utilises a 2-channel sequencing technology 
that allows for a significant reduction in cycles duration and overall processing time 
for each run. NextSeq 500 employs Illumina’s highly accurate and reliable 
sequencing by synthesis (SBS) technology that uses fluorescently-labelled 
deoxynucleotides triphosphates (dNTP) to sequence millions of clonal clusters. 
First DNA libraries are created for each sample as mentioned below, DNA 
fragments are tagged with unique Illumina adapters (oligonucleotides with a 
known sequence). Additionally, motifs are introduced to those adapters, consisting 
of sequencing binding sites and regions complementary to the oligonucleotides 
bound to the flow cell surface. PCR amplification is performed to clonally amplify 
the library. This adapter technique allows the ability to pool multiple samples in to 
a single run rather than a single library.  
 
Strands of DNA are amplified multiple times directly on to the surface of the flow 
cell to generate millions of clonal clusters through bridge amplification. Sequencing 
is performed on the forward strands and starts when the first single labelled dNTP 
(or fluorophore) is added to the nucleic acid chain.  
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The NextSeq 500, uses a two-colour chemistry to determine all four base calls, by 
taking only red and green images, base C is labelled with red fluorophore, T is 
labelled with green fluorophore, when both green and red images are received it 
is flagged as A, while no emission is flagged as the unlabelled base G base Figure 
2.9). Nucleotides are pushed through the flow cell lanes and single dNTPs are 
allowed to anneal to the these clusters based on the template, once annealed the 
clusters are excited by a light source, and each dNTP emits a fluorescent signal that 
is measured and then the fluorophore is cleaved to make way for the following 
dNTP. During processing, the raw reads from pooled samples are separated based 
on the unique adapters introduced during the library preparation.  
 
 
Figure 2.8: NextSeq 500 sequencing platform at Manchester Metropolitan University, UK. 
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Libraries of the selected phage DNA samples (input DNA 0.2 ng/μl) were prepared 
using the Illumina Nextera XT DNA Sample Preparation Kit following 
manufacturer’s instructions. With this kit, the DNA is fragmented and tagged 
simultaneously by the modified Nextera transposon, quality of each library was 
assessed and verified using the Agilent Bioanalyzer HS DNA kit and quantified again 
using a Qubit, the values of each sample was used to calculate the nM for cluster 
generation using the formula.  
 
 
 
Figure 2.9: Two-channel sequencing by synthesis (SBS) technology employed by the Illumina NextSeq 500 
sequencing platform to capture the fluorescently-labelled deoxynucleotide triphosphate (dNTP). 
Adapted from Illumina. 
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Libraries were pooled and diluted to a loading concentration of 1.5pM instead of 
1.8pM in attempt to avoid over clustering. Overclustering is most commonly 
caused by insufficient library clean-up and inaccurate library quantification, which 
creates a number of negative issues including increases in signal brightness, loss of 
focus as well as poor template generation, cluster registration and image analysis. 
High-throughput sequencing of phage DNA (paired-end 2 x 150 High output) was 
carried out using the Illumina NextSeq500 platform at Manchester Metropolitan 
University, UK. 
 
 Genome assembly 
Next Generation Sequencing can generate a significant amount of sequences data 
in a single run, the quality control and filtering of this raw data is considered to be 
one of the most crucial steps during the preliminary stages of data processing. 
Several kinds of sequencing artefacts have to be processed including poor quality 
reads, sequencing errors, possible contaminating or overrepresented reads and 
outlier detection. The identification and subsequent removal (trimming) of these 
low quality sequence segments will allow for a more successful downstream 
analysis. Quality of reads were initially checked with FASTQC v0.11.5 [229], lanes 
were concatenated into a single file for each forward and reverse read. Low quality 
end reads were trimmed using Sickle v1.33 [230], Trim Galore! v0.4.3 [231] was 
used to remove the Illumina adapters by trimming 20bp from 5’ end and 25bp of 
3’ end. Sequence data was mapped against a host reference genome sequence 
using Bowtie2 v2.3.2 to remove host bacterial DNA reads that may affect assembly 
[232]. SAMtools was used to manipulate each forward and reverse Bowtie2 output 
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SAM file to a binary BAM file format, the BAM file was then converted to a fastq 
file, which is much easier for computer programs to read [233]. Assembly of each 
phage was achieved using SPAdes v3.11 [234]. The pipeline script is shown in Figure 
2.10. 
 
All phage assemblies using Spades resulted in a single large contig plus a number 
of small repeats. The largest contig and their coverage was assessed and visualised 
using Bandage [235], individual genome assemblies were analysed using Artemis 
[236] and the largest scaffolds were compared to the similarity of previously 
sequenced genomes using basic local alignment search tool BLASTn [237].  
 
 Expansion of whole genome phage sequence collection 
Based on the similarity between our query sequences and the top hits (closely 
related genomes) identified using BLASTn, whole genome sequences (FASTA 
format) of all related phage infecting S. aureus were retrieved from GenBank 
(https://www.ncbi.nlm.nih.gov/nuccore) and the European Nucleotide Archive 
(ENA) databases in February 2018 to achieve a final collection of 62 phage 
genomes. 
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Sickle 
sickle pe –sanger –f <inputdir/forward_sequence.fastq> –r 
<inputdir/reverse_sequence.fastq>  
-o <outdir/forward_sickled_file.fastq> -s <outdir/reverse_sickled_file.fastq> -p singles.fastq 
 
Trim Galore! 
perl trim_galore --nextera  --length 80 --clip_R1 20 --clip_R2 25 --paired 
<inputdir/forward_sickled_file.fastq>, <inputdir/reverse_sickled_file.fastq> -o <outdir> 
 
Bowtie2 build index reference genome database 
bowtie2-build <inputdir/TM300_reference_genome.fasta> TM300 
 
Bowtie2 
bowtie2 -x TM300 -1 <inputdir/forward_sickled_trimmed.fastq> -2 
<inputdir/reverse_sickled_file.fastq> -S <outdir/mapped.sam> 
 
SAMtools 
samtools view -bS <inputdir/mapped.sam> > <outdir/mapped.bam> 
 
Samtools bam2fq <inputdir/mapped.bam> > <outdir/mapped.fastq> 
 
SPAdes 
spades.py --careful --cov-cutoff auto -k 71,91,111 --pe1-1 
<inputdir/forward_mapped.fastq> --pe1-2 <inputdir/reverse_mapped.fastq> -o 
<outdir/Phage_spadesout> 
 
 
 
 
 
 
 
Figure 2.10: Whole genome assembly script pipeline from raw sequencing reads. 
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 Phage genome annotation 
Annotation of all study phage and downloaded phage genomes was done from 
scratch using the same protein database as this ensured that each annotation will 
be the most up to date and will be the same for all phage. Open reading frames 
(ORFs) were predicted and annotated with the Prokka v1.12 software tool [238] by 
searching against the Phaster viral protein database (http://phaster.ca/databases) 
using default parameters. The script used was as follows:- 
 
The genomes were visualised using Artemis [236] to locate target sequence 
features and protein sequences. Translated ORFs that were initially annotated as 
hypothetical proteins were characterised and compared with known proteins 
using BLASTp, HHpred and HMMER providing further insight in to predicted protein 
function [239,240]. 
 
Prokka 
Build database 
prokka -- setupdb /location/of/database 
 
Prokka search  
prokka –outdir <outdir/Phage_prokkaout> --proteins <inputdir/protein_database.db --
locustag <Phage> --prefix <Phage> --genus Caudovirales <inputdir/phage_assembly.fasta> 
 
 
 
 
 
 
 
Figure 2.11: Prokka script used to annotate all phage genomes in this study. 
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 Comparative genomics 
A neighbour-joining tree was constructed using mash distances using Mashtree 
[241], the resulting phylogenetic tree was transformed to a cladogram and 
subsequently converted to Newick format using FigTree v1.4.3 [242]. For pairwise 
comparisons, Mash sketches were performed for each of the phage assemblies 
using a default sketch size of 1000, resulting in a single all.msh file using a script 
(http://s3.climb.ac.uk/ADM_share/run_mash_on_dir.pl) kindly provided by Dr 
Andy Millard (University of Leicester, UK). To compute all-against-all pairwise 
distances among the phage genomes, we employed Mash using the all.msh output 
file [243]. The matrix file was converted by subtracting the similarity value from 1 
(e.g 0.2 becomes 0.8 = 80 %), The Mash distance matrix was visualised using the 
heatmaply package in RStudio [244,245].  
 
Prokka outputs of annotated genomes were used to conduct pan-genome analyses 
to determine the core and accessory genomes of all study phage. Construction and 
interrogation of the pan-genome was achieved using Roary with the high speed 
multiple sequence alignment program (MAFFT) option using default minimum 
protein BLAST identity at 95 % [246]. Visualisation of pan-genome for all phage and 
each subsequent cluster was achieved with the interactive visualisation tool 
Phandango, by using the Roary gene presence/absence output table and the Mash 
distance tree in Newick format [247]. Genome comparisons were performed using 
BLAST ring image generator (BRIG) and aligned using Easyfig [248,249]. 
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Predicted proteins were further compared to known proteins using HH-suite [250], 
for this, protein FASTA output files of the multiple translated CDS sequences for 
each phage sequence were split into individual FASTA files containing a single 
sequence using splitfasta.pl tool in the HH-suite software package 
(https://github.com/soedinglab/hh-suite). Each file was searched against the 
PDP70 database, outputs produced an individual file for each gene with a summary 
hit list with a minimum of ten alignments with an E-value cutoff in result alignment 
of 0.00001, a maximum E-value in summary and alignment list of 0.00001 and 
maximum coverage with master sequence of 80 %. The scripts used were as 
follows:- 
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Mashtree 
mashtree numcpus 12 <inputdir/*.fasta> > <outdir/allmash.dnd> 
 
Mash 
Mash dist -t <inputdir/all.msh> <inputdir/all.msh> > <outdir/all_v_all.txt> 
 
Heatmaply 
Heatmaply (all_v_all_with_percentage, hclust_method=”average”, sym=”T”, 
main=”Staphlococcal_Phage”, branches_lwd=0.4, k_row=10 , k_col=10, 
margins=c(NA,100,120,40),  file=”Staphylococcal Phage.html”) 
 
Roary 
roary -f <outdir/> -e -n *.gff 
 
hhsearch 
hhsearch -Z 10 -e 0.00001 -E 0.00001 -cov 80 -i <inputdir/*.faa> -d <inputdir/hh-
suite/Databases/pdb70> 
 
 
 
 
 
 
 
Figure 2.12: Pipeline script used to perform comparative genomics of phage genomes. 
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Isolation of novel lytic phage 
infecting S. aureus  
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 Introduction 
Staphylococcus aureus is a global cause of hospital- and community-associated 
infections that range in severity from simple skin and soft tissue infections to life 
threatening infections including sepsis, endocarditis and necrotising pneumonia 
[251]. Its versatility has enabled it to adapt to the selective pressures of antibiotics 
where it serves as a reservoir for antibiotic-resistant genes within healthcare 
settings. With resistance to all -lactam antibiotics, methicillin-resistant S. aureus 
(MRSA) infections are often difficult to treat presenting a major healthcare burden. 
Invasive MRSA infections are usually treated with the glycopeptide antibiotic 
vancomycin, which requires intravenous infusion but this is a nephrotoxic agent 
requiring enhanced patient monitoring [252,253]. Resistance to vancomycin is rare 
[254], but MRSA with reduced susceptibility (Vancomycin Intermediate S. aureus – 
VISA), are much more common [255–257].  
 
Alternatives to vancomycin exist including linezolid and daptomycin, of which, both 
have received regulatory approval for use in treating complicated skin and soft-
tissue infections [85,258]. However, resistance has emerged to all antibiotics used 
to treat S. aureus and already daptomycin-nonsusceptible phenotypes have been 
observed in 38 to 83 % of VISA isolates [259]. There is an acute need for new drugs 
or regimens to treat infections caused by this species. Alternatives or adjuncts to 
antibiotic chemotherapy were listed in a 2016 report aimed at prolonging the 
useful life of antibiotics [260]. In this article bacteriophage (phage) therapy was 
highlighted as being potentially useful based on its history of safe and effective use 
in some countries. 
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Attractive features of obligately lytic phage that would be considered for their use 
in human medicine would include a short adsorption time with a relatively short 
generation time inside of its host, in addition to producing a high number of viral 
progeny (burst size) following lysis [261]. This would ensure rapid killing of target 
cells and a reduction in the chances of bacteria developing resistance to phage 
infection [159,262], traits that are highly desirable when considering their use 
within therapy.  
 
The first phase of this project was the isolation and characterisation of a collection 
of lytic phage. Although phage are generally very abundant in nature, phage 
infecting a particular species will not be present in the absence of their bacterial 
host. Recovery of phage from environmental sources where bacterial and phage 
numbers are low can be enhanced through enrichment of samples with large 
numbers of a suitable host species to promote the amplification of phage infecting 
the species of interest [263,264]. S. aureus phage have been isolated from water 
courses, soils and foodstuffs and directly from animal and human faeces. However 
the richest sources according to most previous studies are sewage / wastewater 
treatment sites [261,265,266], although isolation from such sites has proven 
challenging to others [267]. Staphylococcal phage have been recovered from such 
samples have displayed extensive host ranges compared to phage infecting other 
species [261]. Two of the most commonly described S. aureus phage groups are 
the Twort-Like (TL) myoviruses and lytic podoviruses (LP) [112,158,205,211,268–
270] which have been used to successfully treat human S. aureus infections 
[271,272]. Several of which have demonstrated a polyvalent nature capable of 
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infecting and killing 70 to 90 % of all clinical S. aureus isolates tested against 
[187,188,269,273,274].  
 
In most published studies that include the isolation of novel phage several 
techniques are generally used in characterising these new entities.  Phage fitness 
studies help determine the overall growth characteristics of each individual phage, 
including adsorption rate, generation time, burst size, in addition to understanding 
their stability under different storage conditions and temperatures. Electron 
microscopy can reveal morphological features to help better characterise the 
phage and is used as a major criterion for phage classification [275]. Additionally, 
it is considered that one of the most important criterion when deliberating the 
phage therapeutic potential, is its host range, and specificity against test strains. If 
the host range is too specific this may limit its therapeutic potential, conversely, 
phage exhibiting a broad host range (polyvalence), capable of infecting, a large 
number of bacterial hosts, may not lack virulence potential, i.e. high burst size, 
latent period and required phage dose [276]. The phage can also be studied in 
liquid culture to examine their in vitro kill dynamics and as well as the emergence 
of phage resistant mutants [262,264,277]. These studies will help determine 
whether the phage is capable of killing the bacterial host through infection and 
lysis by phage proteins, and not caused through the ‘lysis from without’ 
phenomenon. An event when phage are able to kill bacteria without intracellular 
replication, as the bacteria is lysed induced by a multiplicity of phage adsorption, 
thus puncturing the bacterial membrane [278], 
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This chapter focuses on the isolation and characterisation of novel lytic S. aureus 
phage and examines their efficacy against a large panel of methicillin - sensitive 
(MSSA) and – resistant (MRSA) isolates.  
 
 Methods 
 Sample site 
Environmental samples were collected from several locations around the north 
west of England. Initially, animal samples were collected from Fields Farm in 
Castleton, in the heart of the Peak District National park 28 miles southeast of 
Manchester and 16 miles west of Sheffield. Samples were also collected from 
Chelford livestock market, 19 miles south of Manchester (Figure 3.1).  
Figure 3.1: Animal sampling site locations. 
A) Fields Farm Castleton(Derbyshire, UK), and B) Chelford Cattle Market (Cheshire, UK). 
 
                     A 
 
B 
91 
 
 
Davyhulme wastewater treatment works (WwTW) is United Utilities largest WwTW 
serving 1.5 million people for the Greater Manchester conurbation, where it also 
processes the sludge imports from other WwTWs including Eccles WwTW. 
Figure 3.2: Wastewater treatment works sample sites.  
A) Davyhulme Wastewater treatment works (WwTW), inlet (green), primary settlement tanks 
(blue) and ASP tanks (red). The location of Eccles WwTW and its proximity to Davyhulme has been 
marked. B) Eccles WwTW site layout. 
Eccles WwTW 
A 
 
 
 
 
 
 
 
B 
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Davyhulme consists of two parallel aerated sludge process tanks (ASP1 and ASP2) 
made up of 8 separated lanes each, directly downstream of the inlet Figure 3.2A. 
Eccles WwTW is located just up the canal from Davyhulme WwTW and serves a 
population equivalent of ~117,000 as of 2018. The primary treatment at Eccles is  
made up of four primary settlement and sludge tanks with eight biological filter 
chambers although no sludge treatment on-site Figure 3.2B.  
 
 Bacterial Strains 
A modified Staphylococcus carnosus strain, TM300 kindly provided by Dr Guoqing 
Xia (University of Manchester, UK) was used to increase the chances of isolating 
novel lytic bacteriophage from environmental samples, as well as purify and 
propagate. The antibiotic-resistance marker carried by the TM300 allows all 
enrichment media to be supplemented with chloramphenicol (10 μg/mL) that 
would allow the selective growth of TM300. Additionally, an alternate host S. 
aureus D329 was also used for when sample enrichments didn’t produce plaques 
on TM300.  
 
The bacterial strains used in this study to evaluate the lytic ability of the phage 
collection are listed in Appendix A. The panel is made up of 185 major methicillin 
–  sensitive (MSSA) and – resistant (MRSA) clones from human and animal sources, 
consisting of 56 different Sequence Types (ST) based on multilocus sequence 
typing (MLST) see section 1.3.3.1. 
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 Results  
 Isolation of staphylococcal phage using samples enrichments 
Samples were originally collected from four sources, Castleton, Chelford, Eccles 
and Davyhulme wastewater treatment works (WwTW) sporadically over a period 
of a year. However, animal samples were collected until the closure of Chelford 
livestock market in 2017, and collections from Eccles were discontinued as no 
phage plaques were observed following sampling over a period of several months. 
The activated sludge process (ASP) treatment primarily exploits the use of 
microorganism to break down and metabolise organic matter, therefore each 
sample should contain extremely high densities and diverse communities of 
microorganisms. On average, 12 to 16 wastewater samples were collected from 
different lanes of the two ASP tanks across Davyhulme WwTW on a weekly basis 
for several months.  
 
 Plaque morphology 
Phage that were found present in animal faecal samples produced pinpoint sized 
plaques that were often difficult to pick and purify, these phage were also 
inconsistent when attempting to propagate and produced very low titre lysates. 
The screening of around 150 wastewater samples collected from ASP tanks at 
Davyhulme WwTW, yielded 46 lytic bacteriophage following centrifugation and 
sample enrichments with the selected host strains. The plaque morphologies of 
each phage were circular with smooth edges and generally rather small, some with 
halos but could not be propagated. Plaques varied in size mostly ranging from less 
than 0.5 mm to 1.5 mm, with EW36 and EW41 producing the largest ranging from 
94 
 
1 – 2 mm and can be seen in Table 3.1. The phage isolated from Davyhulme were 
found to produce significantly larger plaque with more defined edges than the 
phage isolated from animal faeces  
 
However, morphological diversity of plaques were still observed even when phage 
were subjected to several rounds of plaque purification (Figure 3.3). It was also 
noted that a number of phage produced different plaque morphologies when 
determining which host to propagate on.  
 
  
Figure 3.3: Plaques visible on host TM300 using enriched sewage samples collected from Davyhulme 
wastewater treatment works, UK. 
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Phage Host  Plaque size  Source  
EW 1 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 2 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 3 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 4 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 5 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 6 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 7 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 8 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 9 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 10 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 11 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 12 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 13 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 14 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 15 S. carnosus TM300 1 - 1.5 mm Davyhulme WwTW, UK 
EW 16 S. carnosus TM300 1 - 1.5 mm Davyhulme WwTW, UK 
EW 17 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 18 S. carnosus TM300 1 - 1.5 mm Davyhulme WwTW, UK 
EW 19 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 20 S. aureus D329 1 - 1.5 mm Davyhulme WwTW, UK 
EW 21 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 22 S. carnosus TM300 1 - 1.5 mm Davyhulme WwTW, UK 
EW 23 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 24 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 25 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 26 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 27 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 28 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 29 S. aureus D329 0.5 - 1 mm Davyhulme WwTW, UK 
EW 30 S. aureus D329 < 0.5 mm Davyhulme WwTW, UK 
EW 31 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 32 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 33 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 34 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 35 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 36 S. carnosus TM300 1 - 2 mm Davyhulme WwTW, UK 
EW 37 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 38 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 39 S. carnosus TM300 < 0.5 mm Davyhulme WwTW, UK 
EW 40 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 41 S. aureus D329 1 - 2 mm Davyhulme WwTW, UK 
EW 42 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 43 S. carnosus TM300 0.5 - 1 mm Davyhulme WwTW, UK 
EW 44 S. aureus D329 0.5 - 1 mm Davyhulme WwTW, UK 
EW 45 S. aureus D329 0.5 - 1 mm Davyhulme WwTW, UK 
EW 46 S. aureus D329 1 - 1.5 mm Davyhulme WwTW, UK 
 
Table 3.1: Isolated staphylococcal phage on their respective host and their plaque size 
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In order to identify the most effective phage against our current panel of bacterial 
isolates, a collection of 32 staphylococcal phage from previous studies were re-
isolated and propagated onto one of the two hosts mentioned above. A collection 
of seven phage were kindly provided from Dr Guoqing Xia (University of 
Manchester, UK), the remaining 25 phage were selected from a collection provided 
by Professor Mark Enright (Manchester Metropolitan University, UK) and Dr Diana 
Alves (University of Bath, UK). In total, the collection consisted of 78 lytic phage. 
Concentrated crude lysates were produced from single plaques after three rounds 
of propagation, with titres ranging from 107 – 1010 pfu/mL, phage lysates were 
normalised to the same titre of roughly 106 pfu/mL for further experiments. 
 
 Phage Host range 
The host range of each phage was determined by spotting purified phage lysates 
onto soft agar overlays containing S. aureus using 185 genetically diverse S. aureus 
isolates based on MLST. The determination of the host range for each phage was 
classified based on the degree of clearing on the bacterial lawn following the spot 
test method (section 2.5, Figure 2.4). Phage varied from each other considerably: 
1 - Complete lysis, 2 - Clearing but hazy 3 - Turbid, 4 – Slight disturbance with 
individual plaques (could possibly be prophage induced from host) as observed in 
Figure 3.4. Phage that were able to produce ‘bullet hole’ spots with almost 
complete clearing but still had a number of phage resistant mutant colonies 
present within the zone of clearing, were classed as intermediate (Figure 3.5). 
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Overall, the majority of the phage exhibited a broad host range capable of infecting 
a large proportion of the S. aureus collection tested against, 40 out of the 78 phage 
used in this study were capable of infecting over 90 % panel. From the collection, 
15 were capable of disrupting the growth of over 95 % (178 / 185) of the panel. 
The most effective phage were EW70 and EW71 that were capable of infecting 184 
out of the 185 isolates tested against. The one resistant isolate was a MRSA252 
phage K mutant isolate, acquired from Dr Diana Alves (University of Bath, UK). 
EW70 and EW71 capable of completely clearing 53 % (96) and 55 % (101) of the 
184 isolates it can infect respectively. When considering the phage ability to cause 
intermediate and complete lysis to the lawns of the test panel, the phage that was 
most capable of causing complete lysis was EW74 clearing 59 % (107) of the 183 
isolates it can infect, with the lowest consistency of producing phage mutant 
colonies within the cleared zones.  
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Interestingly, both EW16 and EW17 were only able to infect 59 % (109) and 63 % 
(116) isolates of the 185 isolates in the panel. But of those isolates that they could 
infect, they were both able to cause complete clearing of the host lawn for 51 % 
(59) and 52 % (57) of the 109 and 116 isolates respectively.  
     
 
 
                                        
           A       B3     
 
 
    
       B2              
 
 
 
       C                            B1 
Figure 3.4: Host range assay of 16 EW phages on host FIN 76167.  
Plaque formation was scored based on the level of clearing, A) Resistant with no disturbance to lawn, 
B) Intermediate varied from B1 – Few plaques with slight disturbance to lawn, B2 – Substantial 
turbidity throughout clear zone, B3 – High degree of clearing of with numerous mutant colonies 
present, C) Sensitive with complete clearing of bacterial lawn. 
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Figure 3.5: A selection of study phages spotted on to the lawns of a number of genetically diverse S. 
aureus isolates 
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Each host range was performed in triplicate, a number of phage were found to 
create complete clearing of the bacterial lawn on all three plates with one of the 
replicates producing phage resistant mutant colonies. In this case they were 
classed as sensitive, whereas if two of the three plates had mutants then it would 
be classed as intermediate by majority.  
  
Phage
Isolates 
Resistant
Isolates 
Intermediate
Isolates 
Sensitive
Coverage Phage
Isolates 
Resistant
Isolates 
Intermediate
Isolates 
Sensitive
Coverage
EW1 80 104 1 56.76% EW40 17 158 10 90.81%
EW2 80 104 1 56.76% EW41 6 124 54 96.76%
EW3 27 149 9 85.41% EW42 6 163 16 96.76%
EW4 59 124 2 68.11% EW43 11 159 15 94.05%
EW5 26 153 6 85.95% EW44 44 112 29 76.22%
EW6 42 137 6 77.30% EW45 36 147 2 80.54%
EW7 48 117 20 74.05% EW46 65 116 4 64.86%
EW8 163 21 1 11.89% EW47 123 62 0 33.51%
EW9 70 110 5 62.16% EW48 60 122 3 67.57%
EW10 59 117 9 68.11% EW49 14 147 24 92.43%
EW11 97 83 5 47.57% EW50 139 41 5 24.86%
EW12 71 112 2 61.62% EW51 15 151 19 91.89%
EW13 82 100 3 55.68% EW52 6 152 27 96.76%
EW14 80 101 4 56.76% EW53 27 149 9 85.41%
EW15 7 119 59 96.22% EW54 16 94 75 91.35%
EW16 69 57 59 62.70% EW55 76 96 13 58.92%
EW17 76 52 57 58.92% EW56 19 119 47 89.73%
EW18 3 98 84 98.38% EW57 16 116 53 91.35%
EW19 70 59 56 62.16% EW58 14 107 64 92.43%
EW20 71 60 54 61.62% EW59 13 101 71 92.97%
EW21 18 109 58 90.27% EW60 12 84 89 93.51%
EW22 26 102 57 85.95% EW61 13 99 73 92.97%
EW23 37 119 29 80.00% EW62 12 94 79 93.51%
EW24 30 139 16 83.78% EW63 12 99 74 93.51%
EW25 46 130 9 75.14% EW64 11 97 77 94.05%
EW26 7 116 62 96.22% EW65 13 107 65 92.97%
EW27 5 126 54 97.30% EW66 12 96 77 93.51%
EW28 19 146 20 89.73% EW67 11 94 80 94.05%
EW29 6 142 37 96.76% EW68 11 97 77 94.05%
EW30 16 158 11 91.35% EW69 10 103 72 94.59%
EW31 19 154 12 89.73% EW70 1 88 96 99.46%
EW32 54 122 9 70.81% EW71 1 83 101 99.46%
EW33 19 160 6 89.73% EW72 5 91 89 97.30%
EW34 36 138 11 80.54% EW73 13 95 77 92.97%
EW35 4 169 12 97.84% EW74 2 76 107 98.92%
EW36 7 164 14 96.22% EW75 8 81 96 95.68%
EW37 14 167 4 92.43% EW76 10 83 92 94.59%
EW38 36 148 1 80.54% EW77 13 89 83 92.97%
EW39 142 41 2 23.24% EW78 10 85 90 94.59%
Table 3.2: Percentage coverage of EW phage against 185 S. aureus isolates.  
The phage host range is scored as Resistant, Intermediate and Susceptible based on the level of clearing on 
the host lawn. Percentage coverage is the cumulative number of isolates that displayed intermediate and 
sensitive susceptibility to phage. 
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 Phage nomenclature 
Phage isolated in this study and the phage provided from previous stocks were 
initially named EW(n) until the phage morphology and/or family is determined (e.g. 
EW1). Once sequenced they were deposited on to public databases, the phage 
were renamed as vB_SauM_EW(n) but still referred to as EW throughout this 
study. The name denotes a virus of Bacteria with S. aureus Myovirus morphology, 
named EW(n). 
 
 Growth kinetics of bacterial hosts 
The growth kinetics of two bacterial strains -TM300 and D329 that were used for 
isolation and propagation and strains MRSA252 and 15981 were used to study 
phage lytic ability (Figure 3.6). These were also useful when determining the 
appropriate time point to apply phage during phage growth curve studies, in order 
to ensure that all host strains used were in log phase when phage were introduced. 
Additionally, measuring the CFU at different optical densities was essential when 
calculating the multiplicity of infection (MOI) of phage in order to eliminate the 
‘lysis from without’ phenomenon, the MOI chosen for this study was 0.1. This was 
also important, as the growth curves indicated the appropriate timings for each 
bacterial host when it reaches the mid-exponential growth phase. Which is helpful 
when attempting to determine the phage growth parameters through adsorption 
time and one step growth curve experiments.  
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TM300 displayed the longest lag phase (4 h) among the four strains, over 2 hours 
longer than the others. Once TM300 entered log phase, bacterial concentration 
increased exponentially within a much shorter period of time compared to the 
other hosts, peaking around 11 hours, then immediately began to decline as it 
entered death phase. Whereas with D329, MRSA252 and 15981, the lag phase of 
these strains was relatively short entering its log phase within 2 hours, followed by 
a steady growth rate that was still increasing by the 20 h time point. During the 
assay, it was observed that when 15981 and MRSA252 were both growing, they 
both have a tendency to form clumps and once big enough would eventually sink 
to the bottom of each well and/or universal tube, creating large sticky masses of 
bacteria despite regular shaking intervals throughout the assay which may have 
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Figure 3.6: Growth curve comparisons of four staphylococcal isolates.  
Three S. aureus strains D329 (Red), MRSA252 (Green), 15981 (Purple) and one S. carnosus TM300 (Blue) 
in TSB within a microtitre plate. Absorbance readings at 600 nm were taken using a plate reader every 
30 minutes for 19 hours whilst shaking at 37 ˚C, three independent experiments were performed in 
total. 
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had an effect on the readings. CFU counts and generation time for each host was 
determined by sampling at different bacterial concentrations of 0.2, 0.3 and 0.4 
OD540. CFU counts for each host at each selected bacterial densities remained 
consistent across all hosts throughout each growth curve assay except for timing 
of individual growth phases.  
 
 Time/kill assay of selected phage against planktonic S. carnosus TM300 
To elucidate the interactions between the selected phage and its host, we 
examined its ability to significantly reduce numbers in bacterial broth cultures and  
study the rate of phage resistant mutant emergence. The ten most effective phage 
– defined as those with the broadest host range were chosen for further analysis.  
 
 
Figure 3.7: Time-kill curve of mid-exponential phase planktonic S. carnosus TM300 by selected phage 
at a multiplicity of infection (MOI) of 0.1.  
Absorbance readings at 600 nm were taken using a plate reader every 30 minutes for 19 hours whilst 
shaking at 37 ˚C, three independent experiments were performed in total. 
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Suspensions of these ten phage were tested against strains TM300, D329, 
MRSA252 and 15981. Phage were introduced to growing cultures to achieve a 
multiplicity of infection (MOI) of 0.1, and incubated for 19 hours, with each 
experiment performed in triplicate. Killing curves of the ten phage against TM300 
are presented in Figure 3.7. Both EW41 and EW52, propagated on D329 were the 
only phage ineffective against TM300, the remaining eight phage were successful 
in reducing the growth of TM300 within 4 hours following introduction and 
preventing potential phage resistant mutants after 19 hours.  
 
 Time/kill assay of selected phage against planktonic S. aureus D329 
With strain D329, phage EW27 and EW29 initially took an hour longer than other 
phage before having any effect on the host as seen in Figure 3.8. However, both 
EW27 and EW29 effectively reduced the growth of D329 after four and six hours 
respectively, whilst preventing the emergence of phage resistant mutants. As for 
EW72, it was unsuccessful at depleting bacterial numbers before phage resistant 
mutants emerged after five hours, although this had an effect on the growth rate 
of D329 when compared to controls. Interestingly, an increase in bacterial density 
compared to the control was observed in D329 following addition of EW36. To 
elucidate the possibility of bacterial contamination within the lysate introduced in 
to the wells, loops were streaked out on to TSA plates and no bacterial colonies 
were retrieved following incubation.  
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Time/kill assay of selected phage against planktonic S. aureus MRSA252 and 15981 
Individual growth phases appear less clearly defined with MRSA252 when 
challenged with phage (Figure 3.9), which is also observed with strain 15981 
(Figure 3.10) It is clear that a number of phage could not effectively reduce 
bacterial numbers before resistant mutants emerge. A reduced rate of killing was 
observed among phage when challenged against other strains compared to their 
propagating hosts, decreasing bacterial numbers at a much more gradual rate, 
with some phage such as EW15 taking several hours. Interestingly, phage EW71 
and EW74 appeared to have a bacteriostatic effect on the strain 15981 with no 
change in absorbance observed for ~14 hours before slowly increasing.  
 
As observed in D329, EW36 seemed to have a positive effect on the growth 
characteristics of MRSA252 when compared to the control as a significant increase 
Figure 3.8: Time-kill curve of mid-exponential phase planktonic S. aureus D329 by selected phage at a 
multiplicity of infection (MOI) of 0.1.  
Absorbance readings at 600 nm were taken using a plate reader every 30 minutes for 19 hours whilst 
shaking at 37 ˚C, three independent experiments were performed in total. 
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in OD600  can be seen. The same trend was also observed with EW72 on the growth 
of 15981, however, only slightly more than the control. Interestingly, EW52 
appeared to have a brief positive effect on the growth rate of MRSA252 for a 
period of two hours when initially introduced to the wells, followed by a prolonged 
infection period in which MRSA252 appeared to increase in concentration 
momentarily, before eventually decreasing in bacterial density below the initial 
concentration after 15 hours.  
 
For all three S. aureus strains used, phage that were able to successfully reduce the 
optical density and prevent bacterial regrowth were able to achieve it within the 
initial eight hours relative to the control.  
 
 
Nevertheless, there were a number of phage including EW15, EW27, EW29 and 
EW52 that exhibited a lower degree of bacteriolytic ability against the selected 
Figure 3.9: Time-kill curve of mid-exponential phase planktonic S. aureus MRSA252 by selected phage 
at a multiplicity of infection (MOI) of 0.1.  
Absorbance readings at 600 nm were taken using a plate reader every 30 minutes for 19 hours whilst 
shaking at 37 ˚C, three independent experiments were performed in total. 
0 h 1 h 2 h 3 h 4 h 5 h 6 h 7 h 8 h 9 h 10 h 11 h 12 h 13 h 14 h 15 h 16 h 17 h 18 h 19 h
0.0
0.5
1.0
1.5
2.0
2.5
Time (h)
B
ac
te
ria
l d
en
si
ty
 (
O
D
 6
00
)
EW15
EW18
EW27
EW29
EW36
EW41
EW52
EW71
EW72
EW74
Negative Control
107 
 
hosts, taking up to ~13 hours to have any inhibitory and bactericidal effect on the 
bacteria. Both EW18 and EW52 experienced resistance from 15981. However 
EW52 was successful enough to reduce bacterial density eventually, whereas with 
EW18, although resistance did occur, it had implications on the growth rate of 
15981. When challenged with phage, 15981 was found to withstand infection the 
most, appearing to be the least susceptible to phage infection. Reductions to 
growth were at a much lower rate compared to other hosts and the appearance of 
phage-resistance was observed in a number of wells during each of the tests. 
 
 
 
EW41 was the most effective at inhibiting the growth of all three S. aureus isolates 
at the quickest rate as bacterial densities rapidly plummeted within two hours 
following application. However, EW41 was isolated and propagated on D329 which 
could be the reason why it had no effect on the growth of S. carnosus TM300.  
Figure 3.10: Time-kill curve of mid-exponential phase planktonic S. aureus 15981 by selected phage 
at a multiplicity of infection (MOI) of 0.1.  
Absorbance readings at 600 nm were taken using a plate reader every 30 minutes for 19 hours 
whilst shaking at 37 ˚C, three independent experiments were performed in total. 
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 Selection of top four phage 
A selection of four phage candidates were chosen for further study on the basis of 
their lytic characteristics Table 3.3. These exhibited unique growth characteristics 
as well as a broad host range against all isolates in the panel as described 
previously, whilst demonstrating a high efficacy in planktonic cultures - effectively 
and rapidly killing test strains whilst preventing the emergence of phage-resistant 
mutants. The four phage selected were EW27, EW36, EW41 and EW71. These can 
theoretically infect 99 % (n = 184) of all 185 bacterial isolates used in this study, of 
which 69 % (n = 128) are sensitive. 
 
Table 3.3: Top four phage selected following assessment of their lytic ability against the test panel of S. aureus 
isolates. 
 
  
Phage Host Isolates Intermediate Isolates Sensitive Total Coverage 
EW27 TM300 126 54 97.30 % 
EW36 TM300 164 14 97.84 % 
EW41 D329 124 54 96.76 % 
EW71 D329 83 101 99.46 % 
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 Discussion 
A collection of 78 phage was screened across a large panel of clinically relevant and 
genetically diverse S. aureus isolates including the major clonal groups with high 
prevalence within the UK and United States. This collection includes 32 
uncharacterised phage from previous studies that were kindly provided for this 
study, and 46 novel lytic bacteriophage that were successfully isolated following 
enrichments of sewage treatment samples collected from one of the largest 
wastewater treatment works in the UK.  
 
Phage are widely distributed in the environment and can be found present in 
various sources including wastewater samples, faecal matter, soil, sea and fresh 
water [279]. Numerous studies have relied heavily on wastewater and sewage 
samples as a reliable source to isolate a wide diversity of phage targeting 
Escherichia coli, Klebsiella spp. and S. aureus [187,280–283]. However, phage 
presence is largely determined by the existence of their bacterial host within that 
environment, and although abundant in nature, phage infecting a particular 
species / strain may be present in very low numbers in a given sample. An 
enrichment step therefore increases the chances of finding phages of interest from 
any particular sample where phage numbers may be low. 
 
 S. carnosus [284] and Staphylococcus xylosus [285]) have been used in previous 
studies to isolate and propagate staphylococcal phage as these species are 
avirulent in humans without the virulence factors found in S. aureus.  This should 
improve the safety of phage lysates intended for use in healthcare, food and 
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veterinary applications [285]. The acquisition of a modified S. carnosus TM300 was 
crucial to our study, the plasmid-encoded SaPI enables the expression of a S. 
aureus N-acetyl-D-glucosamine-modified ribitol-phosphate (RboP) repeating units 
of the wall teichoic acid on to the cell surface of the TM300. These are key phage 
receptors that may aid with phage adsorption, thus increasing the likelihood of 
phage isolation. By centrifuging and filtering the samples before enriching, it 
eliminated the nutrient competition between other bacterial species and allowed 
our TM300 host to grow unchallenged, resulting in an increased rate of detection 
and isolation of species-specific phage. The use of double strength TSB during 
enrichments further maximised the numbers of the growing host by ensuring 
plenty of nutrients were made available. This approach allowed us to isolate and 
purify 46 phage from roughly >150 wastewater samples over a period of several 
months. Achieving a mean hit percentage of 30 %, a significantly higher probability 
of isolating staphylococcal phage compared to the difficulties reported elsewhere 
[267]. With the addition of 32 uncharacterised phages kindly provided to us, we 
assembled a total collection of 78 phage isolates that were successfully propagated 
on either TM300 or S. aureus D329.  
 
The plaques produced when using the TM300 strain as a host were generally small 
and clear ranging from in size from < 0.5 – 1.5 mm, with EW36 and EW41 producing 
the largest with ‘bullet hole’ plaques between 1 and 2 mm. One interesting 
observation throughout the screening of samples, was a number of phage 
produced plaques with very small halos around them. Although very faint these 
results were often never replicated during purification effort, with similar 
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observations also mentioned previously [286]. The presence of these halos suggest 
the production of soluble enzymes that may have broken down the extracellular 
polymeric structures from the host strain, which have shown great potential for 
disrupting biofilms [226,287], as well as with previous phage studies using 
Pseudomonas putida and Klebsiella pneumoniae isolates [157,288].  
 
The specificity of each phage was determined using the spot test method against 
185 S. aureus isolates, consisting up of 56 different Sequence Types (ST). The host 
range of the phage is largely based on the level of clearing on the bacterial lawn 
when the phage is spotted on to it, the system used for assessing the success of 
infection is as mentioned previously [289], where any clearing scored as 1 – 3 were 
classed simply as intermediate. For this experiment, the host range was 
determined by taking into consideration both intermediate and sensitive results. 
Our phage collection was successfully able to infect 99 % (184 / 185) of the S. 
aureus isolates tested against, with 40 / 78 phage exhibiting a broad host range 
(polyvalent), defined as infecting >=90 % of study isolates.  
 
Phage EW70 and EW71 displayed the highest polyvalence and were able to disrupt 
the lawns of 184 of the 185 S. aureus isolates tested, completely clearing the lawns 
of 96 and 101 isolates respectively. However, the phage that was able to cause 
complete lysis (59 % - 107 / 183) among the susceptible isolates was EW74, also 
displaying the least turbidity or frequency of phage mutant colonies present within 
the cleared zones. As the majority of the phage collection were isolated from 
environmental sources, it was interesting to see a large proportion of the phage 
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have lytic capabilities against almost all S. aureus isolates from both clinical and 
animal samples. Polyvalent phage are commonly isolated from natural microbially 
diverse communities, such as within Activated Sludge Process tanks (wastewater 
treatment works) where genetic exchange is highly common, and have shown to 
thrive and reach greater densities within that microcosm [290–292]. The extended 
host range of our phage collection suggest they have characteristics comparable 
to most S. aureus phage including the most effective Twort-like phage such as 812 
[293], Phage K [189] and ISP [294]. All of which have displayed substantial 
polyvalent activity against study isolates and suitable properties for potential 
therapeutic application. It must be noted that, the single strain resistant to the 
entire phage collection was a mutant phage-resistant MRSA 252 isolate, which was 
specifically chosen for this study in attempt to identify possible phage that could 
infect this mutant [187].  
 
Using the host range data, the ten most effective phage were selected to evaluate 
their killing ability against planktonic cultures of three S. aureus strains and S. 
carnosus TM300 over a period of time whilst shaking. Killing assays help study the 
lytic potential of each phage against selected hosts in a more dynamic 
environment. Providing a much more detailed representation of the bactericidal 
ability of each individual phage and allows us to observe the rate of killing and 
mutational events in both bacteria and phage over time. Initially, when performing 
the killing assays, absorbance readings were taken every 180 seconds. However, 
when formulating the time/kill graphs, only the measurements every 30 minutes 
were displayed in order to distinctly identify error bars for each time point. 
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Throughout these assays, mid-log cultures were exposed to the appropriate 
number of phages at a multiplicity of infection (MOI) of 0.1, in this environment 
phages have to adsorb to the host through random collisions rather than spotted 
on to a static lawn of bacteria [295]. By doing this at an MOI of 0.1, it not only 
reduces the amount of phage/host collisions but also decreases the probability of 
the ‘lysis from without’ phenomenon, a potential limitation from using the spot 
test assay to determine the phages lytic ability [168]. When applied at low 
concentrations (MOI 0.1), phage must infect and replicate enough to increase 
plaque forming units to surpass the rate of replication for the bacterial host. Which 
would explain why most hosts continued to grow for at least one hour following 
introduction. In similar studies comparing phage infection at various MOIs [296–
298], the greater the MOI the more effective the phage was in the study. Which, 
presumably was largely due to the increased rate of phage collisions and infections, 
thus leading to higher densities in viral progeny in a shorter time frame. As well as 
an increased probability of possible lysis from without as mentioned above. A 
decline in the optical density (600 nm) throughout the entire experiment was 
considered to be caused by phage lytic activity for all three S. aureus hosts, 
whereas with S. carnosus TM300 a slight decline was expected after 10 hours 
based from the growth curves. It was observed that the lag phase for TM300 was 
two hours longer than the three S. aureus hosts used, we suspect that this may be 
due in part to the presence of the modified plasmid it needs to replicate every 
growth cycle.  
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In the current study, all of the ten phage selected were able to infect at least one 
of the four strains tested against, six of which were able to infect and significantly 
reduce the growth of at least two S. aureus isolates. It is interesting to see the 
variation of results every phage has against each individual isolate. EW41 was 
found to be the most effective under planktonic conditions, and was able to 
immediately reduce the bacterial concentration preventing the regrowth of all 
three S. aureus isolates, yet had no effect on the S. carnosus isolate. As it was 
propagated on a S. aureus host, the specificity may be limited to just this species.  
Throughout the killing assays, EW15, EW18, EW36 and EW72 had no effect on the 
growth of at least one of the three S. aureus hosts to some degree. However, phage 
that were effective were able to prevent the appearance of resistant mutants 
throughout the duration of the experiment. It was interesting to note that when 
resistance did occur, the growth rate and fitness for these phage-resistant cells was 
clearly affected and did not recover to the levels achieved by uninfected controls. 
This suggests that resistance to phage infection was at the expense of growth 
capacity for those cells [299,300]. Spontaneous resistance mutation can be 
associated with changes to the host-specific receptors found on the bacterial cells 
surface to what the phages adsorb to in order to initiate infection [301]. This could 
also have an effect on the cells ability to take up nutrients from the environment 
[302]. 
 
When applied at low concentrations (MOI 0.1), phage must infect and replicate 
enough to increase plaque forming units to surpass the rate of replication for the 
bacterial host. This would explain why most hosts continued to grow for at least 
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one hour following introduction. In similar studies comparing phage infection at 
various MOIs [296–298], the greater the MOI the more effective the phage was in 
the study. Which, presumably was largely due to the increased rate of phage 
collisions and infections, thus leading to higher densities in viral progeny in a 
shorter time frame. As well as a more increased probability of possible lysis from 
without as mentioned above. 
 
  
116 
 
  
 
Phage-mediated dispersal of S. 
aureus biofilms 
 
 
 
 
 
 
 
 
 
 
 
  
117 
 
  Introduction 
In the previous chapter, four phages were isolated that have high lytic efficiency 
and virulence against a panel of S. aureus isolates under static and planktonic 
growth conditions. These phages were further characterised for their anti-biofilm 
properties against a test panel of clinical S. aureus isolates belonging to two major 
MRSA lineages with global prevalence. 
 
 Staphylococcus aureus pathology 
Staphylococcus aureus is one of the most common causes of biofilm-associated 
and device-related infections within healthcare. The bacterium presents a burden 
for healthcare systems and patient safety as it commonly colonises chronic wounds 
and the surfaces of indwelling medical devices such as intravenous catheters, 
cardiac pacemakers and joint prostheses [53,54]. Such infections are often difficult 
to treat using conventional antibiotics, with medical devices having to be replaced 
much more frequently compared to those infected by other staphylococcal species 
[55]. A notable characteristic of S. aureus biofilms is their ability to produce vast 
amounts of EPS, composed of teichoic acids, polysaccharide intercellular antigens 
(PIA), DNA and staphylococcal / host protein components [29]. Their success in 
biofilms can be linked to their ability to produce an array of proteins known as 
microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMS), that can help manipulate the human host defence, aid in adherence 
and attachment to the surface of cells, tissues and prosthetic devices [18]. Their 
decreased susceptibility to antimicrobial agents contributes to their persistence in 
infection.  
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S. aureus biofilms can be major foci of infection with detachment and dispersal of 
aggregates through the vascular system leading to colonisation of new niches. This 
can result in progression of disease from, for example, wound infection to 
disseminated / systemic disease including endocarditis, necrotising pneumonia, 
meningitis and septicaemia [56]. S. aureus is endemic in hospital environments, 
and is also a major cause of community-associated infections. These are typically 
skin and soft tissue MSSA infections but in some locales and population groups 
community-associated MRSA infections (CA-MRSA) are common in the absence of 
the risk factors associated with healthcare-associated infections [57]. 
 
The local, national and international emergence and transmission of major MRSA 
clones is a highly dynamic process that can be simply characterised as epidemic 
waves corresponding to the emergence, spread and eventual decline of clones 
with novel MSSA genetic background / SCCmec combinations [83]. The vast 
majority of major epidemic MRSA isolates belong to five distinct lineages or clonal 
complexes (CCs) named after their founder sequence type (ST) CC5, CC8, CC22, 
CC30, and CC45 [81,82].  
 
ST22 MRSA is the major lineage associated with invasive disease in healthcare 
within the UK. The rapid dissemination of epidemic MRSA clones belonging to ST22 
followed its emergence in the UK in the early 1990s. It then spread across Europe 
reaching with cases reported in Australia, the Middle- and Far- East [91] where it 
still remains prevalent [303]. In contrast to ST22, ST36 is frequently isolated in the 
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UK, however its prevalence has declined more rapidly and is not perceived as 
successful as ST22 Table 4.1, including other countries as mentioned above [304]. 
Members of the CC30 lineage include epidemic clone EMRSA-16, isolates of ST36 
have are pandemic, found in both hospital and community settings and responsible 
for many major outbreaks [88]. 
 
 
 Model biofilm systems 
Evaluating the antimicrobial effects of phage in planktonic bacterial cultures may 
provide useful preliminary data on the potential utility of a phage strain, however 
their behaviour in experimental biofilm systems may be closer to the in vivo 
situation. A number of studies have demonstrated that bacteria embedded within 
biofilms exhibit very different behaviour and physiology compared to their 
planktonic counterparts [305,306] and therefore the effects of any antimicrobial 
agent should be tested under such conditions. Studies using biofilm models may 
be a good way to determine the pathogenicity of some species due to the varying 
levels of biofilms produced from individual isolates [223]. 
 
Table 4.1: Proportion of EMRSA-15 (ST22 - CC22) and EMRSA-16 (ST36 - CC30) isolates collected from 25 clinical 
laboratories within the UK and Ireland during four study years (2001,2004, 2005 and 2007) [92]. 
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There are several experimental model biofilm platforms that have been 
established to simulate the in vivo environment to help address fundamental 
questions about biofilm structure and physiology. Data using these models can 
help provide preliminary empirical data to guide future in vivo (animal model) and 
hopefully, human therapeutic studies. 
 
 Lytic phage as biocontrol agents 
The experimental use of phage and their derivatives have been demonstrated in 
many studies as a means of targeting and controlling clinically relevant pathogens 
responsible for biofilm-associated infections. Their ability of phage to self-replicate 
at the site of infection, increasing in numbers thus requiring smaller initial doses 
makes phage an appealing choice as an alternative or complimentary therapeutic 
agent. Whole phage have been observed to penetrate the glycocalyx reaching 
deep-lying bacterial cells within the biofilm matrix that were previously protected 
[307]. Studies have also used phage lytic enzymes that target the key components 
of the biofilm matrix, causing the biofilm biomass to detach and disperse whilst 
demonstrating promising results in the control and prevention of biofilms 
[308,309]. Such enzymes include holin, lysin and depolymerases that target the 
host cell wall, and thus have the potential to degrade the biofilm matrix as 
discussed in section 1.4.5. 
 
Phage candidates for human therapeutic use should ideally be obligately lytic and 
polyvalent - capable of infecting multiple strains of a pathogenic bacterial species. 
Such phage may have potential as biocontrol agents in S. aureus biofilm models. 
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The most effective and frequently studied are the S. aureus phage belonging to the 
Twort-like myoviruses [187,202,204,294] and lytic podoviruses [270,309,310].  
These have good bactericidal activity in both in vitro and in vivo models, infect 
multiple strains of S. aureus including MRSA isolates as well as coagulase-negative 
staphylococcal (CONS) species [5]. 
 
  Extended methodology 
 Bacterial strains  
S. aureus strain 15981 was used in initial biofilm studies to help optimise growth 
conditions as this strain is an abundant biofilm producer with excellent adherence 
properties [198,311,312]. However this strain was not used throughout this project 
as the aims of this work were to characterise lytic phage activity against isolates of 
clinically important MRSA lineages. S. aureus ST22 and ST36 isolates used in this 
study are listed in Table 4.2, 14 ST36 isolates were kindly provided by Professor 
Ross Fitzgerald (The Roslin Institute, University of Edinburgh, UK) to increase the 
variety of study isolates. Isolates selected for this study were chosen on the basis 
that the majority of their isolates had their genomes sequenced and were publicly 
available. This was to allow for potential future genome-wide association studies 
(GWAS) to identify genetic associations with biofilm formation and phage 
susceptibility phenotypes. 
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Isolate  ST Accession  Isolate ST Accession 
1018.07 22 SAMEA957299   M810 08 22 SAMEA957236  
1091 22 SAMEA957277   NL011399-5 22 SAMEA957209  
370.07 22 SAMEA957217   RH 0600 0061/09 22 SAMEA957269  
403.02 22 SAMEA957188   SwedenAO9973 22 SAMEA957194  
434.07 22 SAMEA957182   T277 06 22 SAMEA957222  
723.07 22 SAMEA957184   T505 30 22 SAMEA957234  
729192 April 22 SAMEA957186   W449 36 22 SAMEA957235  
921.07 22 SAMEA957210   WW1678/96 22 ERS034629 
930.02 22 SAMEA1030324   UK96/32010 36 SAMEA957275  
98.4823.X 22 SAMEA957295   NottmA2 36 SAMEA957246  
98/10618 22 ERS002153   NottmA 36 SAMEA957262  
99ST18131 22 SAMEA957293   MRSA252 36 BX571856.1 
AR 0650 784 22 SAMEA957185   H352 36 Not Available 
ARI 10 22 SAMEA957259   H119 MRSA 36 SAMEA957179  
ARI 11 22 SAMEA957266   FIN75916 36 SAMEA957178  
ARI 12 22 SAMEA957203   EMRSA 16 36 SRS003281 
ARI 26 22 SAMEA957298   CDC 960758 USA 200 36 SAMN02314232  
ARI 29 22 SAMEA957258   BTN 766 36 Not Available 
ARI 31 22 SAMEA957255   BTN 2292 36 SAMEA957180  
ARI 4 22 SAMEA1030317   BTN 2172 36 SAMEA957297  
ARI 5 22 SAMEA957218   BTN 1429 36 SAMEA957183  
ARI 7 22 SAMEA957177   98.5806.F
† 36 SRR453046  
BTN 1626 22 SAMEA957294   97.2483.Hb
† 36 SRR453045  
C101 22 SAMN02595338   07.7206.Y
† 36 SRR453044  
C720 22 SAMEA957287   07.6659.K
† 36 SRR453043  
EMRSA15-90 22 SAMN02767598   07.6636.Y
† 36 SRR453042  
F869 56 22 SAMEA957239   07.3481.N
† 36 SRR453041  
H182MRSA 22 SAMEA957195   07.2880.V
† 36 SRR453040  
H431 62 22 SAMEA957230   07.2589.M
† 36 SRR453039  
H65 22 SAMEA957286   07.2496.L
† 36 SRR453038  
H914 91 22 SAMEA957233   07.2449.K
† 36 SRR453037  
HO 5096 0412 22 HE681097  07.1696.F
† 36 SRR453034  
HO 5322 0548 09 22 SAMEA957260   07.1227.Z
† 36 SRR453033  
HO 7230 0407/05 22 SAMEA957292   06.9570.L
† 36 SRR453032  
HO 7374 0468 22 SAMEA957289   03.1791.F
† 36 SRR453031  
 
† Isolates kindly provided by Professor Ross Fitzgerald (Roslin Institute, UK) 
 
 
Table 4.2: List of clinical S. aureus strains with their sequence type (ST) and accession. 
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 Phage on biofilm study 
For this study, a closed-system biofilm model was selected as the experimental 
platform. This in vitro model system is the most commonly used method employed 
for studying bacterial biofilms in their simplest form, it was therefore considered 
to be a good platform to study the bactericidal properties of phage. To help 
optimise the system, three approaches were employed to investigate the 
difference in cell attachment and biofilm formation based on: i) Two preparations 
of liquid media - TSB and TSBg (supplemented with 1 % D-(+)-glucose) ii), Different 
concentrations of TSB media at 100 %, 75 %, 50 % and 25 %  iii) Using standard 
polystyrene or cell culture microtitre plates. 
 
Viable cells recovered from 48 h biofilms were enumerated in order to calculate 
the required multiplicity of infection for phage preparations according to each 
host. Phage lysates were initially prepared and diluted in the selected growth 
media used to support biofilm formation as above. 
 
  Results 
 Optimisation of biofilm growth conditions 
For this assessment, S. aureus 15981 was used due to its ability to form significant 
amounts of biofilm. Microtitre plates were incubated for 48 hour to allow biofilms 
to form, wells were washed twice, stained with crystal violet and allowed to dry. 
Dried biofilms were solubilised in 30 % acetic acid and their densities were 
measured at an OD590 nm. Higher levels of biofilms were present in wells containing 
TSB supplemented with 1 % D-(+)-glucose (TSBg) at concentrations of 100, 75 and 
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50 % TSBg when compared to wells with TSB alone. Biofilms grown in 100 % TSBg 
produced the highest levels of biofilm biomass with an average optical density of 
2.7 (590 nm). There was a significant difference between 100 % TSBg and 100 % 
TSB concentrations (p < 0.01), however, when 100 % TSBg was compared against 
other concentrations, there was no significant difference between 75 % TSBg, 75 
% TSB and 50 % TSBg. Additionally, when comparing biofilm densities between 
tissue culture and standard microtitre plates, there was no significant difference 
between media at the same concentrations. However, significant differences were 
observed when 100 % TSBg and 75 % TSBg grown in tissue culture plates against 
lower concentrations using standard microtitre plates. 
Figure 4.1: Relative biofilm formation of S. aureus isolate 15981 after 48 hour incubation within different 
growth conditions.  
Biofilms were assessed when grown in various concentrations of growth medium, with and without the 
presence of D-(+)-glucose using standard and tissue culture microtitre plates. Each assay was performed 
in triplicate, data presented as mean values ( standard deviation). 
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 Assessment of S. aureus ST22 biofilm production 
To identify appropriate candidates for use in future biofilm studies, a collection of 
43 S. aureus ST22 isolates were studied for their biofilm producing capabilities. It 
must be noted that, only ST22 isolates from our collection that have had their 
complete genome sequenced were included in this study. Experiments quantifying 
biofilm formation by 43 ST22 strains were assessed by crystal violet staining and 
their absorbance measured (OD590) using a FLUOstar Omega plate reader to 
determine the most abundant biofilm producing isolates. Biofilm densities of 
isolates are shown in Figure 4.2. The average optical density across all strains was 
0.254. A nominal value of 0.4 OD590 or above was consequently used to classify 
bacteria as strong biofilm producers. From the 43 strains, only seven were 
considered strong biofilms formers above the cut-off value, with isolates ARI 10 
and W449 36 producing the highest levels of biofilm production that were 
significantly different to all other strains in the collection (p < 0.001). Furthermore, 
there was no significant difference between the nine strains also above the 
threshold. From this work, four isolates - ARI 10, W449 36, 1018.07 and 370.07 
were selected for biofilm experiments using lytic phage.  
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 Assessment of S. aureus ST36 biofilm production  
A selection of 27 genome sequenced ST36 isolates were available for use in this 
study. The isolates ability to form biofilms was assessed as above in and can be 
seen in Figure 4.3. The majority of ST36 strains were capable of producing strong 
biofilms with an average optical density of 1.93. The level of biofilm formation had 
higher variance among ST36 strains compared to those produced by ST22 isolates, 
of the 27 strains within the collection, 25 produced biofilms with an OD of 1.2 or 
above. The two strongest biofilms formers – isolates 07.1696.F and 06.9570.L 
along with the two weakest biofilms formers BTN 2172 and 07.2496.L were 
selected for further study. Both BTN 2172 and 07.2496.L were selected on the basis 
that they produced biofilms corresponding to OD590 values below or equal to 1.2, 
which were similar to the best ST22 biofilm formers. It was thought that this would 
allow for better comparisons of phage activity between and within ST22 and ST36 
isolates. 
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 Enumeration of viable bacterial cells from 48 hour mature biofilms 
In order to quantify the number of viable cells in biofilms, and relate this to crystal 
violet absorbance, eight S. aureus isolates were selected for study. These 
compromised four ST22 isolates - ARI 10, W449 36, 1018.07, 370.07 and four ST36 
isolates - 07.1696.F, 06.9570.L, BTN 2172 and 07.2496.L. In order to obtain 
quantitative information about the composition of each biofilm, 48 hour mature 
biofilms were established and viable cell counts were performed as represented in 
Figure 4.4 These results show that the variation in biofilm biomass between 
strongest and weakest biofilm formers does not correlate to the number of viable 
cells present within the biofilms. In terms of colony forming units (CFU/mL) 
recovered from the 48 h biofilm, isolate 06.9570.L produced the highest viable cells 
found present within each biofilm (7.9x107 CFU/mL), whereas the lowest, from 
isolate 07.2496.L, had the fewest biofilm numbers (1.8x107 CFU/mL). There was a 
significant difference between recoverable cells present in the biofilms of isolates 
07.1696.F and 06.9570.L (p < 0.01) with isolate 06.9570.L producing twice as many 
cells, however there was no significant difference between the optical density 590 
nm of biofilm biomass. Interestingly, when comparing the CFU counts of isolates 
07.1696.F and 370.07 there is no significant difference between both, but they are 
very different as measured by optical density.  
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Figure 4.4: Biofilm densities of eight S. aureus, including four ST22 and four ST36 strains grown in cell 
culture-treated microtitre plates over 48 hours.  
A – Biofilms initially stained with crystal violet and optical density was measured at an absorbance of 
590 nm. Each assay was performed in triplicate, data presented as mean values ( standard deviation). 
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ST22 strains displayed a propensity to form moderately adhered biofilms that had 
significantly lower ODs than the best ST36 biofilm formers, yet they had 
consistently higher cell counts - similar to those values observed from ST36 
isolates. The levels of biofilm biomass developed by each of the ST22 and ST36 
isolates after 48 h can be can be observed by eye following crystal violet staining. 
The biofilms produced by S. aureus were found at the air-biofilm interface, 
although tended to form large aggregates leading to extensive solid-liquid 
colonisation at the base of the microtitre plate wells as pictured in Figure 4.5.  
 
 
 
  
ARI 10        W449 36 1018.07 370.07 
07.1696.F       06.9579.L BTN 2172 07.2496.L 
Figure 4.5: Variation in biofilm production by ST22 (A) and ST36 (B) isolates after 48 h incubation in 
TSB supplemented with 1 % D-(+)-glucose. Biofilms were visualised following staining with 0.1 % crystal 
violet. 
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 Assessing the anti-biofilm properties of phage EW27 against ST22 and ST36 
isolates 
Mature (48 hour) biofilms of four ST22 and four ST36 strains were challenged with 
EW27 lysates at a multiplicity of infection (MOI) of 1 and 0.1 PFU per viable S. 
aureus cell. Viable cell counts and absorbance measurements were taken after 6h 
and 24h exposure and compared to controls - Figure 4.6 and Figure 4.7. Viable cell 
counts recovered from each phage-treated biofilm for all ST22 and ST36 isolates 
except for isolate 07.2496.L, were significantly reduced (p < 0.001) following six 
hour exposure to EW27 when compared to untreated biofilm controls.  
 
However following an initial decrease in CFU/mL after six hours, an increase in 
bacterial concentration can be seen across all phage treated ST22 isolates after 24 
hours, suggesting resistance to phage had occurred within that time. There was no 
significant difference between CFU counts from wells treated with phage for 6 and 
24 hour (p < 0.05). When considering the overall biofilm biomass following phage 
exposure and crystal violet staining, results revealed phage EW27 was highly 
effective at reducing the biofilms produced by all ST22 and ST36 strains. 
 
For EW27 treated ST36 isolates, biofilm biomass significantly increased in isolates 
07.1696.F, 06.9570.L and BTN 2172 using both MOI 1 and 0.1 (p < 0.05), despite a 
minor reduction in bacterial numbers after 24 hour treatments compared to 6 
hours. Following treatment of EW27 after both timepoints, EW27 at a MOI of 0.1 
proved to be the most effective at both reducing bacterial cells and biofilm biomass 
for almost all ST22 and ST36 strains. 
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Figure 4.6: Effect of phage EW27 on mature biofilms of S. aureus ST22 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms initially stained 
with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells were 
recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
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Figure 4.7: Effect of phage EW27 on mature biofilms of S. aureus ST36 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
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 Assessing the anti-biofilm properties of phage EW36 against ST22 and ST36 
isolates 
Phage EW36 was applied to mature biofilms of four ST22 (Figure 4.8) and four ST36 
(Figure 4.9) isolates at two different multiplicity of infections (MOIs) of 1 and 0.1 
over periods of 6 and 24 hours. Absorbance values at 590 nm following crystal 
violet staining of washed phage-treated biofilms revealed significant reductions in 
biofilm densities across all ST22 and ST36 test strains following treatment of EW36 
after both 6 and 24 hours. Significant reductions in biofilm biomass was observed 
across all study isolates except for isolate 07.2496.L when challenged with EW36 
at both MOIs (p < 0.01), with MOI 0.1 proving to be the most effective phage dose 
for degrading biofilm biomass. For both ST22 and ST36, no increase to biofilm 
density was observed from 6 hour to 24 hours suggesting EW36 successfully 
disrupted the S. aureus biofilms preventing biofilm regrowth. This is further 
supported by the greater reduction in viable cell counts when biofilms were 
treated for 24 hours. 
 
Interestingly, the populations of viable bacteria recovered from each biofilm 
produced by the four ST22 and ST36 isolates were found to be higher in wells 
treated by EW36 MOI 0.1, despite producing lower absorbance readings than 
biofilms treated with a higher titre of phage at a MOI 1. EW36 was able to reduce 
viable cell numbers for both ST22 and ST36 isolates by at least one-log reduction 
after 6 hours and two-log reductions after 24 hours at an MOI 0.1. With biofilms 
treated at an MOI 1, two-log reductions were observed after 6 hours and three-log 
reductions after 24 hours.  
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Figure 4.8: Effect of phage EW36 on mature biofilms of S. aureus ST22 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
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Figure 4.9: Effect of phage EW36 on mature biofilms of S. aureus ST36 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
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 Assessing the anti-biofilm properties of phage EW41 against ST22 and ST36 
isolates 
Phage EW41 was applied to mature biofilms of ST22 and ST36 isolates similarly to 
phage EW27 and EW36,. Significant reductions (p < 0.01) in biofilm biomass was 
observed for all ST22 and ST36 isolates tested against except for isolate 370.07 
where two-log reductions in cells recovered and 60 – 93 % reductions in biofilm 
biomass were observed after 6 hour treatment with phage EW41 (Figure 4.10 and 
Figure 4.11). Interestingly, EW41 had the least effect in reducing biofilm biomass 
of isolate W449 36 after 6 hours -reducing it by roughly 22 % at an MOI 1 and 19 
% at an MOI 0.1, however viable cell counts were relative to all other isolates and 
two-log reductions were observed across both time points. Furthermore, biofilm 
biomass and viable cell counts recovered from the biofilms challenged with EW41 
after 24 hours maintained levels similar to 6 hours exposure. Phage EW41 was able 
to further reduce biofilm levels of W449 36 by ~85 % when exposed for 24 hours.  
 
ST36 biofilms challenged with EW41 for 24 hours produced higher levels of biofilm 
biomass and increase in cells recovered by up to one-log when compared to 6 hour 
exposure, suggesting regrowth had occurred within that time. Across all ST22 and 
ST36 isolates, both biofilm biomass and viable cells recovered were consistently 
lower in wells challenged with EW41 at an MOI 0.1 when compared to MOI 1, 
although there was no significant difference between MOI 1 and MOI 0.1. 
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Figure 4.10: Effect of phage EW41 on mature biofilms of S. aureus ST22 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with EW36 
at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially stained 
with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells were 
recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate wells 
and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values ( 
standard deviation). 
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Figure 4.11: Effect of phage EW41 on mature biofilms of S. aureus ST36 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
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 Assessing the anti-biofilm properties of phage EW71 against ST22 and ST36 
isolates 
Phage EW71 produced the lowest values out of the four phage studied for both 
biofilm density and recoverable cells across all ST22 and ST36 biofilms when 
compared to untreated control wells (Figure 4.12 and Figure 4.13). Phage EW71 
was effective at reducing (p < 0.01) biofilm biomass after 6 h treatment whilst 
greatly limiting the amount of regrowth after 24 h for all isolates tested against. 
Furthermore, phage EW71 was successful in reducing the number of viable cells by 
up to three-log after 6 h, and continued to reduce after 24 h treatment by up to 
four-log reductions versus those of the controls. Biofilm densities of ST22 following 
treatment of EW71 after 6 h ranged from 63 – 87 %, whilst consequently 
preventing the regrowth of all four ST22 hosts after 24 h further reducing biofilm 
densities.  
 
Greater reductions in biofilm densities were also observed when ST36 isolates 
were challenged with phage EW71 with OD590 values reduced by 59 – 95 % after 6 
h. Interestingly, a marginal increase in absorbance was observed in across all four 
ST36 biofilms when exposed to phage for 24 h. However, increases to viable cell 
counts were only observed for 07.1696.F and 07.2496.L suggesting phage 
resistance and regrowth had occurred within the two sampling periods. Phage 
applied to biofilms at an MOI 1 were found to be the most effective at reducing 
viable cell counts within the biofilm after 6 and 24 h exposures, however biofilm 
densities were somewhat higher with this MOI. Even so, biofilm biomasses were  
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Figure 4.12: Effect of phage EW71 on mature biofilms of S. aureus ST22 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface 
plate wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean 
values ( standard deviation). 
 
 
 
 
 
A 
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Figure 4.13: Effect of phage EW71 on mature biofilms of S. aureus ST36 isolates.  
Static biofilms were initially grown in tissue-culture microtitre plates for 48 hours and challenged with 
EW36 at a multiplicity of infection of 1 and 0.1 for a period of 6 and 24 hours. A – Biofilms were initially 
stained with crystal violet and optical density was measured at an absorbance of 590 nm. B - Viable cells 
were recovered from phage treated wells by scratching and dislodging the biofilms from the surface plate 
wells and plated out in triplicate. Each assay was performed in triplicate, data presented as mean values 
( standard deviation). 
 
 
 
 
 
A 
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approximately similar across the majority of hosts for both 6 and 24 h treatments, 
except for isolate W449 36, however this difference was not significant. 
 
 Colony morphology 
Figure 4.14 depicts heterogeneous colony morphologies that were commonly 
found among isolates from various phage-treated biofilms. This heterogeneity was 
most marked with phage EW71 treated biofilms. However, regardless of which 
phage the mutant had acquired resistance to, the mutants exhibited no 
susceptibility against the other three selected phage following spot testing on agar 
overlays. 
 
 Confocal laser scanning microscopy of phage-treated S. aureus biofilms  
Disruption of mature S. aureus biofilms grown on the surface of polystyrene tissue-
culture microtitre plates was visualised by confocal laser microscopy (Figure 4.15). 
The quantity of live (green) and dead (red) bacteria within the biofilm was assessed 
using LIVE/DEAD staining. A clear reduction in biofilm biomass and living cells can 
Figure 4.14: Heterogeneous colony phenotypes produced by phage-resistant mutants of 07.2496.L and 
07.1696.F following exposure to EW71. 
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be observed after 6 h exposure to phage, with further reductions following 24 h 
phage treatment.  
 
 
 Evaluation of phage biofilm assays 
Table 4.3 summarises the percentage reduction of S. aureus ST22 and ST36 isolate 
biofilms when challenged by EW27, EW36, EW41 and EW71 at MOIs of 1 and 0.1 
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Figure 4.15: LIVE/DEAD staining of phage treated biofilms observed under confocal laser scanning 
microscopy (x40).   
Biofilms were grown for 48 hours at 37 C, mature biofilms where challenged with phage EW41 for 6 
and 24 hour. Presence of live (green) and dead (red) bacterial cells can be observed on the surface of 
the polystyrene well base. 
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after 6h and 24h. For all ST22 isolates the median reduction in biofilm biomass for 
MOI 1 and MOI 0.1 after 6 h was 59 % and 71 % respectively, whereas the median 
reduction for MOI 1 and MOI 0.1 after 24 h exposure was 72 % and 75 % 
respectively. Whereas, for ST36 isolates the median biofilm biomass reduction for 
MOI 1 and MOI 0.1 after 6 h was 80 % and 79 % respectively. After 24 h treatment, 
the median reduction for MOI 1 and MOI 0.1 for ST36 isolates was 75 % and 80 % 
respectively. 
 
Overall, the highest biofilm biomass reductions after 6h and 24 h phage treatment 
was observed with phage EW41 and phage EW71 respectively, with an MOI of 0.1. 
Although significant reductions in biofilm biomass was observed when treated with 
both MOIs of phage, the greatest reductions across all ST22 and ST36 isolates after 
6 and 24 h exposure was achieved when biofilms were treated at an MOI 0.1. 
Although each phage was able to disperse the biofilms of all study isolates, 
Table 4.3: Summary table showing the relative difference in biofilm reduction of study phage at two 
multiplicities of infection (MOI) against four ST22 and four ST36 isolates. 48 hour biofilms were challenged with 
phage for 6 and 24 hours, percentages are based on control values. 
MOI 1 MOI 0.1 MOI 1 MOI 0.1 MOI 1 MOI 0.1 MOI 1 MOI 0.1
ARI 10 1.2034 -44% -61% -47% -63% -80% -85% -84% -87%
W449 36 1.1929 -71% -78% -77% -78% -22% -19% -75% -68%
1018.07 0.5941 -59% -74% -58% -72% -59% -70% -67% -73%
370.07 0.4381 -43% -68% -52% -63% -43% -69% -63% -76%
ARI 10 1.2034 -58% -55% -81% -82% -82% -83% -87% -86%
W449 36 1.1929 -68% -77% -82% -85% -85% -86% -84% -84%
1018.07 0.5941 -20% -49% -68% -69% -69% -70% -76% -74%
370.07 0.4381 -25% -43% -59% -68% -63% -66% -78% -75%
MOI 1 MOI 0.1 MOI 1 MOI 0.1 MOI 1 MOI 0.1 MOI 1 MOI 0.1
07.1696.F 3.0191 -89% -89% -79% -79% -90% -86% -95% -95%
06.9570.L 2.7274 -75% -60% -81% -80% -71% -74% -91% -92%
BTN 2172 1.0997 -74% -72% -76% -73% -86% -85% -83% -83%
07.2496.L 0.7536 -64% -69% -20% -29% -70% -70% -81% -79%
07.1696.F 3.0191 -77% -80% -88% -90% -86% -89% -89% -95%
06.9570.L 2.7274 -25% -51% -89% -90% -59% -84% -90% -92%
BTN 2172 1.0997 -30% -57% -73% -78% -83% -68% -77% -83%
07.2496.L 0.7536 -40% -66% -56% -60% -36% -66% -59% -79%
EW27 EW36 EW41 EW71
24 Hour
6 Hour
OD590ST22
6 Hour
24 Hour
EW27 EW36 EW71
OD590
EW41
ST36
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complete elimination of cells was not observed across any of the hosts at either 
MOI as cells were recoverable when exposed to phage for 6 and 24 h treatments. 
 
  Discussion 
The experiments detailed in this chapter aimed to investigate the efficacy of four 
lytic staphylococcal bacteriophage in disrupting and degrading S. aureus biofilms 
in an in vitro static biofilm system. 
 
Biofilm-associated S. aureus infections are a major threat within healthcare, 
complicated further when caused by highly resistant MRSA isolates that make 
antimicrobial treatment with conventional antibiotics more difficult. The success 
of MRSA infections within healthcare is largely associated with (but not limited to) 
the emergence and spread of five globally predominant clonal lineages. Isolates 
from two of these successful lineages, CC22 and CC30, became the dominant 
MRSA within UK hospitals. ST22 and ST36 MRSA isolates (from CC22 and CC30 
clonal lineages) were responsible for 95.6 % of MRSA cases between the early 
1990s to mid-2000s (61, 62). Through our collection of genome-sequenced MRSA 
isolates, we were able to assess the biofilm forming ability of 43 ST22 and 27 ST36 
isolates to identify the strongest and weakest biofilm producers in our static biofilm 
system.  
 
The static biofilm model system was implemented to study the in vitro formation 
and development of S. aureus ST22 and ST36 isolate biofilms. This model is simple 
and relatively inexpensive and is the more commonly used experimental approach 
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for such studies, as it offers the ability for high throughput analyses and enables 
the rapid assessment of biofilm formation of various bacterial species, proving to 
be extremely useful with assays with multiple changing variables and growth 
conditions [223,313]. However, the closed-system approach does have its 
limitations, with finite supply of nutrients, these assays are prone to nutrient 
depletion and exhaustion [35]. Biofilm formation is directly correlated to the 
availability of nutrients and once depleted it can greatly limit the biofilm 
development. Additionally, lack of aeration and accumulation of metabolites can 
also be detrimental to biofilm growth [314]. To alleviate this issue, the 
replenishment of media is recommended and in these studies this was conducted 
following 24 hours incubation [315]. 
 
The formation of S. aureus biofilms on polystyrene surfaces relates to the ability of 
the bacteria to adhere to abiotic and biotic surfaces mediated by microbial surface 
components recognising adhesive matric molecules (MSCRAMMs) [316]. The 
production of polysaccharide intercellular adhesin (PIA) by ica operon-operated 
enzymes is the one of the best understood mechanisms for cell to cell adhesion 
and contribution to biofilm formation among staphylococci [317]. However, 
expression of ica operator across S. aureus clinical isolates has been found to be 
tightly controlled within in vitro conditions [46,318,319]. Despite this, a number of 
factors are known to influence PIA production thus leading to increased biofilm 
production in vitro, including response to anaerobic growth conditions and the 
presence of sugars in growth media [320–322]. The supplementation of growth 
medium with 1 % D-(+)-glucose greatly induced biofilm forming abilities of all our 
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study isolates, which is consistent with previous S. aureus biofilm studies 
[223,319,321,323]. 
 
A direct comparison of ST22 and ST36 isolates in this study revealed significant 
variation in the level of biofilm produced as seen in Figure 4.2 and Figure 4.3, with 
members of ST36 exhibiting significantly greater biofilm production. Such findings 
were also observed with members of CC30 (ST36) proving to be prolific biofilm 
producers compared to members of CC22 (ST22) under similar growth conditions, 
whilst demonstrating a strong correlation with the level of biofilm formation 
associated with specific lineages [224]. Reports on the degree of biofilm 
production, composition or expression levels of genes responsible for stages of 
biofilm formation can be associated with members of a particular ST lineage among 
S. aureus [324]. However differences in experimental conditions and the methods 
employed throughout various biofilm studies can make it difficult when trying to 
select the appropriate growth conditions for a biofilm study. In this study differing 
growth conditions were tested to optimise biofilm production in microtiter plates. 
Compared to ST36 isolates, the majority of ST22 isolates were found to be weak 
biofilm producers, as only 11 were considered above the nominal threshold 
selected to indicate good biofilm formation.  However, only two ST22 isolates 
produced biofilm densities similar to the biofilms formed by that of the least 
productive ST36 isolates. So for a more accurate comparison between the two 
lineages, two weak biofilm producers from ST36 were selected for the phage-
biofilm studies. Interestingly, although the average optical density (absorbance at 
590 nm) was 1.92 across ST36, more than 6x larger than the top two ST22, the 
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number of viable cells recovered from each of the biofilms were considerably 
similar to each other between all isolates.  
 
The four S. aureus phage studied in this chapter were selected based on their lytic 
potential demonstrated in Chapter 3. All four phage exhibited generally high 
efficacy in effectively reducing biofilm biomass and cell numbers of each S. aureus 
isolate after 6 and 24 h. Cell regrowth was detected following 24 h infection with 
phage compared to 6 h by at least one of the hosts suggesting growth of phage-
resistant mutants had occurred, however this was at the expense of biofilm 
regrowth. These observations were similar to those reported in a previous study 
of S. aureus biofilm [190]. The observation of biofilm regrowth and phage 
resistance still remains a major issue and is something regularly observed in 
biofilms when are challenged by single lytic phage that promotes mutant selection 
[212]. This necessitates a phage combination approach using phage cocktails or co-
administration with antibiotics to prevent the emergence of phage-resistant 
mutant bacteria. Previous studies have made use of the disruptive ability of phage 
to reduce biofilm structures produced by S. aureus and reduce bacterial 
populations enough to facilitate the penetration of antibiotics and eradicate 
infection [219,325]. Previous evidence suggests that the phage resistance 
phenotype increases sensitivity to antibiotics and also results in a loss of fitness 
[326]. Additionally, the application of phage cocktails consisting of multiple 
polyvalent phage that target different receptor proteins to prevent multi-
resistance, but also increase the rate of killing, thus greatly reducing the probability 
of hosts acquiring resistance to phage [327]. The anti-biofilm capabilities and broad 
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host range demonstrated by the four study phage make them promising 
candidates for possible future combination studies. 
 
Previous phage/host studies have demonstrated that by increasing the 
concentration of phage-to-bacteria (MOI), which, essentially increases the rate of 
collisions between phage and biofilm cells leads to increased rate of bacterial killing 
[268,328]. Additionally, greater reductions could have been facilitated by direct 
bacterial lysis with the possible ‘lysis from without’. However there was no 
significant difference between MOI values, suggesting that an increased phage-to-
bacteria ratio offered no advantages in reducing biofilm biomass, as described 
previously [328]. Overall, reductions in biofilm biomass (OD590) were generally 
higher in biofilms treated at an MOI 0.1 (compared to 1) using any of the four 
phage after both 6 and 24 h treatments. The effectiveness of the low MOI 
demonstrates the self-perpetuating nature of lytic phage to proliferate in number, 
therefore only requiring small initial doses. 
 
As mentioned above, fitness costs associated when acquiring phage-resistance, 
can often lead to various structural and morphological changes [329,330]. One 
approach is concealing the surface receptors that the phage used as docking sites 
to adsorb to their hosts, however these sites are often used for the uptake of 
nutrients [331], thus possibly limiting their growth and virulence which may be why 
cell numbers were able to recover after 24 h treatment compared to 6 h, yet 
biofilm densities remained considerably low.  
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Compared to the characteristic smooth, round colonies phenotypes typically 
produced by S. aureus, the recovery of heterogenous morphotypes produced by 
phage-resistant derivatives following phage exposure were regularly detected 
during this study, although most commonly observed in biofilms treated with 
EW71. These irregular shaped colonies have been reported in previous phage 
challenges and are thought to be caused by a subpopulation within that colony 
that has reverted back to a phage-sensitive phenotype, subsequently leading to 
cell death as the colony is forming  [331–333]. However, the observations of 
‘pacman-like’ colonies have not been as well documented. 
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Genomic diversity of Twortvirinae 
infecting S. aureus 
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 Introduction 
Advancements in next generation sequencing (NGS) technology has greatly 
improved the reliability, speed and accuracy of sequencing entire genomes over 
recent years. The relative ease and reduction in the cost of sequencing has led to 
an increase in bacteriophage genomes being deposited on to databases such as 
National Centre for Biotechnology information (NCBI), RefSeq and the European 
Nucleotide Archive (ENA), and as of May 2018 there are currently >9000 complete 
(or near complete) sequenced phage genomes available on the NCBI website 
(http://millardlab.org/bioinformatics/bacteriophage-genomes/). An increasing 
ability to perform high throughput NGS thus further increasing the number of 
sequenced novel bacteriophage genomes made available on public databases will 
greatly improve our understanding of their complexity and evolutionary 
relationships with their hosts [228]. Double-stranded DNA (dsDNA) tailed phage 
make up the majority of sequenced bacteriophage genomes (>95 %) [334]. This 
increasing amount of genomic data has recently led to the re-evaluation of the 
bacteriophage taxonomic classification framework and the proposition of unifying 
classical and genomic approaches [112,335]. The order of Caudovirales consisting 
of four families of tailed bacterial viruses Myoviridae, Siphoviridae, Podoviridae and 
the new family Herelleviridae, greatly exceeds any other group of bacterial viruses 
in both phage abundance and diversity. The recent reorganization of Caudovirales 
and its subfamilies resulted in the movement of Spounavirinae and spouna-like 
viruses in to five subfamilies within the new  Herelleviridae family: Bastillevirinae, 
Brockvirinae, Jasinkavirinae, Spounavirinae and Twortvirinae [131]. 
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Phage genomes display extensive mosaicism and are largely modular, pointing to 
an evolutionary history driven by horizontal gene transfer of functional modules 
and non-homologous recombination [111,336] This makes it extremely challenging 
for species definitions and characterisation of phage population structures. 
Evidence suggests that phage within the same genus or type, share relatively high 
homology with other members of that genus, implying very limited genetic 
exchange between the gene pool of these phage, with differences mainly due to 
single nucleotide polymorphisms, insertions and/or deletions [337]. Previous 
comparative studies have largely focused on phage infecting pathogenic bacterial 
species, collections of phage from a single family, or phage belonging to all families 
infecting the same bacterial strain, which include phage exhibiting lytic and 
lysogenic lifestyles [220,283,338–343]. 
 
 Staphylococcal phage 
Many of the virulent phage infecting S. aureus are members of the Twortvirinae 
subfamily comprising of five genera (Kayvirus, Sepunavirus, Silviavirus, Twortvirus 
and unclassified Twortvirinae) representing as distinct clades in Figure 1.11 
[112,211]. The majority of staphylococcal phage belonging to the Twortvirinae 
subfamily and display a relatively broad host range against diverse isolates from 
various clonal lineages, demonstrating great potential for use in phage therapy. 
These types of phage  as well as their lytic enzymes have been studied previously 
[147,187,283]. However when compared at the proteome and nucleotide level, 
they can share little homology among themselves. Phage genome comparisons are 
sometimes difficult due to the limited availability of robustly annotated genes. 
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Many annotated phage genomes contain high levels of hypothetical or unknown 
proteins and in some cases, these may comprise >50 % of genes identified [344]. 
More accurate and thorough gene annotations will allow for better comparisons 
and understanding of the phage pan-genome and the distribution of shared genes 
within a study group. The identification and annotation of genes is crucial in order 
to gain a greater knowledge and understanding of the phage. Identification of 
these genes can lead to define the nature of the expressed protein, when and 
where the gene will be expressed and their genetic diversity among a large data 
set. 
 
All phage lyse their bacterial hosts and in most cases, this is achieved through a 
holin-endolysin system [345]. These phage-encoded enzymes act to lyse their 
bacterial host cell causing the release of viral progeny. In S. aureus they degrade 
the peptidoglycan layer that is the main component of their cell wall. Despite their 
conserved biological function, endolysins are extremely architecturally diverse and 
vary in length and size [345]. This chapter examines the genomic differences and 
similarities of a collection of lytic phage infecting S. aureus belonging to the 
Twortvirinae subfamily and the distribution of their lytic enzymes. We previously 
isolated, sequenced and assembled the genomes of 22 novel bacteriophage that 
displayed a broad host range against a large panel of highly diverse S. aureus 
isolates. We compared these genomes to the 38 Twortvirinae infecting S. aureus 
genomes in the GenBank database. This allowed us to classify our 22 novel phage 
based on sequence homology with currently classified phage to the genus level.  
157 
 
We also characterized the diversity and distribution of lytic enzymes genes 
amongst our phage genomes and compared these to those in the public domain. 
 
 Methods 
All complete S. aureus infecting bacteriophage genomes belonging to the 
Twortvirinae subfamily were retrieved from GenBank (https://www.ncbi.nlm. 
nih.gov/genome) and the European Nucleotide Archive (ENA) databases in 
February 2018.  Each phage was individually identified as to its morphology and 
family by literature searching. Open reading frames (ORFs) were predicted and 
annotated with Prokka v1.12 [238] by searching through a user-provided protein 
database, in our case the Phaster viral protein database which consists of ~260,000 
phage proteins (http://phaster.ca/databases) [346]. Any unannotated sequences 
were then searched using BLAST+ and BLASTp. However if no match was found, 
CDS were subsequently labelled as ‘hypothetical protein’. The generated general 
feature files (gff) were visualised using Artemis [236]. Phage genomes were 
compared using DNA sequence similarity algorithm Mashtree [241] and plotted on 
FigTree [242].  
 
Mash was used to compute all-against-all pairwise distances among the phage 
genomes, using parameters similar to those employed by homology based Average 
Nucleotide Identity (ANI) measures.  
 
 
158 
 
The output Mash matrix was visualised using heatmaply v0.14.1 [244]. Clusters 
were identified based on sequence similarity and visualised using BRIG v0.95 [248], 
individual dendrograms were created using Mashtree and pan-genomes were 
created for each cluster as mentioned above. Afterwards, construction of a pan-
genome using the multiple sequence alignment program (MAFFT) option was 
achieved with Roary v3.10.2 [246]. The pan-genome was visualised with 
Phandango [247]. Annotated genomes were split in to individual sequence (fasta 
format) files and examined using HHsearch [239] (>80%, E-value < 0.01) to predict 
the function and structure of all identified genes in order to identify lytic enzymes 
homologues based on profile similarity. HH-suite utilises the hidden Markov model 
(HMMs) tool employed by HHpred to query translated sequences against three 
dimensional protein structures currently in the Protein Data Bank (PDP). This 
approach is uniquely different to other sequence search methods as it predicts the 
protein structure using homology modelling, providing greater insight in to the 
predicted function of each protein conserved among sequences within a cluster. 
 
 
 
 Results  
In order to further characterise our 22 staphylococcal phage that we isolated and 
sequenced, we compared their genome sequences to the complete genomes of 
38 phage infecting S. aureus belonging to the Twortvirinae subfamily downloaded 
from GenBank and public databases, to give a total number of 60 genomes for 
analysis. All 60 phage genomes were re-annotated to ensure uniformity, however, 
there are a number of viral protein databases available that vary in size and the 
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quality of their annotation such as ACLAME [347], RefSeq (ftp://ftp.ncbi. 
nih.gov/refseq/release/viral/viral.1.protein.faa.gz), Phaster (https://phaster.ca/ 
databases), RAST (http://rast.theseed.org/FIG/rast.cgi), UniProt (ftp://ftp. 
uniprot.org/pub/databases/uniprot/current_release/), Caudovirales (http:// 
millardlab.org/bioinformatics/lab_server/phage-genome-annotation/).  
 
Comparisons of these databases were performed to assess which database 
successfully and evenly annotated our phage genome collection. Although some 
databases managed to annotate a number of phage considerably well leading to 
higher amount of coding regions of a gene – coding sequence (CDS) with a 
function, some phage were poorly annotated evidenced by a high number of 
hypothetical protein predictions. This could be partly due to the number that 
included outdated annotations from older phage sequences retrieved from 
GenBank. Among the EW phage sequenced in this study, hypothetical proteins 
accounted for 61 – 67 % of the predicted genes, whereas with phage downloaded 
from public databases hypotheticals were less prevalent accounting for 45 – 70 % 
of predicted genes. A number of these original annotations were still hypothetical 
for example ‘ORF083 staphylococcal phage G1’ was the top gene shared across the 
phage collection. The protein was searched using BLASTp and shared 96% 
sequence homology (E-value 5.9e-112) to a holin gene. Furthermore, a number of 
protein databases were found to contain older versions of phage genomes that are 
poorly annotated, mainly consisting of hypothetical proteins
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such as staphylococcal phage G1, leading to large set of genes were simply annotated 
as ‘ORF G1’. To prevent this, specific annotations such as the hypothetical phage G1 
proteins were removed from the database and all phage were subject to re-annotation, 
resulting in an increase in number of genes annotated with a predicted function. Each 
phage was annotated using Prokka against the Phaster protein database, the genomes 
of these phage ranged from 127,188 bp to 148,564 bp. The average G+C % content of 
the S. aureus host is 32.9 %, whilst S. carnosus possesses the highest of all sequenced 
staphylococcal genomes with 34.6 %. The average G+C % content of the phage is 30.5 
± 1.1 %, a lower percentage than their bacterial hosts.  
 
 Phylogenetics 
The collection of 60 phage genome sequences were compared through pairwise 
sequence comparisons using Mash to study their phylogenetic relationship, the 
resulting dendrogram was plotted using Figtree and exported as a Newick tree. The 
dendrogram resolved several distinct clusters that are highlighted below (Figure 5.1), 
these clusters represent closely-similar phage sharing a high degree of homology with 
those of other study genomes. Long branch lengths between clusters show how 
divergent some clusters are from others, whilst close relationships between phage 
members within each cluster can be observed. The clusters containing the phage 
sequenced in this study were further analysed. It also highlights a number of singletons 
that exhibit very little sequence homology to the other phage with no close genetic 
relatives, including the notable phage Twort. 
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 Pan-genome analysis 
A total of 1634 ORFs of at least 122 bp were predicted within all 60 phage genomes. 
Of these, 380 ORFs (23 %) had predicted gene functions based on the Phaster 
database, analysis of phage sequence annotations revealed the percentage DNA that 
codes for proteins (percentage coding) ranged from 84 to 91 % with phage qdsa_001 
possessing the lowest and phage EW9 the highest, with an average number of genes 
per kilobase of 1.41.  
 
In order to characterise the core and accessory genome amongst all 60 phage, the pan-
genome pipeline tool Roary was used. Interrogation of the pan-genome identified no 
predicted genes that were found to be present in all phage genomes, with the highest 
number of phage that were found to share the same gene was 48. In total, 31 genes 
were shared across 48 phage and further analysis identified that these genes consisted 
of mainly, structural proteins associated with DNA repair, replication and tail 
structures. A number of unidentified CDS genes (hypothetical proteins) that were 
shared across phage present within distinguishable groups were individually examined 
using UniProt BLASTp (http://www.uniprot.org/blast/) in order to assign their function. 
This helped to identify a number of genes that had originally been overlooked during 
initial annotation with Prokka. The proportion (%) of accessory genes that are not 
found present across all of the phage genomes can be designated according to Roary 
as i) ‘soft-core’ - genes found in ≥95 % to <99 % of genomes, ii) ‘shell’ genes : ≥15 % to 
<95 %) or iii) ‘cloud’ genes: present in <15 % of genomes. When all 60 phage are 
compared there are a considerable number of accessory genes (<95 %) that are unique 
and specific to a single phage and these are for the most part annotated as hypothetical 
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or unknown function (Table 5.2). Furthermore, a large number of unidentified ORF’s 
(initially annotated as hypothetical proteins) that were found to be shell genes, were 
individually examined using UniProt BLAST option in order to assign their function. 
Gene by gene comparisons to identify homologues sharing high synteny allowed us to 
identify a large number of hypothetical proteins previously overlooked during initial 
annotation. This was mainly achieved using comprehensive sequence and structural 
homology searches using BLASTp and HHpred tools respectively. From this, we were 
able to identify genes based on their predicted protein structures that were present 
across each phage. The pan-genome was visualised with Phandango, whose input is a 
Roary ‘gene presence/absence’ tab separated values text file and a Newick format 
dendrogram file, in this case a Mashtree dendrogram, to examine the distribution of 
proteins in relation to DNA sequence similarity is show in Figure 5.2.   
  
 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4a 
Cluster 4b 
and 4c 
Core  
120         
(47%) 
109         
(29%) 
163         
(65%) 
140         
(40%) 
113         
(25%) 
Soft-core 0 0 0 
20          
(5%) 
0 
Shell 
99         
(38%) 
229        
(61%) 
87         
(35%) 
19         
(28%) 
178         
(40%) 
Cloud 
39         
(15%) 
35         
(10%) 
0 
94         
(27%) 
154        
(35%) 
N = genes 258 373 250 351 445 
Table 5.2: Number and distribution of genes in the core and accessory genome across members of each 
cluster. 
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 Comparative genomics 
Pairwise sequence similarities of all phage genomes plotted against each other were 
computed using Mash distances. The Mash matrix was read in Rstudio and plotted as 
a heat map using heatmaply (Figure 5.3). Mash pairwise values were also converted in 
to percentages, values among phage sharing a high percentage identity were coloured 
green and red if phage were more divergent, allowing the distinction of phage species. 
Of the 60 sequenced phage, 58 were organised in to 4 clusters, with one cluster 
consisting of only two phage members, and Cluster 4 being sub-divided into a further 
3 sub-clusters.  
 
These phage were grouped into clusters based on genome synteny using an all-vs-all 
approach, high similarity (1 = 100 %) is indicated by yellow and blue indicated low 
similarity (0.7 = >70 %). Several clusters and two singletons are clearly visible and these 
are labelled in Figure 5.3 and correspond to the clusters identified in Figure 5.1. These 
distinct clusters observed were found to reflect current ICTV genera, 1 – Silviavirus, 2 - 
Unclassified EW, 3 – Unclassified Kayvirus subgroup, 4 – Kayvirus and two singleton 
clusters Twort the lone member of Twortvirus and LM12 which appears to share a 
higher degree of similarity to Kayvirus members.  
 
Interestingly, our sequenced phage (EW1 – EW22) were present in all three major 
clusters, of which, one in particular Cluster 2 was found to possess exclusively phage 
from this study. A number of the phage from this study displayed extensive similarity 
up to 100 % similarity with phage K and other EW phage. Members of Cluster 3 shared 
the highest similarity of 91 – 92 % to those in Cluster 4, whose two members Clo6 and 
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S24 are currently placed in an unclassified phylogenetic subgroup of Kayvirus sharing 
92 % sequence similarity with key members of the Kayvirus genus found in Cluster 4. 
Cluster 2 shares 89 – 90 % homology with phage of Cluster 4, and considerably 
different to Silviavirus Cluster 1 with only 75 – 76 % nucleotide similarity. Of which are 
highly divergent sharing only 75 – 77 % with all other clusters, however Twort phage 
still remains the only member of its genus and its incredibly divergent genome shows 
no levels of synteny with other staphylococcal phage. 
 
The distinguishable clusters visible on the heatmap (Figure 5.3) are congruent to those 
identified in both the dendrogram (Figure 5.1) and pangenome (Figure 5.2). It was clear 
that members of cluster 1 and phage Twort exhibit relatively low homology with 
members of the remaining clusters, and may suggest why there are no core genes 
found shared across all phage genomes. During analysis, we found that members 
within clusters that were previously classified correlated to the phage genus previously 
assigned. Clusters were further interrogated in order to understand the pan-genomes 
and similarities of study phage and members within those groups. Not only did this also 
help assign unclassified phage to fall in to their respective genus, it helped determine 
where our 22 study phage could belong and also understand more about them in 
relation to already classified phage. 
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 Cluster 1 
Cluster 1 contains 11 phage, of which, five members were from this study. Pairwise 
comparisons for each phage using an all-against-all approach identified the five EW 
phage to have a high degree of coverage (>95 %) with members of Silviavirus between 
97.46 % and 100 % (Table 5.3), sharing significantly lower homology to members of 
Kayvirus (~75 %) and Twortvirus (~73 %). EW phage were compared against the 
genomes of current members within the cluster stAP1, qdsa001, SA11, Stau2, Romulus 
and Remus. When compared to the Remus, the type strain for Silviavirus genus, the 
EW phage demonstrated a high degree of synteny - EW15 (98.5 %), EW20 (98.5 %), 
EW22 (98.5 %), EW27 (98.5 %) and EW41 (99.3 %) and should be rightfully considered 
as new additions to this genus. However, we note that a number of EW phage share a 
significantly high sequence identity to each other – of up to 100 %, indicating that they 
are essentially the same phage that were most likely present in numbers across 
multiple ASP2 tanks at the Davyhulme wastewater treatment site as a number of  
  
SA11 100%
StAP1 99.27% 100%
Stau2 99.05% 98.65% 100%
qdsa001 97.57% 97.96% 97.46% 100%
Remus 98.32% 98.78% 98.14% 97.87% 100%
Romulus 98.25% 98.70% 98.11% 97.89% 99.90% 100%
EW15 98.31% 98.70% 97.99% 97.67% 98.51% 98.47% 100%
EW20 98.31% 98.70% 97.99% 97.67% 98.51% 98.47% 100% 100%
EW22 98.31% 98.70% 97.99% 97.67% 98.51% 98.47% 100% 100% 100%
EW27 98.31% 98.70% 97.99% 97.67% 98.51% 98.47% 100% 100% 100% 100%
EW41 98.23% 98.53% 98.11% 97.94% 99.33% 99.33% 98.35% 98.35% 98.35% 98.35% 100%
SA11 StAP1 Stau2 qdsa001 Remus Romulus EW15 EW20 EW22 EW27 EW41
Table 5.3: Pairwise comparisons of phage infecting S. aureus belonging to the Twortvirinae subfamily.  
Phage of Cluster 1 are compared against each other to determine their sequence homology, the level of 
identity is given as a percentage and coloured from green to red based on the degree of homology. 
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samples were collected on each day.  
 
Pan-genome analysis was performed against the 11 phage as depicted in Figure 5.4. A 
total of 258 predicted genes were identified across the 11 phage within Cluster 1. The 
group shares a core genome consisting of 120 (47 %) predicted and a shell consisting 
of 99 (38 %) genes and a cloud of 39 genes (15 %). Of which, 96 genes had predicted 
function with 162 hypothetical proteins. The core genome consisted of 120 genes with 
49 having a predicted function that include virion structural proteins such as major 
capsid and tail proteins, lytic enzymes and transcriptional regulatory proteins.  
 
A number of unique genes often present only in a single phage were classed as 
individual groups, further interrogation of these genes using BLAST and HHpred 
identified each of them to produce the same protein of similar structure with high 
identity and coverage. For example, group_38 (Roary output) only present in phage 
qdsa001 (qdsa001_00144) putatively encodes for a DNA polymerase I protein. To 
confirm this, the sequence was searched on HHpred, the top hit matched it up to a 
DNA polymerase (PDB ID - 1KFS_A - 99.2 %). The PDB ID 1KFS_A was searched across 
the HHpred outputs (hhr files) of all phage belonging to Cluster 1. Interestingly, the 
1KFS_A hit was found to be the top hit for group_37 which was shared among the other 
10 phage. Group_37 was initially annotated as a hypothetical protein, and is found 
present in all 11 phage including qdsa001, but as (qdsa001_00143). The amino acid 
sequence for qdsa001_00144 (group_38) was aligned against a number of protein 
sequences that were classed as group_37 from different phage in the cluster (Figure 
5.5) using UniProt align function. 
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Alignment identified a high similarity between these genes, except for the sequence of 
group_37 which contained a 1200 bp insertion (Figure 5.5). This intragenic region was 
picked out and manually searched through HHpred and found a 100 % hit to an 
endonuclease found in Pyrococcus furiosus (1DQ3_A). When 1DQ3_A was searched 
through the hhr files, it was found present in all 10 phage except for qdsa001. The 
genes encoding for this protein all belonged to group_207 rightly titled intron-encoded 
putative endonuclease, which was found shared across all 10 phage except for 
qdsa001. It appears that group_38 (qdsa001_00144) which is only present in qdsa001, 
is essentially group_37 with group_207 inserted in the middle of the gene. Inteins that 
interrupt protein-encoding genes are a regular occurrence in phage genomes including 
Spounavirinae, especially members of the Silviavirus genus [131,348],  and may present 
a challenge with gene prediction tools suggesting possible issues with annotation, thus 
leading to errors within pan-genome analysis.  
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Figure 5.5: The location of group I intron. 
The inserted endonuclease that phage qdsa001 harbours can be seen when the gene (Group_38 ) is 
aligned against the sequences of a number of members possessing Group 37 gene, and is a recognised 
group I intron that often encodes for endonucleases. 
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 Cluster 2 
The 11 members of Cluster 2 consist of only phage from this study and demonstrate a 
high level of shared homology (Table 5.4), with pairwise sequence alignments ranging 
from 95.41 % to 100 %. Examination of the Mash matrix indicates that EW1, EW2 and 
EW4 to be the same phage, in addition to EW3, EW5 and EW7. This can also be applied 
to EW36 with EW42 both being 100 % identical phage too, possibly suggesting that 
these phage were present in a number of ASP sewage tanks when samples were 
collected. It is also worth noting that, EW9 shares an extremely high similarity of 99.98 
% to EW3, EW5, EW6 and EW7. The sequence similarity of EW36 and EW42 against the 
other phage is 95.41 %. When compared to other clusters, EW phage in Cluster 2 share 
a relatively high identity with members in all subgroups of Cluster 4 and Cluster 3 
ranging from 89.40 % to 90.83 %, whilst sharing around 75.30 % to members of Cluster 
1. 
  
EW1 100%
EW13 98.21% 100%
EW2 100% 98.21% 100%
EW3 97.37% 97.43% 97.37% 100%
EW36 95.41% 95.54% 95.41% 95.41% 100%
EW4 100% 98.21% 100% 97.37% 95.41% 100%
EW42 95.41% 95.54% 95.41% 95.41% 100% 95.41% 100%
EW5 97.37% 97.43% 97.37% 100% 95.41% 97.37% 95.41% 100%
EW6 97.37% 97.43% 97.37% 99.99% 95.41% 97.37% 95.41% 100% 100%
EW7 97.37% 97.43% 97.37% 100% 95.41% 97.37% 95.41% 100% 100% 100%
EW9 97.38% 97.43% 97.38% 99.98% 95.42% 97.38% 95.42% 99.98% 99.98% 99.98% 100%
EW1 EW13 EW2 EW3 EW36 EW4 EW42 EW5 EW6 EW7 EW9
Table 5.4: Pairwise comparisons of phage infecting S. aureus belonging to the Twortvirinae subfamily.  
Phage of Cluster 2 are compared against each other to determine their sequence homology, the level of 
identity is given as a percentage and coloured from green to red based on the degree of homology. 
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Phylogenetic analysis placed these newly isolated phage in a distinct clade closest to 
members of Kayvirus genus. When searched using BLASTn these same members were 
among the top hits for the EW phage. The 11 EW phage of Cluster 2 were compared 
against the Kayvirus type strain phage K used as a reference using the circular genome 
analysis tool, BRIG (Figure 5.6). BRIG comparison illustrates the high level of synteny 
between EW phage shared with phage K, however also revealed a number of segments 
that were not present among the cluster 2 members compared to phage K.  
 
 
Figure 5.6: Comparison of 11 unclassified EW staphylococcal phage of cluster 2.  
The BRIG image illustrates the variability among members of the Kayvirus genus, each coloured ring 
represents an EW phage genome similarity against the Kayvirus type strain Phage K used as a 
reference. The brightness and shading of the colour for each phage represents the percentage (%) 
similarity against the phage K genome. Percentage identity of less than 40 % are indicated by no 
colouration. 
Cluster 2 
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Pan-genome analysis identified a total of 373 predicted genes across the 11 phage of 
Cluster 2 as depicted in Figure 5.7. Of which, 99 had a predicted function. The group 
shared a rather small core genome consisting of 109 (29 %) a shell of 229 (61 %) and a 
cloud genome of 35 (10 %). The hypothetical proteins present across all cluster 2 
members were further interrogated using HHpred, and found that the predicted 
protein structures share high homology to structural virion proteins, transcriptional 
and interestingly several lytic enzymes. Gene-by-gene comparisons were performed in 
order to detect overlooked genes and determine whether genes found only in a single 
phage were in fact unique or due to poor annotation. 
 
 Cluster 4 
Cluster 4 consisting of three sub-clusters 4a, 4b and 4c is made up of 35 phage 
genomes, 6 of which were from this study. Members belong to the biggest genus of 
the Twortvirinae subfamily known as Kayvirus. This cluster can be further sub-divided 
into 3 small clusters based on >3 % sequence similarity (Figure 5.1). However, cluster 
pairwise sequence comparisons revealed that phage EW18, EW26, EW29, and EW72 
were 100 % identical to each other. In addition, EW71 and EW74 were found to also 
share 100 % similarity. Nucleotide similarities (Table 5.5) against the 29 members of 
Kayvirus identified 6 EW phage, both EW71 and EW74 to be 100 % identical to genus 
type strain phage K and 99.93 % to phage 812. On the other hand, phage genomes 
sharing the lowest similarity to EW phage were P108 (94.39 %) to EW71 and EW74. 
Interestingly, P108 is also the most similar genomically to phage Clo6 and S24 of Cluster 
3 which have not yet been classified. When clusters are taken into consideration, 
members of Cluster 4a share a 1 % difference between phage in Cluster 4b, whereas  
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phage members of 4b share a 4 % difference between 4c, although the majority of 
phage share >95 % similarity amongst each other.  
 
In total, 503 genes were predicted across the Cluster 4. Of which, 85 genes had a 
predicted function following annotation, although a large majority of these genes were 
annotated as ‘ORF [Phage]’ which may have impeded proper annotation.  Cluster 4 
phage comprise a core genome consisting of 99 (20 %) genes conserved across all 
phage, with only 12 with predicted function. In addition, an extensive accessory 
genome was present compromising of a soft core consisting of 24 genes (5 %), a shell 
of 144 (28 %) and a cloud of 236 (47 %) that makes up the accessory genome as 
demonstrated in Figure 5.8.  
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 Lytic proteins  
Individual deduced phage protein sequence were used to interrogate that of known 
sequences using HHpred database. This uses structural rather than sequence 
homology (BLAST) to search for similar proteins. We identified 407 potential genes out 
of 12906 by searching for structural lytic protein and enzyme homologues. We 
screened all matches for key words including hydrolase, endolysin, transglycosylase, 
N-acetylemuramoyl-L-alanine, amidase, lysozyme, autolysin, peptidoglycan, LysK, 
CHAP domain, endopeptidase and holin in HHpred output files to identify possible 
genes encoding for lytic proteins.  
 
The 407 potential genes were individually screened to filter out low probability hits 
with a cut-off value of 90 % probability and an E - value of 0.0001, resulting in a final 
collection of 237 genes encoding for putative lytic enzymes. Once filtered, each 
HHpred output was aligned to their hosts and compared to the original gene 
presence/absence table obtained from the pan-genome analysis of all phage (Figure 
5.2) in order to determine the original nucleotide sequence that each group was 
assigned to. The 237 genes discovered in the database fell in to 21 individual groups 
that were originally assigned by Roary, the sequence for each group was translated to 
its amino acid and aligned using MUltiple Sequence Comparison by Log-Expectation 
(MUSCLE). The dendrogram produced using MUSCLE was aligned against the manually 
curated lytic enzyme gene presence/absence using all 60 phage, that were ordered 
based on the Mash distance tree above. This helped detect lytic enzymes that were 
specific to a single cluster or shared across numerous clusters (Figure 5.9). 
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All 60 phage in this study possessed a gene that shares structural homology to a 
cysteine, histidine-dependant amidohydrolase/peptidase domain (CHAP domain) 
protein (2K3A_A – Staphylococcus saprophyticus subsp.), an endopeptidase that is 
found within a distinct clade in tree A, highlighted in red (Figure 5.9) among all the 
identified lytic enzyme genes. The CHAP domain protein that Twort possesses shares 
the lowest sequence similarity to members of Cluster 4. Members of Cluster 2, 3 and 
4 are found to share the same CHAP domain protein (2K3A_A, group_19), further 
analysis of the three groups 18, 19 and 20 found that two large insertions at the start 
of group_18 and 19. Yet displayed 80 % similarity among all three when these 
insertions weren’t considered. Additionally, all phage possessed a gene that shared 
similarity in protein structure to LysK (4CSH_A – staphylococcal phage K), a well-studied 
phage endolysin that has been reported to lyse live staphylococcal cultures [146]. 
Although no single gene was found present among all the phage used in this study, all 
phage carried genes encoding for lytic enzymes that shared structural similarity to the 
same predicted protein. 
 
The majority of phage in each cluster share the same number of genes encoding for 
lytic enzymes ranging from 4 to 6. Cluster 4 displays the highest diversity amongst 
genes with a number of phage sharing uniquely different genes encoding for the same 
protein. Furthermore, a number of phage were found to possess up to 2 additional 
genes encoding a hypothetical protein sharing high structural similarity to an endolysin 
(group_10 and group_298) within their genomes. This was also found in Cluster 2 
where EW1, EW2 and EW4 carrying an extra gene to other members of that cluster, 
which was also predicted to be an endolysin (lss). 
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Among the group of lytic enzymes found, HHpred identified a number of genes that 
shared protein structural homology to resuscitation promoting factor (4EMN_B, 
4CGE_A and 2N5Z_A). It has been discovered that these resuscitation promoting factor 
(Rpf) proteins share a high structural similarity to lysozymes and soluble 
transglycosylases [349], and can be seen with group_1366, group_1636, group_329 
and group_23, sharing high structural homology to group_329 and group_23 encoding 
for lysozymes. These Rpf-related proteins are capable of hydrolyzing the peptidoglycan 
motifs of the membrane [350], degradation of the peptidoglycan is required for the 
resuscitation of dormant cells [149]. It was also found that a specific motif within a tape 
measure protein of a Mycobacterium tuberculosis phage, sharing high structural 
similarity to an Rpf protein, facilitated the efficiency and infectivity of phage against 
stationary cells. All clusters were found to encode genes predicted to be Rpf-related 
proteins and lysozymes, however further analysis of the HHpred outputs among 
Cluster 1 identified Group_413 that shared structural similarity to a peptidoglycan 
hydrolase (4Q4G_X), also shares high similarity to a resuscitation promoting factor 
protein (3NE0_A). 
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 Discussion 
We successfully sequenced the genomes of 22 study bacteriophage that displayed a 
broad host range against a large panel of clinical Staphylococcus aureus (including 
methicillin-resistant S. aureus – MRSA) isolates. The results of annotation and genomic 
comparison revealed that these phage are highly similar to members of the 
Twortvirinae subfamily. Due to the high degree of similarity of some of the study phage 
with other members of the cluster representing a distinct phage group, the unclassified 
study phage could therefore be included with that existing group. The genomes of 38 
phage infecting S. aureus belonging to the Twortvirinae subfamily that were publicly 
available at the time were downloaded from the National Centre for Biotechnology 
Information (NCBI) and the European Nucleotide Archive (ENA).  
 
Assembled genomes of the study phage were initially screened through BLASTn, all top 
hits aligned against S. aureus phage belonging to the Twortvirinae subfamily. We 
employed Mash to perform quantitative pairwise sequence comparisons between our 
study phage and all Twortvirinae infecting S. aureus that were publicly available using 
an all-versus-all approach, outlining several clusters and two singletons (Fig. 1). One of 
the major setbacks when working with large whole genome datasets is the significant 
computational power required to compute the rigorous nucleotide and amino acid 
sequence alignments using BLAST or Average Nucleotide Identity (ANI). Mash requires 
considerably less computational power enabling a much more rapid and efficient 
approach to estimate sequence similarity alignments based on kmers of assembled 
genome sequences by using the MiniHash technique for creating sketches to allow 
rapid distance estimates and resemblance between whole genomes without the need 
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for high memory requirements [243]. A collection of sequences are hashed in to 
MiniHash sketches and each sketch is compared between each other to estimate the 
fraction of shared k-mers (Jaccard index) and the rate of sequence mutation. By using 
the kmer-based approach it can be extremely useful when comparing highly diverse 
phage genomes. However, Mash calculates similarly without the requirement of 
alignment, therefore does not correlate with evolutionary divergence [334].  
 
The output matrix was presented in a heatmap to demonstrate the pairwise 
comparison scores for each phage, all phage in this study displayed remarkably high 
homology between each other with the lowest being >68 %, a characteristic unique to 
Spounavirinae members [131]. Clusters were found to represent individual genera, 
with Cluster 1 made up of members belonging to Silviavirus, the single Twort virus and 
Cluster 4 consisting of Kayvirus being split into three smaller sub-clusters. Two smaller 
clusters and a singleton were also identified, all of which are still yet to be classified 
into a genus by the ICTV. Our study phage shared high similarity with previously 
sequenced phage, allocating them amongst the individual clusters. Additionally, cluster 
2 consisting of only EW phage members sequenced in this study represents a distinct 
phage group, sharing only 91 % identity to the closest phage in Cluster 3, of which, 
members of this cluster are so far unclassified by the ICTV.  
 
Mashtree provides a relatively simple but efficient approach to rapidly compare whole 
genome sequences in order to identify and study groups of similar phage that cluster 
together. Comparing predicted genes and the structural homology of the predicted 
protein those genes encode in combination with clustering is a relatively simple 
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approach as a means of identifying relationships between phage especially amongst 
phage within a specific genus. This approach has helped as to which family or genus 
the study phage may fall in to prior to morphological classification. The use of 
clustering has been used extensively when studying phage based on sequence identity 
and homology [338,351,352], however almost each one of these studies using a unique 
and different approach utilising an assortment of bioinformatics tools and programs. 
To appropriately classify the EW phage sequenced in this study, further genetic 
characterisation and morphological analysis will be required using ICTV approved 
methodology and programs, such as those that were utilised during the recent 
reorganisation of the current classification system for Caudovirales [131].  
 
An initial pan-genome assessment comparing the predicted phage encoded proteins 
was performed in attempt to locate possible core genes conserved among all phage. 
However even when considering phage from the entire subfamily, no single gene was 
found to be shared across all phage genomes. As divergent as phages are, it would 
make sense that they should share genes that encode for key proteins essential to 
phage life. When examining the pan-genome, an immediately recognisable pattern are 
the blocks of genes arranged in rows shared across members unique to a cluster, closer 
examination of these clusters reveals that the members (of which were previously 
classified) also share the same genus. By comparing the genomes of phage within that 
individual cluster (genus), not only did they share a greater degree of similarity 
amongst each other, but we could identify core genes conserved among all its 
members. The identification of a core set of genes shared by a group of phage has been 
observed in similar studies, interestingly, they focused on just members of the same 
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genus, identifying a conserved core of essential genes including metabolic enzymes 
and structural components [352,353]. Phage lack the conserved, universal markers 
such as the 16S rRNA genes that form the basis of bacterial taxonomy, as there are no 
suitably conserved universal genes found in phage genomes [354]. With no single 
conserved protein marker shared across all phage, comparisons between phage 
diversity across genera and families is therefore very difficult. Consequently preventing 
a taxonomic system based on a single locus analogous to 16S rRNA approach for 
bacteria. Pairwise comparisons between sequences usually provide a robust method 
for species demarcation [355]. Based on genome similarity data obtained, several of 
the phage sequenced in this study appear to share indistinguishable levels of 
nucleotide identity with one another (100 %), suggesting that they are exactly the same 
phage. This could be down to various reasons, from the same phage being present 
among a number of tanks when collecting samples, to possible cross contamination 
during initial library preparation.  
 
Surprisingly, the distribution of phage across genera is somewhat limited. Out of the 
60 Twortvirinae genomes available, 35 (58 %) of those, belong to the Kayvirus genus 
and the remaining 27 (45 %) shared across the other genera.  Interestingly, a distinctive 
characteristic of the Kayvirus is the relatively large accessory genome and the 
considerable gene diversity among those members, suggesting there are a number of 
hot spots for recombination. We note that the distribution of phage in clusters and the 
proportion of singletons (2 / 60 phage - 3.2 %), in addition to the two clusters 
composed of two individual members, is comparable with the proportion found in 
similar comparative phage genome studies, when investigating the diversity among 
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Enterobacteriaceae phage (18 / 338 – 5.3 %) [356], Mycobacteriophage (8 / 627 – 1.27 
%) [341] and Arthrobacter phage (2 / 42 – 4.76 %) [357]. However, considerably lower 
compared to Bacillus phage (15 / 83 – 18 %) [358] and Pseudomonas phage (30 / 130 
– 23.1 %) [342]. The gene coding potential for each of the phage genomes in this study 
averaged around 88 %, exhibiting a gene density of 1.47 genes per kilobase pair (kbp). 
These values are similar to that observed in other studies on Pseudomonas aeruginosa 
phage (93 % - 1.5 kbp) [339], Bacillus phage (88 % - 1.47 kbp) [358], Arthrobacter phage 
(1.52 kbp) [357], Mycobacteriophage (93 % - 1.42 kbp) [343] and a larger 
Mycobacteriophage study including members from the previous study (1.49 kbp) [341]. 
It must be noted that, these values were calculated by filtering out the Twortvirinae 
phage genome characteristics from tables and supplementary material provided. 
 
The diversity of Twortvirinae was further demonstrated by the low level of genes 
shared among the clusters, as mentioned previously no single gene was present in all 
phage. The most commonly shared gene was found in 48 (80 %) phage out of the 60, 
belonging to clusters 2, 3 and 4 which shared a high degree of similarity among each 
other. Of the 1634 individual gene groups predicted by Roary, there were 583 (35.6 %) 
single gene groups found in one phage member, remarkably similar to those observed 
with mycobacteriophage (31 %) [341], and similarly with Arthrobacter phage (26 % ) 
[357]. The proportions of cluster-associated core and accessory genes vary 
considerably depending on the clusters, demonstrating the level of diversity that is 
found between them. However, the encoded protein remains consistent across all 
clusters, as the majority of identified genes encode for essential proteins including 
major capsid, tail and baseplate proteins (structural), RNase, endonuclease and DNA 
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polymerase (metabolic), holin, endolysin and virion-associated peptidoglycan 
hydrolases (lytic enzymes). 
 
With the rapidly increasing number of phage genomes being deposited in public 
databases, the possibility of using every single phage genome remains to be a 
problematic issue when attempting to perform comparative genomic studies. When 
this study first started in February 2018, only 38 genomes of phage infecting S. aureus 
were currently available at the time. However in the time it’s taken to analyse this data, 
that number has almost doubled in size (http://millardlab.org/bioinformatics/ 
bacteriophage-genomes/). Furthermore, the number of phage infecting S. aureus 
currently available is rather difficult to identify. Not all publications on staphylococcal 
phage have reported their host species, and not every phage has a publication 
associated with it, therefore limiting the sample size of this study. Future studies will 
consider a more comprehensive dataset by including phage infecting an entire 
bacterial genus. 
 
The varying quality and differences of annotated genomes across older and more 
recently deposited genomes, as well as multiple genome entries for a single phage 
genome can greatly affect gene production analysis [359]. To improve the original 
annotation for some of the genomes and ensuring uniformity, all 60 phage genomes 
used in this study were re-annotated with Prokka against a database of known viral 
proteins. Regardless of the database used, uncharacterised hypothetical proteins 
accounted for the majority of identified coding sequences, as is commonly the issue 
during annotation [344]. A considerable amount of information remains to be 
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elucidated from these phage, however, the need to enrich protein databases with 
identified genes remains a major challenge in attempt to successfully annotate phage 
genomes. The validity of this work significantly depends on the successful and correct 
identification of gene boundaries and coding sequences using updated protein 
databases, gene-predicting programs and manual annotation.  
 
The presence of self-splicing elements such as group I introns have been previously 
described in tailed phage, especially within those infecting S. aureus [348]. Introns 
intervening gene sequences has become a challenging issue for annotation and gene 
prediction programs. For example, upon closer inspection of gene groups associated 
with a single phage, the presence of introns encoding for an endonuclease. These 
endonucleases are often found embedded within introns and appear to be a 
characteristic feature of S. aureus twortlikeviruses and found in a variety of genes such 
as, DNA polymerase, helicase and ribonucleotide reductase large-subunit 
[211,338,360]. Even with staphylococcal phage sharing the least similarity at the DNA 
level such as members of Silviavirus and Kayvirus genus, they still possess similar group 
I introns present within functional homologs [348]. 
 
As no single gene was found shared among all phage genomes, the predicted structure 
of genes were assessed and those that shared structural homology to previously 
identified lytic enzymes were screened. Most staphylococcal phage endolysins are 
multi-domain proteins harbouring a C-terminal SH3B-type cell wall binding domain 
(CBD), an amidase and a catalytic N-terminal endopeptidase domain (cysteine, 
histidine-dependant amidohydrolase/peptidase domain - CHAP) [361]. Phage 
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endolysins can be divided based on the target substrate in bacterial cell walls, their 
modular structure allows the possibility of different domains to be swapped producing 
different domain arrangements, thus enabling endolysins to have altered enzymatic 
specificity and efficacy [362]. We found that each of the phage clusters possessed a set 
of genes that were grouped in to a distinct branch, these genes all shared structural 
similarity to the same CHAP domain (2K3A_A), suggesting that the endolysins that each 
phage encoded most probably shared the same endopeptidase N-terminus. Notably, 
the 3-domain endolysin LysK, derived from the staphylococcal phage K that features a 
CHAP domain has been previously truncated to retain only the CHAP domain,  has 
demonstrated a two-fold higher lytic activity against live S. aureus including MRSA 
[146].  
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 Discussion 
A key factor of Staphylococcus aureus virulence is its ability to form biofilms on a 
number of biotic and abiotic surfaces [363]. The production of biofilm is a common 
mechanism employed by bacteria as means of protection against the environment and 
components of the host immune system. Cells within biofilms can also be protected 
from the action of antibiotics and disinfectants leading to persistent, recalcitrant 
infections and delays in healing [364].  
 
S. aureus (including methicillin-resistant S. aureus – MRSA) is a major cause of biofilm-
associated infections frequently encountered within healthcare settings that can lead 
to disseminated, systemic infections that can result in patient death. Despite infection 
control measures that have reduced the numbers of MRSA outbreaks in UK hospitals 
[68], biofilm-associated S. aureus infections are still responsible for considerable rates 
of morbidity and mortality. Frequently multiply antibiotic resistant, these infections are 
usually treated with intravenous vancomycin to which intermediate susceptibility 
frequently emerges. Future strategies for the control of MRSA and other major 
antibiotic resistant pathogens necessitates the development of adjuncts and 
alternatives to antibiotics such as immunotherapy and bacteriophage therapy. These 
will hopefully offer future treatment options for infections that do not respond to 
antibiotic chemotherapy. 
 
The application of phage preparations in the treatment of bacterial infections has so 
far produced promising results. Lytic phage have been shown to be favourable 
candidates for therapeutic use and have already proven to be highly effective in the 
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control and treatment of S. aureus infections, including MRSA and their biofilms. The 
objective of this project was to assess the lytic potential of novel phage infecting S. 
aureus and determine their anti-biofilm properties against a number of major epidemic 
MRSA isolates belonging to two highly prevalent clonal lineages that are endemic in UK 
hospitals. To fulfil this aim, it was necessary to isolate and characterize a collection of 
phage from various environmental samples and laboratory stocks.  
 
While phage are widespread within the environment, their presence correlates to the 
existence of their bacterial host and may only be present at low frequency. Difficulties 
in isolating lytic S. aureus bacteriophage from various sources including wastewater 
samples, faecal matter and environmental samples have been reported in numerous 
studies compared to enteric bacteria that are highly prevalent in sewage environments 
[267,365]. Lytic S. aureus phage are much less easy to isolate than those infecting other 
bacterial hosts such as the gram-negative species Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Escherichia coli and Salmonella species [267,366,367].  
 
Enrichment protocols can help create a bias towards the target phage with desirable 
characteristics for a specific host, where it can propagate and increase in number to 
detectable levels [367]. The enrichment method offers various opportunities to modify 
and tailor the protocol based on:- the type of environmental sample, the number and 
species of isolation hosts, detection of phage, formulation of growth media, the 
handling and processing of samples prior to infection and post infection [367]. The 
optimisation of a working enrichment protocol that would allow us to achieve the 
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greatest yields when attempting to isolate phage infecting S. aureus presented the first 
major hurdle in this study.  
 
Initial sample enrichment attempts were performed using S. aureus D329 and H402 as 
hosts, resulting in low plaque yields. The high host specificity of phage greatly limits 
the likelihood of isolating possible phage present within the samples when using only 
two bacterial hosts and are otherwise missed. To counter this, one approach 
considered was to use more than a one host during sample enrichments by introducing 
a combination of several target hosts strains [290,368]. This bacterial cocktail approach 
has proven to be beneficial within previous studies isolating a number of phage 
effective against S. aureus [190,369]. However, increasing the diversity and numbers 
of bacterial hosts proved to be inefficient and biofilms produced by labour intensive, 
as replicates of each enrichment sample had to be plated out on to each of the hosts 
using the soft agar overlay during screening. The use of a modified S. carnosus TM300 
strain which expresses N-acetyl-D-glucosamine-modified ribitol-phosphate (RboP) 
repeating units of the wall teichoic acid on to the surface of the cells, a known S. aureus 
phage receptor, was crucial to successfully isolating 46 novel obligately lytic phage 
from wastewater samples in this study. The addition of 32 phage from our laboratory 
stocks further expanded our collection to a total 78 phage as recorded in Chapter 3.  
 
When considering phage as a potential therapeutic, obligately lytic phage are preferred 
due to their ability to rapidly kill the bacterial host, reducing the possibility of the host 
developing resistance. They should also lack genes responsible for genome 
incorporation that may mediate horizontal gene transfer of virulence or antibiotic 
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resistance genes. Determination of the host range (lytic spectrum) for each newly 
isolated phage should be assessed against a host panel in order to determine the level 
of polyvalence. We tested each phage against a genetically diverse representative 
group of 185 S. aureus isolates including a number of major MRSA clones. Host range 
analysis demonstrated that 40 of the 78 phage were able to infect over 90 % of isolates 
tested. The broad host range exhibited among the large majority of our phage 
collection shared similar broad host range properties to notable polyvalent phage that 
belong to two of the common and widely used (in phage therapy) staphylococcal phage 
groups, the Twort-Like (TL) myoviruses and lytic podoviruses (LP) [202]. 
 
One issue to consider in selecting phage isolates for therapeutic development is the 
minimum number of susceptible bacterial hosts strains required in testing to 
adequately determine whether a phage exhibits a broad or narrow host range. This 
was recently addressed by a number of phage scientists [367], feedback from this 
showed very little agreement on the size of the panel used which ranged from single 
figures up to 800 in some cases. Several respondents indicated that there were 
multiple variables to consider depending on the bacterial host, such as the diversity 
among test isolates and the proportion of closely- or distantly- related host of that 
selected species. Additionally, the planned use of the phage will also be important to 
consider, for example whether it will used to specifically target strains isolated from 
clinical, environmental or animal sources. Studies rarely characterise phage against the 
same bacterial isolates and panel size as others making it difficult to assess phage host 
range from study to study. One consideration could be the introduction of an 
international standard panel unique to the target host species or even genus to be 
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included for every test, consisting of well-studied ‘type strains’ host or members from 
highly successful and prevalent lineages associated with epidemics. 
 
Killing assays were employed to further assess the efficacy of each phage against 
planktonic cultures being demonstrated in vitro. Ten phage from our collection that 
previously exhibited a relatively broad but varied host range with coverage of almost 
all bacterial isolates within the panel tested against were selected for this experiment. 
The treatment of three S. aureus isolates and a S. carnosus TM300 host used for phage 
isolation provided a detailed representation of the unique growth kinetics of each 
phage whilst highlighting the variation in host specificity in liquid culture. This assay 
monitored the bactericidal ability of each phage in real-time by measuring changes in 
absorbance, whilst being able to observe the growth of phage resistant mutants.  
 
Differences in virulence factors among S. aureus isolates has been linked to specific 
lineages based on sequence type (ST) [72,370] or spa protein [371], with some clones 
demonstrating a higher propensity to form stronger biofilms or greater adherence to 
surfaces than others [224,372]. The association between biofilm production capacity 
and clonal lineages[224,372], specifically by ST22 and ST36 clones was assessed in 
Chapter 4. Due to the relatively low biofilm levels produced by our collection of ST22 
isolates, a cut-off value of 0.4 (OD590) was used to distinguish between strong and weak 
biofilm formers, resulting in only seven isolates being considered as strong biofilm 
formers. Biofilm biomass was significantly greater among ST36 isolates with two 
isolates in particular capable of producing three times more biofilm mass than the 
highest producing ST22 isolates. To allow a more accurate comparison, two of the 
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weaker biofilm producers of ST36 that achieved densities similar to those obtained by 
the most successful biofilm producers of ST22 were selected. The selected isolates 
used in this study demonstrated an association between biofilm forming capacity and 
clonal lineage, in agreement with those observed in previous S. aureus biofilm studies 
[227,363].  
 
However, when considering the most successful biofilm formers, our results were not 
consistent with those revealed in a previous study, out of the 13 clonal complexes 
studied the EMRSA-15 clone (ST22) appeared to be the more successful at forming 
stronger biofilms when compared to EMRSA-16 isolates (ST36) [363]. It must be noted 
that in this study the authors used lower starting inoculum diluted to an optical density 
(600 nm) of 0.04 to grow their biofilms, whilst also using the Calgary biofilm device 
(polystyrene pegs on the coverlid) approach. This allows biofilms to form on the pegs 
of the lid as a resultant of sessile development rather than cell sediment. Therefore, it 
is important to consider that differences in biofilm strength and formation between 
studies can be largely associated with the growth conditions and protocol used, that 
may include the various type of plates, different media strengths, supplemented with 
glucose used for the assay [373]. 
 
In a clinical scenario, treatment of severe S. aureus infections is usually performed 
using a combination of antibiotics to further enhance their activity in attempt to reduce 
and prevent and reduce the emergence of antibiotic resistant mutants [374]. However, 
bacteria embedded within biofilms are inherently difficult to treat with antimicrobials 
and bactericidal agents, demonstrating a reduced susceptibility to antibiotics. The anti-
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biofilm properties of phage and their enzymes make them an attractive alternative to 
antibiotics and an effective antimicrobial towards controlling bacterial population 
dynamics within S. aureus biofilms. The glycocalyx and EPS may hinder the diffusion of 
phage particles, however the concentration of lytic enzymes and peptidoglycan 
hydrolase activity may play a role in the degradation and disruption of the biofilm 
matrix, thus facilitating phage diffusion enabling phage to reach cells that were once 
protected.  To test this statement, the four most effective phage based on their success 
in Chapter 3, were selected to further assess the efficacy and anti-biofilm capacity 
against four ST22 and four ST36 clinical isolates using the microtitre plate biofilm assay. 
In this study, each of the four phage demonstrated high efficacy against biofilms and 
were successful in greatly reducing cell viability and biofilm biomass following single 
application for 6 and 24 h at an MOI 1 and 0.1.  
 
Overall, reductions in biofilm biomass were generally greater in biofilms when treated 
with an MOI 0.1 for each of the phage. Interestingly, we found that biofilm densities 
did not correlate with viable cells numbers, biofilm cell regrowth was observed when 
exposed to phage for 24 h than 6, however resistance may have come at the expense 
of biofilm production as no further increase in biofilm densities was observed during 
both sampling timepoints. The inability to completely eradicate infection-causing 
pathogens within biofilms and development of phage resistance, presents a major 
limitation when considering the therapeutic potential of phage. Previous studies have 
demonstrated the bacteria and phage undergo antagonistic coevolution in vitro. 
Suggesting that over time, bacteria develop and become more resistant to infective 
phage when exposed for long periods of time. However as time progresses, so too does 
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the phage, subsequently evolving to become more infectious to the resistant bacteria 
[375]. 
 
However, the ability of phage to successfully disperse biofilms but not completely kill 
all bacteria can still work as an advantage, the prospect that phage could be used in 
conjunction with antibiotics and other antimicrobials agents in the treatment of 
biofilms has been previously considered and extensively reviewed [376,377]. By 
utilising phage and their enzymes to disrupt the key components of the biofilm EPS, it 
exposes the once protected cells that have been found to be susceptible to sub-
inhibitory concentrations of antibiotics in attempt to prolong their utility. Studies have 
identified potential synergistic relationships between phage and antibiotics, the 
combined or sequential administration of both of these has been shown to improve 
their efficacy, resulting in enhanced biofilm disruption and reduction to viable cells in 
vitro [217,219].  
 
Historically, morphology-based classification was the main approach used as a means 
of characterising and gaining a better understanding of phage taxonomy. One of the 
mandatory taxonomical classification criteria for categorising phage is the examination 
of its morphology characteristics through electron microscopy, thus allowing to 
determine the family based on tail morphology and its nucleic acid. However, the 
significant increase in numbers of novel phage genomes being sequenced and 
submitted to public databases every year has revealed that tailed-phage are much 
more diverse than originally thought [131]. Alternative and more modern approaches 
for genomically classifying phage have been considered as many biologists feel the 
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current taxonomy is outdated [109]. Chapter 5 describes the whole-genome 
sequencing of 22 novel lytic phage genomes. These exhibit high sequence homology 
to previously characterised phage infecting S. aureus belonging to the newly 
established Twortvirinae subfamily. The complete genomes of all 38 phage infecting S. 
aureus were download from public databases and comparative genomic analyses was 
subsequently carried out using Mash distances. This resolved several clusters with 
phage from this study grouping with clusters containing previously described phage 
genomes. However a small number of phage isolated in this study formed a distinct 
cluster to that of other phage genomes. Further assessment revealed each unique 
cluster formed using MASH distances represents individual genera within the 
Twortvirinae subfamily with members within each cluster sharing a high level of 
homology between each other. The assignment of phage genomes in to clusters closely 
reflects the relationship among phage groups based on sequence similarity or gene 
content and has been employed extensively when performing comparative analyses 
with large genome datasets [341,351,358]. This type of clustering based on pairwise 
distances does not substitute for a reticulate taxonomy, however it may be employed 
to extend the classification of staphylococcal phage, providing insight in to the 
assignment of phage in to families or possible genera prior to morphological 
classification. 
 
Further analysis of selected phage genomes in Chapter 5 identified a number of phage 
from this study that demonstrated indistinguishable levels of identity between one 
another and were found to be identical. The cause for this could be down to a number 
of possible factors, suggesting that these phage were most probably present in a 
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number of ASP sewage tanks when samples were collected, possible contamination 
during the processing of wastewater samples during screening, or operator error 
during phage when isolating and purifying phage plaques. Pan-genome analysis 
allowed for gene presence/absence comparisons amongst the study group, revealing 
no single gene was shared between all phage, with the most commonly shared gene 
present among 80 % (48/60) of the phage collection. However, lack of gene content 
present between phage made comparative genomics of the phage collection 
challenging. Furthermore a significant proportion of the gene groups identified (35.6 
%) were only present in a single phage, yet further interrogation of these gene 
sequences revealed the presence of Group I introns that often encode for homing 
endonucleases inserted within key metabolic and structural genes that were classed as 
individual gene groups but were otherwise identical [348,378]. By utilising HHpred, the 
majority of genes that were shared among phage shared structural protein homology 
with lytic enzymes and virion structural proteins. Genes encoding for lytic enzymes 
were further assessed, revealing all phage encoded for a protein that shared high 
structural similarity to the same CHAP domain protein, suggesting that each phage 
encodes an endolysin that most probably shared the same endopeptidase N-terminus. 
 
The number of phage genome sequences being deposited and made available on 
public databases continues to rapidly increase, with staphylococcal phage genomes 
almost doubling in size since this study started. One issue was the number of 
sequenced genomes of lytic phage infecting S. aureus that were currently available on 
public databases was difficult to determine. Of course, not every phage has a 
publication associated with it that will aid in determining the bacterial host of the 
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phage, however the lack of supporting detail and information provided for each phage 
sequence when initially submitted greatly limited the sample size we used. An informal 
nomenclatural guide on how to name and classify phage was recently introduced in 
2017, proposing each novel phage to be uniformly named according to unique 
identifiers such as bacterial host genus and phage morphology to be provided, whilst 
helping to eliminate the existing issue of having multiple diversely-related phage 
possessing the same name [275]. 
 
 Suggestions for future work 
Further characterisation of the wide-host range phage from this study should be 
investigated to develop a greater understanding of their biology. This would include 
experiments to determine the parameters of growth kinetics such as adsorption rate, 
burst size, eclipse period and lysis time. Methods could also be used to extend the host 
range of those exhibiting a narrow spectrum perhaps using a directed evolution 
approach [379]. Additionally, morphological classification using transmission electron 
microscopy (TEM) continues to be one of the major criterion for phage classification 
and considered to confirm the phage morphology derived by genome similarities. 
 
Four phage, isolated in this study, were highly efficacious in reducing biofilm mass and 
number of viable cells of S. aureus ST22 and ST36 isolates in static microtitre plate 
assays. However this static biofilm system is a relatively crude model - further 
assessment of these phage should be conducted using a dynamic biofilm model with 
continuous flow of nutrients which generates a more realistic (and clinically relevant) 
environment for biofilms to develop in. Such a system using, for example, a modified 
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Robbins device or a Drip Flow Biofilm Reactor could be used to generate robust 
datasets to describe the in vitro characteristics of our phage against S. aureus biofilms. 
It would also be beneficial to assess the action of phage to manipulate biofilms grown 
on to range of medical surfaces such as those used for catheters and implants should 
also be assessed due to the significant rate of implant associated infections associated 
with S. aureus. 
 
Nevertheless, phage virulence in vitro does not always correlate with virulence and 
efficacy in vivo so evaluation of phage efficacy in vivo using using animal models such 
as the mouse or rat would be required as part of a clinical development pathway. As in 
vivo environments are highly complex and dynamic, bacterial behaviour can 
significantly differ from that of the in vitro state which will impact on effect on phage 
kinetics. Overall gene expression can also change, leading to loss of  the surface 
receptors phage require to bind to, which may also lead to reduced sensitivity to phage 
[380–382]. These interactions further increase the complexity of model, greatly 
restricting the ability to screen multiple hosts and phage, therefore the choice of 
animal model should be carefully considered. Furthermore, it is crucial to ensure the 
purity and safety of phage lysates and preparations prior to administration of phage in 
animal systems.  
 
The sequencing of the remaining 56 phage within our phage collection will help to 
further enrich the current databases with more staphylococcal phage genomes, this is 
important as genome sequence databases are accessed at a much higher rate than a 
traditional publication. This will allow other research scientists to access a large 
206 
 
collection of phage genomes to help in efforts to explore phage genomic diversity and 
evolution and understand the complexity of phage genomes and their relation to that 
of their host. Undoubtedly more Twortvirinae will be discovered in the future and their 
sequenced genomes will be uploaded and made available in the public domain. More 
work should be invested in to studying the phages that are currently unclassified, 
although undersampled, they may represent a new genus or possibly subfamily, and it 
is by enriching these databases that will help to assign these phage in to their 
respective genus or subgroups. To consider genome wide association studies (GWAS) 
and pan-GWAS to further investigate the biofilm production between ST22 and ST36 
isolates. Using pan-genome pipelines such as Roary it is possible to identify candidate 
genes that are present or absent within good and weak biofilm producers, and assess 
their contribution to biofilm formation [383].  
 
The high mutability of S. aureus enables the pathogen to rapidly adapt when exposed 
to external stressors. It would also be interesting to study the phage-resistant mutants 
producing various morphotypes that were recovered from phage treated biofilms. 
Whole genome sequencing of the various mutants and untreated isolates would 
enable genomic comparisons to look for genomic changes such as mutations, deletions 
and insertions within the genomes. This would provide a greater understanding of the 
adaptive strategy employed by biofilm-associated S. aureus.  
 
 Concluding remarks 
In summary, this study attempted to assess the lytic activity of phage infecting S. 
aureus. By utilising a modified S. carnosus TM300 with an increase susceptibility to 
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phage adsorption, we successfully isolated 46 novel obligately lytic phage from 
wastewater samples that exhibited a broad host range determined by testing against 
an international panel of genetically-characterised MRSA isolates. With emphasis on 
the phage-biofilm interaction of candidate phage against mature biofilms produced by 
two highly successful and dominant MRSA clones within the UK, ST22 and ST36. The 
top four candidates demonstrated promising anti-biofilm activity against strong biofilm 
producers, however reductions in biofilm biomass did not correlate with reductions in 
viable cells, as phage failed to completely eradicate all adhered cells. Genomic 
comparisons of 22 study phage identified them to share significant nucleotide 
similarity to Twortvirinae phage previously classified, no core genome was identified, 
they did all carry a gene that shared significant structural homology to the same CHAP 
domain. Overall, the phage isolated in this study may be useful therapeutic candidates 
when applied in combination with other phage or antibiotics in attempt to treat MRSA 
infections in the future. 
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